The brain response to peripheral inflammation by McColl, Alison
 
 
 
 
 
 
 
 
 
McColl, Alison (2015) The brain response to peripheral inflammation. PhD 
thesis. 
 
 
https://theses.gla.ac.uk/6764/  
 
 
 
Copyright and moral rights for this work are retained by the author  
A copy can be downloaded for personal non-commercial research or study, 
without prior permission or charge  
This work cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the author  
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the author  
When referring to this work, full bibliographic details including the author, 
title, awarding institution and date of the thesis must be given 
 
 
 
 
 
 
 
 
 
 
 
Enlighten: Theses  
https://theses.gla.ac.uk/ 
research-enlighten@glasgow.ac.uk 
 
  
 
 
 
 
 
 
 
The Brain Response to Peripheral 
Inflammation 
 
 
 
Alison McColl 
BSc (Hons) 
 
 
 
 
Submitted in fulfilment of the requirements for the degree 
of Doctor of Philosophy 
 
 
 
Institute of Infection, Immunity and Inflammation 
College of Medical, Veterinary and Life Sciences 
University of Glasgow 
 
 
 
October 2015 
  
 
 
 2 
Abstract 
Communication between the immune system and the central nervous system 
(CNS) is becoming increasingly topical as evidence suggests the two systems are 
intricately linked. Although the brain is considered an ‘immune-specialised’ 
tissue, it is not free from the influences of the periphery. Recent data indicate 
that peripheral immune stimulation can significantly affect the CNS, and 
patients with chronic inflammatory diseases, including rheumatoid arthritis (RA) 
and psoriasis, are often further burdened by the onset of neuropsychiatric 
conditions such as major depressive disorder (MDD), schizophrenia and anxiety. 
However, despite increases in our understanding, the precise mechanisms 
underpinning this relationship remain unclear. Therefore, the aim of this thesis 
is to investigate the communication pathways that exist between the immune 
system and the nervous system and to enhance our understanding of this 
bidirectional relationship. 
Using a well-characterised animal model of psoriasis-like skin inflammation, I 
have investigated the effects of cutaneous, peripheral inflammation on the 
brain. Psoriasis-like skin inflammation was induced in female C57BL/6 mice via 
the repeated application of Aldara cream to the shaved dorsal skin. Twenty-four 
hours after the fifth application, the transcriptional response in the brain was 
assessed and compared with mice treated with an aqueous control cream, using 
Affymetrix GeneChip arrays. The induction of target genes, identified using 
microarray analysis, was confirmed in an independent model using QPCR and was 
compared to the gene induction following a number of other inflammatory 
models, including a sterile model of cutaneous inflammation.   
Transcriptional profiling techniques allowed me to identify a number of 
differentially expressed genes in the brains of Aldara- and Imiquimod (IMQ)- 
treated mice when compared with the brains of control mice. This response 
included a range of interferon-stimulated genes (ISGs) and chemokines that were 
not induced in the peripheral blood leukocytes (PBL), and occurred 
independently of an overt cytokine response in the PBL. The brain ISG and 
chemokine response was not detected following a sterile model of cutaneous 
inflammation or following the intraperitoneal administration of Imiquimod. 
 
 
 3 
The central induction of a number of chemokines prompted the evaluation of 
immune cell infiltration into the brain parenchyma. In addition, the functional 
consequences of topical Aldara treatment, and the involvement of inflammatory 
chemokines, were determined by assessing dentate neurogenesis and burrowing 
behaviour in wild-type and ACKR2-deficient mice. 
The transcriptional response following cutaneous IMQ-induced inflammation is 
indicative of a peripherally triggered inflammatory response in the brain. In 
addition, the data described in this thesis demonstrate a functional consequence 
of peripheral immune stimulation and suggest that cutaneous inflammation 
could modulate the recruitment of leukocytes to the brain. These data highlight 
a potential mechanism of TLR-dependent communication between the periphery 
and the brain that could be mediated through the activation of the afferent 
vagus nerve. 
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1 Introduction 
1.1 Inflammation and depression 
Major depressive disorder (MDD) and other psychiatric illnesses, including 
schizophrenia and anxiety, are a significant burden to our society. These 
conditions are not only associated with a negative psychosocial outlook but they 
are also a growing concern for the economy, as the cost of long-term treatment 
and loss of earnings is extensive1-3. Neuropsychiatric diseases are commonly 
associated with chronic inflammatory conditions and appear to have a close, and 
often co-morbid, relationship with inflammation and, in particular, with 
inflammatory cytokines4-6. However, the mechanisms underpinning this 
relationship are largely unknown and it remains to be understood how 
inflammation in the periphery can influence the brain and lead to the onset of 
neurological conditions.  To try to understand this relationship, studies have 
been performed in which peripheral inflammation was induced in rodents to 
analyse the onset of sickness behaviours and depressive-like symptoms7, 8. 
However, in addition to many unanswered questions remaining, most of these 
studies have used potent systemic inflammatory stimuli that are not 
representative of the human, tissue-specific conditions that correlate with 
neuropsychiatric disorders. Therefore, the aim of this thesis is to investigate the 
brain response to tissue-specific, peripheral inflammation and to try to identify 
the mechanisms driving this relationship. It is hoped that in doing so, new 
therapeutic targets can be identified and novel treatment strategies can be 
established.  
This introduction will provide an overview of the relevant components of the 
immune system and central nervous system (CNS), before going into detail about 
the current literature with regards to the mechanisms and implications of 
communication between the brain and the periphery.     
1.2 The immune system 
We live in a world surrounded by microorganisms which we come into contact 
with on a daily basis. The term microorganism refers to bacteria, viruses, 
parasites and fungi, and whilst a lot of these pose no threat to a healthy 
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individual, many have the potential to cause disease and are thus referred to as 
pathogenic microorganisms, or pathogens. Pathogens are often kept ‘at bay’ by 
a number of physical and chemical barriers, including epithelial barriers and 
mucous membranes of the gastrointestinal tract and respiratory system. 
However, should these barriers be breached, the immune system acts as our 
internal defence system ready to respond to, and neutralise, any threat. If a 
pathogen enters the tissues or circulation, it will encounter cells of the innate 
immune system. The innate immune system is considered the first line of 
defence and is always primed for a rapid response. As such, innate cells are 
constantly circulating between the blood, tissues and lymph, acting as a 
surveillance system to detect infection by pathogens9. In such circumstances, 
these first responders will target the pathogen for removal using a number of 
mechanisms, and will induce the recruitment of additional effector cells to the 
site of infection. If an infectious organism resists the initial defences of the 
innate response, these cells are also able to initiate an adaptive immune 
response. Unlike the innate immune system, which is both rapid and dynamic, an 
adaptive immune response takes days to develop and is there to support the 
innate immune system should it become overwhelmed. The adaptive immune 
response relies on lymphocytes to mount a pathogen-specific response through 
the activation of an array of T cell subsets and the generation of a diverse 
antibody repertoire. Uniquely, the adaptive immune system is able to generate 
immunological memory via highly specialised antigen receptors. Thus a faster, 
stronger, response will be mounted if the same pathogen is encountered in the 
future. The innate and adaptive immune systems work in concert to identify and 
overcome infectious agents, whilst minimising the damage caused to the body. 
These systems are essential to our survival and both will be discussed in more 
detail in the following sections.   
1.2.1 Innate immune system  
As mentioned, the innate immune system is considered to be the first line of 
defence and is always ready to mount a response when a pathogen has breached 
the body’s physical barriers. This response, unlike that of the adaptive immune 
system, is non-specific and does not lead to long term immunological memory. 
The acute, innate, inflammatory response is characterised by a number of 
physical changes including pain, redness and oedema that are the result of 
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vascular dilation in the local area10, 11. This vasodilation causes an increase in 
blood flow but a decrease in blood velocity and thus allows an influx of 
leukocytes that will clear the pathogens and repair the area. In addition, the 
release of clotting factors will prevent the internal spread of a pathogen or 
serve to minimise blood loss depending on the nature of the insult.  
1.2.1.1 Cells of the innate immune system 
There are many cell types that are hallmarks of the innate immune system, 
including neutrophils, macrophages, dendritic cells (DCs) and natural killer (NK) 
cells10. With the exception of NK cells, which are of lymphoid lineage, innate 
cells are generated from myeloid progenitor cells derived from multipotent 
haematopoietic stem cells of the bone marrow12.  
Neutrophils 
Neutrophils are considered the first immune cell to be recruited to sites of 
damage or microbial infection10. As first responders, neutrophils have a multi-
faceted approach to fighting infection, including phagocytosis, cytokine 
secretion and degranulation13. Another mechanism that neutrophils have evolved 
to combat pathogens is the release of neutrophil extracellular traps (NETs). First 
descried by Brinkmann et al. in 200414, neutrophils can release their granule 
contents along with chromatin to form long fibres, or NETs, through the process 
of NETosis15. NETs help contain pathogens and inactivate their ‘virulence 
factors’ that they use to modify the function of host cells. They also contain 
several proteins that can kill or inhibit microbes16.   
Monocytes 
Large reservoirs of monocytes reside in the spleen and bone marrow and 
circulate through the blood17. Upon sensing appropriate signals, monocytes can 
extravasate through the endothelium and into the tissues where they 
differentiate into either macrophages or monocyte-derived DCs. Monocytes 
therefore serve to replenish the pool of tissue-resident cells in both steady state 
and inflammation.  
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Macrophages 
Macrophages reside in various tissues throughout the body and their turnover is 
reliant on derivation from infiltrating monocytes. However, with the deletion of 
several transcription factors, some tissue-resident macrophages may have the 
capacity to self-renew18. Macrophages, like neutrophils, ingest and consume 
dead cells, host cell debris and foreign material through the process of 
phagocytosis, and are also able to present antigen to cells of the adaptive 
immune system10. Under steady state conditions, macrophages produce large 
amounts of IL-10 in order to maintain tissue homeostasis; however when they 
sense danger, through an array of pattern recognition receptors (PRRs) or in 
response to certain cytokines, macrophages become activated. Activated 
macrophages have been divided into two subsets based on their function in 
aiding specific T-helper (Th) responses, however these M1 and M2 macrophages 
are not mutually exclusive and have demonstrated a degree of plasticity in their 
ability to switch from one to the other in response to environmental signals of 
the local milieu19, 20.       
Dendritic Cells 
DCs possess extensive dendrites that are efficient in sampling the local 
environment in the search for pathogens. DCs share many of the antimicrobial 
qualities of neutrophils and macrophages and are important for innate immune 
defence. However, they are best known for their role as professional antigen 
presenting cells (APC). DCs are present in almost all tissues and organs and are 
capable of migrating out of the tissue, through the lymphatic vessels and into 
organised lymphoid tissues where they can present antigen to T cells10. As such, 
DCs are important for the activation of an adaptive immune response21. 
Increasing literature has highlighted the heterogeneity of this group of cells and 
a number of different classifications of DC subsets now exist based on their 
function and location; however the various classifications and their specific 
functions will not be discussed further and are reviewed by Merad et al22.    
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Natural Killer Cells 
NK cells are able to identify, and target, infected host cells and are activated in 
response to interferons (IFNs) and macrophage-derived cytokines10. NK cells 
produce perforin, allowing them to perforate local infected cells, and 
subsequently use these pores to insert granzymes into the target cell and induce 
apoptosis23. This is important with regards to virus-infected cells to insure that 
they are degraded from the inside, rather than being lysed and their potentially 
harmful contents exposed to the environment.   
1.2.1.2 Pattern recognition receptors 
It is important that the innate immune system can readily identify pathogens 
and other harmful agents. Should the immune system make an incorrect 
judgement, a misdirected immune response would be harmful to the host, as is 
the case in many autoimmune disorders. As such, the innate immune system has 
developed a method of identification that relies on a number of pattern 
recognition receptors10, 24. PRRs have evolved to recognise repeating patterns of 
molecular structure that are only found in pathogens, called pathogen- 
associated molecular patterns (PAMPs), as well as endogenous molecules 
released from damaged cells known as danger-associated molecular patterns 
(DAMPs)25. Binding of PRRs can lead to a number of responses depending on the 
type of receptor and the nature of binding. These include the induction of 
phagocytosis, chemotaxis to the site of infection, the production of effector 
molecules and the initiation of adaptive immunity26. There are four classes of 
PRR families; NOD-like receptors (NLRs), retinoic-acid inducible gene (RIG)-1-like 
receptors (RLRs), C-type lectin receptors (CLRs) and Toll-like receptors (TLRs)25. 
These families, along with their respective ligands, are outline in Table 1-1. 
NLRs and RLRs, which are found in the cytoplasm, are essential for recognising 
virus infected cells and result in the production of anti-viral IFNs27. CLRs are 
membrane bound receptors characterised by the presence of a carbohydrate- 
binding domain. CLRs recognise carbohydrate structures of bacteria, viruses and 
fungi28. With regards to this thesis, TLRs are the most important PRRs and are 
discussed in detail here.  
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Toll- like receptors 
Arguably one of the most important features of the innate immune system is the 
TLR family. Charles Janeway coined the term PRR and first hypothesised that 
cells devised a mechanism of pathogen recognition in 198929, 30, but it wasn’t 
until almost 10 years later that this system was identified. TLR4 was the first to 
be described as a human ortholog of Drosophila Toll, based on the presence of 
the Toll/interleukin-1 receptor (TIR)31 motif. It is the extracellular leucine rich 
repeats (LRRs) of TLRs that allow these type 1 transmembrane glycoproteins to 
bind to PAMPs. As highlighted in Table 1-1, TLRs are found on both the plasma 
membrane and the membrane of endosomes/lysosomes, allowing them to 
recognise both intra- and inter- cellular PAMPs. Upon ligation of TLRs with their 
corresponding ligand, the TIRs will dimerise and will undergo a conformational 
change that is required for the recruitment of downstream signalling 
molecules32, 33. This triggers an intracellular signalling cascade that culminates in 
the transcription of genes encoding necessary mediators, such as inflammatory 
cytokines and chemokines. With the exception of TLR3, all TLRs signal in a 
MyD88-dependent manner to activate NF-κB and other transcription factors via a 
number of protein kinases; however some TLRs, including TLR4 and TLR7, have 
also developed alternative, MyD88-independent signalling pathways33, 34. TLRs 
recognise PAMPs and DAMPs not only to initiate an innate immune response. 
Through MyD88 deficiency, it has been shown that TLR signalling is necessary for 
mounting an effective Th1 adaptive immune response35.  
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Table 1-1 PRRs, their cellular localisation and their known ligand 
Pattern Recognition Receptor Localisation Ligand 
TLRs   
TLR1 Plasma Membrane Triacyl lipoprotein 
TLR2 Plasma Membrane Lipoprotein  
TLR3 Endolysosome dsRNA 
TLR4 Plasma Membrane LPS  
TLR5 Plasma Membrane Flagellin  
TLR6 Plasma Membrane Diacyl lipoprotein 
             TLR7 (hTLR8) Endolysosome ssRNA 
TLR9 Endolysosome CpG-DNA 
TLR10 Endolysosome Unknown 
TLR11 Plasma Membrane Profilin 
TLR12 Plasma Membrane Profilin 
NLRs   
NOD1 Cytoplasm iE-DAP 
NOD2 Cytoplasm MDP 
RLRs   
RIG-1 Cytoplasm Short dsRNA, 5’triphosphate dsRNA 
MDA5 Cytoplasm Long dsRNA 
LGP2 Cytoplasm Unknown 
CLRs   
MINCLE Plasma Membrane SAP130 
Dectin-1 Plasma Membrane Β-Glycan 
Dectin-2 Plasma Membrane Β-Glycan 
 
1.2.2 Adaptive immune system    
The adaptive immune system is not as evolutionarily ancient as the innate 
immune system. Present only in vertebrates, the adaptive immune system is a 
lymphocyte-dependent, specific response and therefore takes days to develop10. 
The adaptive immune system combats pathogens which have overcome the 
innate immune response, using more ‘pathogen-specific’ targeting. Initiating an 
adaptive immune response relies on the presentation of pathogenic antigens in 
the context of major histocompatibility complex (MHC), along with a specific set 
of co-stimulatory molecules and cytokines, to T cells in the secondary lymphoid 
organs36. Antigen presentation subsequently activates the differentiation of a 
number of T cells, some of which have the potential to initiate the production of 
a pathogen-specific humoral (antibody) response. One key advantage of the 
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adaptive immune response is that it leads to immunological memory. As 
mentioned, this highly specialised phenomenon means that subsequent 
encounters with a pathogen will induce a much stronger and faster response.  
1.2.2.1 Cells of the adaptive immune response 
 T cells 
The field of T cell biology has been an area of great interest in recent years and 
has led to a marked expansion in our understanding. As such, many different 
subsets of T cells have now been identified that are characterised and grouped 
based on their diverse effector functions and molecular phenotype. The main 
groups are naïve T cells, cytotoxic T lymphocytes (CTL), regulatory T cells 
(Treg), memory T cells (Tm) and helper T cells (Th), and within each group more 
than one subset may exist10. To go into detail about all the subsets and their 
corresponding functions would be lengthy, and is not of specific relevance to this 
thesis, therefore a very brief overview will be given.  
Most effector T cell subsets will differentiate from CD4+ naïve T cells into Th 
cells, and their fate will depend on the cytokines present during polarisation37, 
38. Amongst these subsets are the well-characterised Th1, Th2 and Th17 cells as 
well as Th22 and Th9 effector cells, which have been more recently described39. 
Th22 cells, although yet to be fully defined, have already been implicated in a 
number of inflammatory skin diseases40-42, whereas Th9 cells produce IL-9 and 
are thought to be involved in the defence against extracellular parasites 
including nematodes43-45. The differentiation of CD8+ cells into effector T cells is 
somewhat more straightforward. These cells will become CTLs and will produce 
perforin, granzymes and IFNγ to direct the killing of infected or transformed 
cells46. As such, they are particularly important with regards to viral infections 
and cancer immunology.    
B cells and antibodies 
B lymphocytes are formed in the bone marrow and are characterised by the 
possession of a B cell receptor (BCR), which exhibits specificity to one particular 
Ag10. B cells are not able to penetrate target cells directly so they are not useful 
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for virus-infected cell targeting or cancerous transformed cells. Instead, B cells 
are responsible for the production of large volumes of Ag-specific antibodies 
(Ab), or immunoglobulins (Ig), which are released into the circulation47. B cells 
can either be short lived Ab-producing cells that survive only a few days, long- 
lived plasma cells that compete for a space in survival niches in the bone 
marrow and spleen, or memory B cells that continue to circulate in the blood. 
The immunological memory conferred by long-lived plasma cells and memory B 
cells allows for rapid antibody secretion during secondary infections. 
1.2.3 Cytokines of the innate and adaptive immune system 
Cytokines are protein messengers that together act as an intercellular 
communication pathway10. They can be produced by both immune- and non- 
immune cells (including endothelial cells and fibroblasts) and they evoke a 
variety of biological activities by binding to receptors on responsive target 
cells48. Cytokines can be both pro- and anti- inflammatory and any one cytokine 
can act on many different cell types. Cytokines can act on the cell that 
produced them (autocrine), on nearby cells (paracrine) or, in some cases, on 
distant cells (endocrine). Cytokine is the name given to these proteins as a 
superfamily; however other names can be given based on particular cell targets 
or presumed functions of the individual cytokines. For example, lymphokines are 
cytokines produced by lymphocytes (T and B cells)49 whereas the term 
interleukin (IL) refers to proteins produced by leukocytes that regulate immune 
responses50. As this thesis relates to the immune response in experimental 
models of inflammation, we will focus only on cytokines relevant to immune 
function and leukocyte migration.  
1.2.3.1 Inflammatory Cytokines 
There are three classic inflammatory cytokines that are characteristic of early 
immune activation; IL-1β, IL-6 and TNFα. These cytokines act in autocrine, 
paracrine and endocrine manners to amplify and maintain the immune 
response10. Inflammatory cytokines influence the accelerated release of 
leukocytes from the bone marrow reserves and TNF upregulates vascular 
adhesion molecules on the endothelium, promoting the extravasation of 
circulating leukocytes into the inflamed tissues11, 51. In addition, inflammatory 
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cytokines are able to activate leukocytes, and non-immune cells, to produce 
more inflammatory proteins, thereby enhancing the local response. IL-1 and TNF 
are endogenous pyrogens which stimulate prostaglandin synthesis leading to a 
rise in body temperature52. This fever response can help evade thermosensitive 
pathogens and can also speed up certain metabolic processes. Inflammatory 
cytokines, specifically IL-6, are also able to induce the synthesis of acute-phase 
proteins by hepatocytes in the liver53, 54. These include C reactive protein (CRP), 
fibrinogen and serum amyloid A (SAA) protein, all of which are thought to 
promote the inflammatory response and the elimination of microbes.  
Inflammatory cytokines can also induce a number of changes to subjective 
experience and behaviour to allow an ill individual to reorganise their priorities 
during acute inflammation55. These changes, which include fever, lethargy, 
hyperalgesia, social withdrawal and increased anxiety, are the result of a 
reorganisation of actions and perceptions and are together called sickness 
behaviours56. The involvement of these cytokines in the induction of sickness 
behaviours is evident from a number of studies6, 8, 57, the details of which will be 
discussed in section 1.6.2.  
1.2.3.2 Interferons 
First discovered in 1957 by Isaac and Lindenmann58, IFNs represent a number of 
proteins that are secreted by cells and are so called on the basis of their ability 
to interfere with viral proliferation in cells. IFNs were the first of the cytokines 
to be discovered and were among the first to be used therapeutically. There are 
three groups within the IFN family, differentiated by their receptor complexes; 
type I-, type II- and type III IFNs. To date, there are nine type I IFNs, four type III 
IFNs and only one type II IFN, IFNγ59. 
IFNγ production is restricted mainly to immune cells but it binds to the widely 
expressed IFN-γ receptor (IFNGR) and plays a number of important roles in 
immune regulation60. These include the activation of macrophages, the 
facilitation of Ag presentation and the differentiation of Th1 effector cells. Thus 
IFNγ is an important mediator of both the innate and adaptive immune systems. 
The importance of this type II IFN is demonstrated using genetic strains in which 
IFNγ production, or signalling, is inhibited61. Deficiency leads to increased 
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susceptibility to a number of intracellular pathogens, as well as loss of tumour 
control62-64.  
There are seven classes of Type I IFNs; IFNα, of which there are 13 human 
subtypes, IFNβ, IFNκ, IFNε, IFNο, IFNδ and IFNτ65. All type I IFNs bind to the IFN 
α/β receptor (IFNAR) and together exhibit a greater degree of complexity as 
they can have different effects in response to different pathogens. For example, 
Type I IFNs induce a protective inflammatory response to pathogens such as 
Escherichia Coli and S. pneumonia66. However, they have been shown to 
increase susceptibility to the likes of L. monocytogenes67-69, Salmonella 
enterica70 and Staphylococcus aureus71 by supressing the innate immune 
response. This range of activity is primarily due to the multiple cellular 
responses that can result from the activation of IFN-stimulated genes (ISGs) and 
their downstream effectors72. Amongst other functions, Type I IFNs have the 
ability to mediate cellular damage and inflammation, induce differentiation and 
migration and inhibit proliferation and angiogenesis73, 74.  
Type III IFNs are the most recent to be discovered and are known to bind to the 
IFN-λ receptor (IFNLR) expressed on epithelial cells, but are not as well 
characterised as type I and II IFNs75. There are three type III IFNs; IFNλ1, IFNλ2 
and IFNλ3, although a fourth member of the group, IFNλ4, has been recently 
described76. Type III IFNs are thought to share a number of common biological 
functions with type I IFNs, including anti-proliferative and anti-viral properties, 
which is perhaps surprising as type I and type III IFNs are produced in response to 
different stimuli and bind different receptors expressed on different cell types75.  
Interferon Stimulated Genes 
The production of IFNs, as the result of PRR ligation, leads to the activation of 
the JAK-STAT signalling pathway and the transcription of a broad set of genes 
called interferon stimulated genes77. Hundreds of these genes have been 
identified using oligonucleotide arrays, however few have been extensively 
characterised in terms of their effector functions and those that have are mainly 
reliant on in vitro data78. In vivo experimentation, even with the use of knock-
out mice, has been hindered by the redundancy of the ISG family, which has 
made it more difficult to decipher the specific functions of an individual gene. 
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Broadly however, ISGs and their products exhibit many antiviral functions and 
together they are able to interrupt almost any step of the viral lifecycle79. Those 
that have been further investigated include the IFN-inducible transmembrane 
(IFITM) family, that block endolysosomal-mediated virus entry into cells80, 81, 
SOCS proteins and USP18 that are negative regulators of IFN signalling and zinc-
finger antiviral protein (ZAP)82, 83, and the IFN-induced protein with 
tetratricopeptide repeats (IFIT) family, the OAS-RNaseL pathway, and PKR which 
all interfere with viral translation80, 84.   
1.2.4 Chemokines 
Chemokines, or chemotactic cytokines, are a family of cytokines that are 
defined by the presence of a highly conserved cysteine motif85. To date, more 
than 50 chemokines and receptors have been identified making the chemokine 
family the largest family amongst cytokines. Chemokines have been divided into 
four subfamilies based on the number and spacing of their conserved cysteine 
motif and are named CCL, CXCL, XCL and CX3CL (Figure 1-1)86. In 1987, the 
chemoattractant activity of CXCL8 in the recruitment of neutrophils was 
established, and subsequently chemokines have become best known for their 
ability to mediate directed chemotaxis87-90. Chemokines are classically involved 
in the regulation and migration of leukocytes; however they have been widely 
implicated in a number of other essential processes including angiogenesis91, 
embryogenesis92 and tissue repair93. Between 1995 and 1996 chemokines were 
also implicated in the pathogenesis of HIV when it was discovered that CCR5 and 
CXCR4 act as co-receptors for viral entry into host cells94-98. A chemokine 
receptor binding to its cognate ligand leads to a classical signalling cascade and 
downstream cellular changes. As well as being divided based on their structure, 
chemokines can be divided into two groups based on the context in which they 
function. Homeostatic chemokines are involved in a number of essential 
processes that help maintain the body in its steady state, whereas inflammatory 
chemokines are upregulated during an immune response and ensure the 
trafficking of leukocytes to and from sites of infection. However, it is important 
to note that this classification is not absolute as a number of chemokines exhibit 
dual-functions.   
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Figure 1-1 Structure of the conserved cysteine motif of the chemokine family 
The chemokine family is based on the presence of a conserved cysteine motif. The four sub-
groups of the chemokine family are so named based on the number and spacing of the cysteine 
residues as shown.  
 
1.2.4.1 Homeostatic chemokines 
Homeostatic chemokines are constitutively expressed in the steady state and are 
essential for regulating a number of key developmental and homeostatic 
functions. These include, but are not limited to, the homing of haematopoietic 
stem cells to their bone marrow niches99, the direction and distribution of 
immature lymphocytes within lymphoid organs100 and the control of stem and 
progenitor cell migration during organ development92. For example, CCL19 and 
CCL21 are constitutively expressed in the secondary lymphoid organs and, 
through their receptor, CCR7, serve to mediate interactions between DCs and T 
cells within lymphoid follicles101, 102. Such interactions are essential for 
regulating the immune system in the steady state and the importance of these 
chemokines is confirmed in the phenotypes of mutant mice. Mice deficient in 
CCR7 present with disruption in the spatial organisation of lymphoid organs, as 
well as a disruption in T cell and DC migration and an impaired ability to mount 
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an antigen-specific inflammatory response102-104. The CXCL12:CXCR4 axis is 
another important relationship with regards to homeostatic function. CXCL12, 
also known as stromal cell-derived factor 1 (SDF-1), was the first chemokine to 
evolve and is highly conserved across many species105. CXCL12 is essential for 
development as mice deficient in CXCL12, or its receptor CXCR4, die perinatally 
as the result of abnormalities in cerebellar neuronal migration and 
haematopoiesis106, 107. In addition to its involvement in development, CXCL12 
regulates a number of essential steady-state processes in the mature CNS, and 
functions to maintain haematopoietic stem/progenitor cell (HSPC) 
homeostasis108.     
1.2.4.2 Inflammatory chemokines 
Inflammatory chemokines are significantly upregulated in response to infection 
and inflammation, and are best known for their role in regulating the migration 
of appropriate leukocytes to sites of inflammation109. The chromosomal 
clustering of inflammatory chemokines suggests that they evolved rapidly in 
response to new pathogens, for example CC chemokines ligands 1-5 are found on 
chromosome 17, whereas CXC chemokine ligands 1-11 are clustered on 
chromosome 4110. Generally, inflammatory chemokines bind many receptors, 
conferring greater promiscuity than their homeostatic counterparts, which are 
normally restricted to just one or two receptors. For example, CCL5, which is of 
relevance to this thesis, binds three receptors, CCR1, CCR3 and CCR585. This 
means that any cell type expressing any one of these receptors, which includes 
specific monocyte and T cell subsets, will be responsive to this chemokine 
ligand. Thus the expression of any inflammatory chemokine will result in the 
recruitment of a range of different cell types. Similarly, chemokine receptors 
are not necessarily restricted to any one chemokine ligand. Chemokines CXCL9-
11 are IFN-inducible genes that all bind to the same receptor, CXCR385. This 
receptor is predominantly expressed on activated T cells and so these 
chemokines are normally secreted during Th1 cell-mediated immune 
responses111.    
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1.2.5 Chemokine receptors 
Chemokines exert their function by binding to chemokine receptors. Chemokine 
receptors are G protein-coupled receptors which contain a seven 
transmembrane-spanning domain (Figure 1-2)10. All chemokine receptors have an 
approximate length of 350 amino acids and consist of an extracellular N-
terminus and an intracellular C-terminus109. The N-terminal end, which binds to 
the chemokine, is important for ligand specificity, whereas the C-terminal end 
confers the intracellular signalling cascade following ligation. The DRYLAIV 
motif, found on the second intracellular loop of the receptor, is important for 
the coupling of G-proteins, which are necessary for mediating downstream 
signalling112. To date, 18 chemokine receptors have been identified which, like 
chemokines, are divided into four sub-families (CCR, CXCR, XCR and CX3CR) 
based on the ligands they can bind to113. Chemokine receptors will only bind to 
ligands from one sub-family; however they can bind to several individual 
chemokines within that family. Receptors, like the ligands, can be divided into 
two groups based on their function; homeostatic and inflammatory. 
Inflammatory receptors bind to many different ligands, for example CCR5 and 
CXCR2 can both bind to as many as seven different ligands85. In contrast, 
homeostatic chemokine receptors are more faithful, often binding only one or 
two ligands. The full complexity of chemokine: receptor interaction is shown 
diagrammatically in Figure 1-3. 
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Figure 1-2 Schematic of a chemokine receptor 
Chemokines exert their functions through ligation with chemokine receptors, which are seven 
transmembrane-spanning G protein-coupled receptors. Interactions involve multiple regions of the 
ligand and the receptor, with particular relevance for the N-terminal domains.   
 
1.2.5.1 Atypical chemokine receptors 
In addition to the chemokine receptors already mentioned, there are four 
receptors that are considered ‘atypical’ due to their lack of classical 
downstream signalling114. These atypical chemokine receptors (ACKRs) are called 
Duffy antigen receptor for chemokines (DARC), D6, CXCR7 and CCRL1, although a 
standard nomenclature has recently been developed and they are now known as 
ACKR1, ACKR2, ACKR3 and ACKR4, respectively115. ACKRs have a seven 
transmembrane spanning domain structure; however they are unable to couple 
with G-proteins due to the missing, or modified, DRYLAIV motif of the second 
intracellular loop116. Although ACKRs are considered ‘silent’, Boronni et al and 
Rajagopal et al have recently reported that ACKR2 and ACKR3, respectively, are 
able to signal downstream in a β-arrestin-dependent, G-protein-independent 
manner117, 118. However, this signalling is unable to induce the classical cellular 
responses we see as the result of ligand binding to other chemokine receptors, 
such as cellular migration. ACKR1 and ACKR2 bind a large number of chemokine 
ligands that are exclusively inflammatory in function. As such, these ACKRs fine 
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tune chemokine ligand gradients by scavenging, storing or transpresenting 
ligand116. 
 
ACKR2 
ACKR2, formerly known as D6, is one of four atypical chemokine receptors and is 
expressed on lymphatic endothelial cells (LECs), trophoblasts and some 
leukocytes119, 120. It binds many CC chemokines (Figure 1-3), all of which are 
classically inflammatory in nature. Upon ligation, ACKR2 will internalise and 
destroy its ligand before circulating back to the cell surface121. For this reason, 
its effects are considered anti-inflammatory, acting as a scavenger to clear 
inflammatory chemokines from the local milieu120. This proposed role of ACKR2 
has been supported by a number of studies in a range of disease models. For 
example, ACKR2-deficient mice have been shown to be more susceptible to a 
range of skin based inflammatory pathologies122, including chemically induced 
skin tumours123.   
With regards to the CNS, ACKR2 is highly expressed in the dentate gyrus of the 
hippocampus, a region of the brain that is classically associated with adult 
neurogenesis. However, its role in this location is unclear, with no clear 
abnormalities being seen in the ACKR2-null mice.  
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Figure 1-3 Complexity of chemokine family interactions 
Chemokine receptor: ligand interactions and atypical chemokine receptor: ligand interactions, 
highlighting the complexity and promiscuity of the chemokine family. The colour corresponds to 
specific receptor subfamilies: CCR (blue), CXCR (purple), CX3CR/ XCR (orange) and ACKR 
(green). 
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1.2.6 Chemokines in disease  
Chemokines and chemokine receptors are essential for the coordinated 
movement of leukocytes during inflammation and infection. During an acute 
response, the work of the chemokine family is, predominantly, beneficial to the 
host. However, in some cases of chronic inflammation or infection, chemokines 
can be detrimental and are therefore implicated in the pathogenesis of many 
diseases. The role of chemokines in CNS inflammation, which is particularly 
relevant to this thesis, is discussed in more detail in Section 1.4.3. In order to 
demonstrate the importance of chemokines, their role in some of the most 
prominent chemokine-mediated diseases is discussed here. 
Human immunodeficiency virus (HIV)  
HIV was isolated for the first time in 1983124; however it took over a decade for 
the mechanisms of transmission to be identified. To gain entry into host cells, 
the HIV-1 envelope glycoprotein 120 (gp120) must bind to CD4, along with one of 
two chemokine receptors that function as co-receptors125. CXCR4 and CCR5 were 
identified as the co-receptors that facilitate HIV entry into host cells after it was 
discovered that CCL3, CCL4 and CCL5, produced by CD8+ cells, were HIV-
suppressive factors94-98, 126, 127. HIV-1 variants that use only CCR5 for entry are 
called R5, whereas those that use only CXCR4 as a co-receptor are referred to as 
X4. If a virus can use both chemokines as co-receptor, they are considered to be 
dual tropic and are called R5/X4128. During early infection, R5 tropic viruses 
dominate and are preferentially transmitted between hosts, whereas X4 viruses 
are more common during the later stages of the disease when patients progress 
towards AIDS129.  
 
A small percentage of the population have a naturally occurring mutation in the 
gene encoding for CCR5, called CCR5Δ32. Around 1% of the Caucasian population 
of European origin are homozygous for this 32bp deletion and are resistant to 
HIV as they do not express a functional CCR5 required for viral entry into host 
cells130. This mutation does not appear to have any adverse effects in healthy 
humans; however people possessing this mutation are thought to be more 
susceptible to severe forms of WNV131. 
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Multiple Sclerosis and EAE 
Multiple sclerosis (MS) is an autoimmune disease characterised by the loss of 
motor and sensory functions as a result of demyelination and axonal damage132. 
MS can be either progressive or relapsing-remitting, with the latter 
characterised by periods of remyelination and amelioration; however MS will 
ultimately lead to paralysis. The pathogenesis of MS has been widely studied 
through the use of animal models, the most common of which is experimental 
autoimmune encephalomyelitis (EAE).  This model is induced using myelin 
specific Th1 and Th17 cells, produced in response to immunisation with myelin 
oligodendrocytes glycoprotein (MOG) in combination with adjuvant, and is 
characterised by the influx of inflammatory leukocytes into the CNS133.  
Chemokines are important in the pathogenesis of MS and EAE, as discussed in 
Section 1.4.3. In brief, many chemokines and their receptors are highly 
upregulated in the brains of MS patients and in EAE mice. Mice deficient in the 
chemokine receptors CCR1, CCR2 and CCR6 display increased resistance to EAE, 
experiencing delayed onset of disease134, 135. However, Gaupp et al have 
suggested that the promiscuity of chemokines means CCR2 deficiency is 
compensated for with the increased expression of other chemokines136.  
1.3 Components of the central nervous system 
The central nervous system consists of the brain and spinal cord, which are 
protected by the skull and vertebral column, respectively, along with three 
layers of membrane called the meninges. The CNS is the processing centre for 
the nervous system and it is responsible for relaying information to, and from, 
the peripheral nervous system. The brain controls both a number of very basic 
functions, including appetite, temperature regulation and coordination of 
movement, as well as more sophisticated functions such as cognition and 
memory. The CNS was once considered “immune-privileged”, meaning it was 
isolated from events in the periphery, including those of the immune system. 
Nowadays, the CNS is thought to be “immune-specialised”, the main difference 
being that people no longer consider the CNS separate from the rest of the body 
but rather unique, or specialised. This is for several reasons; it is protected from 
the periphery by a number of barriers, including the blood-brain-barrier (BBB) 
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and the blood-cerebrospinal fluid-barrier (BCSFB)137 (Section 1.3.2), under 
steady-state conditions, it contains fewer APCs than other peripheral tissues138 
and, until very recently, it was thought to lack a lymphatic network139, 140.  
1.3.1 Cells of the central nervous system 
1.3.1.1 Neurons 
All cells in the nervous system interact with neurons and they are therefore 
considered the basic unit of the system. Neurons consist of a cell body 
containing the nucleus and organelles, branching dendrites, which communicate 
with neighbouring neurons and an axon, along which electrochemical nerve 
signals are conducted. There are three types of neuron, sensory neurons, motor 
neurons and interneurons, which differ in structure and location, but all function 
to carry nerve signals. Individual axons called nerves, along which information is 
transmitted, are protected by a layer of Schwann cell-produced myelin, which 
increases transmission speed. As mentioned earlier, the breakdown of myelin is 
a hallmark of multiple sclerosis, a debilitating neurodegenerative disease132. 
Neurons are generally considered to be terminally differentiated and unable to 
renew, highlighting the importance of their protection. However, it has been 
shown that adult neurogenesis does occur within specific brain regions141, 142. 
This will be discussed further in section 1.6.4. 
1.3.1.2 Glia 
Glial cells are distinguishable from nerves as they are not directly involved in 
synaptic transmission and electrical signalling, although they do function to 
support neurons in this role. In addition, glial cells modulate the response to 
neural injury, maintain the ionic milieu of nerve cells and provide a scaffold for 
certain aspects of neural development. The three subtypes of glia are discussed 
below.    
Microglia 
Representing around 10% of the adult brain cell population, microglia are tissue-
resident macrophages that are found throughout the parenchyma. Like 
macrophages, microglia are phagocytic cells which possess the capacity to 
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become activated in response to various triggers and express low levels of many 
classic macrophage markers, including CD45, CD11b, F4/80 and MHC143. 
However, unlike conventional myeloid immune cells, terminally differentiated 
parenchymal microglia are thought to be derived from cells originating in the 
yolk sac in an IRF8- and PU.1- dependent manner, and are present in the 
embryonic brain from as early as E9.5144. Conventional CNS-microglia, derived 
from blood monocytes, can be found around the boundaries of the brain, for 
example in the choroid plexus, the meninges and the perivascular space145. 
Microglia are the only immune cells found within the parenchyma and are 
responsible for monitoring the intraneuronal space, which they do so by 
screening the local environment for damage every few hours with motile 
processes. When damage is sensed, perhaps via adenosine triphosphate (ATP) 
release by neighbouring cells or extracellular calcium, microglia enter an 
activated state and, like macrophages, can polarise towards M1- or M2- like 
phenotypes146.    
Microglia express many PRRs, including TLRs 1-9 and various scavenger 
receptors, and are thus able to respond to a wide range of pathogens, both viral 
and bacterial147. PRR ligation in microglia induces the synthesis of a number of 
pro-inflammatory cytokines including IL-1β, IL-6, IL-12 and TNFα as well as 
inflammatory chemokines147. Activated microglia are able to kill neurons directly 
or indirectly through the actions of these pro-inflammatory mediators. Their 
broad and generalised response to pathogens means that microglial activation is 
a hallmark of most CNS pathologies. To ensure that microglial activation itself is 
regulated, interactions between the neuronal CD200 receptor and the microglial 
CD200 ligand maintains microglia in a quiescent state148, 149. Mice deficient in 
CD200 show signs of spontaneous microglial activation and a disordered 
arrangement150. CX3CL1 is also thought to play an important role in maintaining 
microglia in a quiescent state under homeostatic conditions151. Cross-talk 
between neurons and microglia in a CX3CL1-dependent manner is thought to 
regulate neurogenesis (Section 1.6.4), synaptic plasticity, motor learning and 
cognitive function152. Aged rodents present with a reduced level of CX3CL1 
expression, along with a reduction in neurogenesis and an increase in 
inflammation. When supplemented with CX3CL1, hippocampal neurogenesis is 
restored and microglia return to a resting state153.   
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Astrocytes 
Astrocytes, which are restricted to the brain and the spinal cord, are the most 
numerous and heterogeneous glia in the brain and are found in the extracellular 
spaces between neurons. In the healthy CNS, astrocytes are primarily 
responsible for maintaining a homeostatic chemical environment within these 
spaces in order to support neuronal signalling, and do so by regulating the 
concentration of substances including potassium ions154, 155. The expression of 
membrane neurotransmitter receptors, their ability to remove excess glutamate 
and their secretion of a number of gliotransmitters means that astrocytes are 
important for regulating neurotransmission and synapse function156. In addition, 
their close proximity to blood vessels, and their ability to produce proteins such 
as prostaglandins of the E2 series (PGE2) and nitric oxide (NO), allows them to 
control blood flow as well as to regulate energy exchange between the blood 
and surrounding cells157, 158. 
In the event of CNS injury or disease, astrocytes undergo a number of functional 
and cellular changes that together comprise the process of reactive astrogliosis. 
During reactive astrogliosis, astrocytes can lose, or gain, certain functions which 
can consequently exert either beneficial or detrimental effects on the 
environment, including glial scar formation159. Many intercellular components 
are capable of triggering reactive astrogliosis. These include, but are not limited 
to, inflammatory cytokines, TLR ligands, neurotransmitters, purines, reactive 
oxygen species (ROS), hypoxia and products of neurodegeneration, such as β-
amyloid160-162. All of these factors can be released by other CNS cells in response 
to a variety of insults. Activated actrocytes produce monocyte and neutrophil 
chemoattractants including CCL2, 3, 4 and 5 and CXCL1 and 2 respectively161, 163. 
Astrocytes may also upregulate adhesion molecules upon TLR ligation which, due 
to their anatomical location, can promote the ingress of circulating leukocytes 
from the perivascular space into the parenchyma.    
Oligodendrocytes 
Mature, myelin-producing oligodendrocytes derive from oligodendrocyte 
precursor cells (OPC) and are responsible for coating axons with the protective 
layers of membrane that are together called the myelin sheath164. Found only in 
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the CNS, oligodendrocytes can contribute to the myelination of several axons. 
Oligodendrocytes share many similarities with Schwann cells; however Schwann 
cells are found in the peripheral nervous system (PNS) and can myelinate only a 
single axon165. Myelin, which is distributed across the length of axons, with the 
exception of certain areas called the ‘Nodes of Ranvier’, provides electrical 
insulation and speeds up action potential propagation166. Therefore, 
disturbances in the myelin sheath, as the result of injury or disease, can have a 
profound effect on normal neural transmission167, 168.   
1.3.2 Barriers in the brain 
As mentioned previously, the CNS is considered to be immune-specialised, in 
part due to the physical barriers that isolate it from the periphery. These 
barriers differ in terms of their anatomical location and cellular properties, and 
are discussed here.   
1.3.2.1 The blood-brain-barrier 
The BBB, found along the capillaries, is a highly selective barrier that protects 
the brain from noxious chemicals, variations in blood composition and 
breakdown of concentration gradients169. The BBB restricts the entry of certain 
molecules into the parenchyma based on their size and polarity.  
The cellular components of the BBB are the cerebral capillary endothelial cells, 
pericytes and astrocytic feet (also known as glia limitans); however the most 
important functional component is the endothelial tight junctions which serve as 
a diffusion barrier. BBB endothelial cells are distinct from their peripheral 
counterparts for a number of reasons. They possess a relatively low number of 
vesicles, they lack fenestrae, have higher electrical resistance and they have 
evolved specialised transport systems170. Molecules and some cells can traverse 
the BBB either through the endothelial cell (transcellular passage) or between 
the cells (paracellular passage). Both the passive diffusion of neutral lipophilic 
substances (with a molecular weight less than 450) and the active transport of 
small and large hydrophilic molecules occurs transcellulary. In addition, many 
essential nutrients that are not able to diffuse are transported by specialised 
membrane proteins. Conversely, ions and solutes diffuse paracellulary down a 
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concentration gradient through the tight junctions171. These tight junctions are 
found between neighbouring endothelial cells and mediate gate function; 
preventing substances with a molecular weight greater than 180 from traversing 
the BBB through paracellular diffusion172, 173.  
In the healthy individual, most toxic substances and antigens are unable to 
traverse the BBB due to its tightly constrained intercellular junctions ; however 
its permeability increases during inflammation. This dysregulation, which allows 
the influx of leukocytes and causes brain oedema, is a characteristic of a 
number of CNS pathologies, including the archetypical neurodegenerative 
disease, MS174, 175.   
1.3.2.2 The blood-cerebrospinal fluid-barrier 
Cerebrospinal fluid (CSF), secreted primarily by the choroid plexus, is important 
for buoyancy and protecting the brain, maintaining chemical balance and 
clearing waste and toxins176. Adults will normally have a total volume of 
between 80 and 150ml of CSF, which is continually being produced and 
reabsorbed, and which circulates within the ventricular system of the brain177, 
178.  
The BCSFB comprises the choroid plexus epithelial cells, found in the vascular 
tissue of all cerebral ventricles, and the arachnoid membrane of the 
meninges179. The barrier is formed by epithelial cells and the tight junctions that 
link them. This barrier allows the free movement of small molecules across the 
endothelial cells of the choroid plexus capillaries through fenestrations and 
intercellular gaps. The BCSFB allows not only free diffusion, but also mediates 
facilitated diffusion and the active transport of molecules into the CSF.  
CSF production is driven by the active ion transport of sodium into the lateral 
ventricles, creating osmotic pressure that draws in water to the CSF space180. 
Electroneutrality is maintained by negatively charged chlorine ions which follow 
positively charged sodium ions. Thus CSF contains higher concentrations of 
sodium and chlorine than plasma, which are the main ionic constituents of CSF.         
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1.3.2.3 The circumventricular organs 
The circumventricular organs (CVO) are structures that allow the passage of 
polypeptide hormones out of the brain without disrupting the BBB181. 
Characterised by their small size, high permeability and fenestrated capillaries, 
CVOs are found around the third and fourth ventricles of the brain. The 
fenestrated nature of the endothelium means that microglia and neurons may be 
exposed to circulating mediators directly. Several hypothalamic peptide 
hormones leave the brain through the CVOs and go on to affect the anterior 
pituitary, or act peripherally following release into the circulation181. These 
include a number of hormones involved in the HPA axis (section 1.6.1) as well as 
vasopressin and oxytocin. In addition to regulating the secretion of hormones out 
of the brain, CVOs allow other substances to trigger changes in brain function. 
Hormones that are unable to cross the BBB can sometimes exert their actions on 
CVO neurons which span the BBB and project into the brain parenchyma. 
1.3.2.4 The meninges 
The meninges are a triple layer of membrane that surrounds the brain and spinal 
cord. The outer membrane, called the dura mater, is fixed to the skull and 
forms a protective sac around the inner membrane. The inner membrane, or 
leptomeninges, is formed by two thin membranes called the arachnoid mater 
and the pia mater182. The meninges are filled with CSF and are best known for 
offering protection to the CNS. Not only do they constitute a physical barrier 
around the CNS, but the fluid-filled cavity within the meninges cushions the 
brain from damaging events. The meninges are also thought to be important for 
maintaining CNS homeostasis and are able to secrete a number of trophic factors 
such as growth factors and cytokines, including fibroblast growth factor (FGF) 2, 
CXCL12 and retinoic acid183-185. During embryogenesis, the meninges are 
essential for correct CNS development, although the exact mechanisms by which 
they contribute remain to be fully understood.     
1.3.3 Immune surveillance and antigen drainage 
Although the CNS is protected by the BBB and BCSFB, the healthy brain is under 
continual surveillance. The sentinel duties of a limited number of cells involved 
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in immune surveillance under steady-state conditions ensures that homeostasis is 
maintained186.  
As mentioned in Section 1.3.1.2, microglia are one of the key cell types involved 
in immune surveillance of the CNS. Due to their expression of a number of PRRs, 
microglia are sensitive to a wide range of insults and their activation leads to 
the production of pro-inflammatory agents that heighten the inflammatory 
response. Thus, microglia are able to efficiently sample the local environment 
and respond effectively to danger. 
Present in small numbers, leukocytes including T cells, macrophages and DCs 
patrol specialised areas of the CNS, outwith the parenchyma, for harmful 
agents. These are all possible sites of extravasation and include the non-
fenestrated vascularised stroma of the BCFSB surrounded by choroid plexus 
epithelial cells, the perivascular space and the postcapillary venules that enter 
the parenchyma directly. Perivascular macrophages are a minor, bone-marrow 
derived, CNS population found within the perivascular spaces adjacent to small 
and medium blood vessels187. PVMs can shroud local blood vessels with long 
processes and are activated in response to neural injury or death as well as 
cytokines or LPS in peripheral blood. Upon becoming activated, these cells can 
synthesise IL-1 production and function as APCs188. DCs, although not detected in 
the parenchyma, are abundant throughout the meninges and choroid plexus of 
healthy rodents and humans, and are found at low levels in the CSF189-192. The 
strong upregulation of MHC and co-stimulatory molecules in the CNS following 
infection and other CNS pathologies suggests that many cells in the CNS possess 
the ability to present antigen193. However, around 80% of immune cells found in 
the CSF are T cells, the majority of which are CD4+ central memory T cells (TCM), 
whose passage into the CSF is facilitated by CCR7, CXCR3, L-selectin and a 
number of other adhesion molecules194. TCM cells remain in the CSF for several 
hours sampling antigen presented on central APCs, before returning to the 
bloodstream. Activation of TCM cells by encountering their specific antigen 
initiates a neuroinflammatory response through T cell effector functions194.  
Some reports have suggested that resident memory T cells can remain in the CNS 
for up to a year after initial infection, far longer than TRM cells in other 
peripheral organs, suggesting the CNS is isolated from recirculating memory 
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pools195, 196. This is most commonly reported following viral infection and it is 
therefore possible that the CNS has a specialised ability to retain CD8+ TRM cells 
that are primed to respond to a secondary insult with their cognate antigen197. It 
is also possible that low levels of activated T cells can enter the brain 
parenchyma. Wekerle et al have used encephalitogenic T cells to show that 
activated T cells are able to cross the BBB in Lewis rats, whereas naïve T cells 
cannot198. If these cells do not find their antigen they simply traffic back into 
the blood or die.       
Prior to June 2015, it was presumed that the CNS lacked a lymphatic network; 
however, using injectable tracers such as Indian ink199 and quantum dot 655200, 
routes by which antigens and cells can traffic out of the brain were identified201. 
In animals and humans, CSF, containing free antigen, drains from the 
subarachnoid space to the nasal mucosa and cervical LNs via a number of 
channels that pass through the cribriform plate of the ethmoid bone202. 
Conversely, interstitial fluid (ISF) and solutes from the brain parenchyma drain 
to the cervical LNs via a separate route, first by diffusion through the 
extracellular spaces and then along the walls of the cerebral capillaries and 
arteries203. Recently, studies by Louveau et al attempted to investigate the 
mechanisms of meningeal immune surveillance and uncovered the existence of a 
functional CNS lymphatic network140. Using sophisticated techniques, whole 
mount meningeal immunohistochemistry revealed the presence of classical 
Prox1+ CD31+ LYVE-1+ Podoplanin+ VEGFR3+ CCL21+ lymphatic endothelial cells 
lining the dural sinuses. Furthermore, ligation studies suggest a physical 
connection between meningeal lymphatic vessels and the deep cervical LNs. The 
presence of T cells, B cells and DCs in meningeal lymphatic vessels under normal 
conditions suggests this system participates in steady-state immune cell 
trafficking through the CNS. The discovery of this network has led to the re-
evaluation of the mechanisms of immune surveillance in the CNS and could 
implicate malfunctioning meningeal lymphatics in a variety of neurological 
diseases204. To ensure that the CNS responds appropriately to insult, cells must 
be able to monitor the local environment and present antigen to T cells when an 
adaptive immune response is required. It is clear that there are a number of 
systems in place that allow continual immunosurveillance and antigen drainage, 
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demonstrating that, in addition to its complex physical barriers, the cells of the 
CNS represent a tightly controlled surveillance system.       
1.4 Chemokines in the CNS 
Chemokine expression throughout the brain differs depending on the context in 
which it is assessed. Many chemokines, particularly homeostatic chemokines, are 
essential during development and continue to be important throughout life for 
maintaining a number of steady state functions205. Of course, during 
inflammation and CNS disease, the chemokine repertoire changes as 
inflammatory chemokines are produced by activated cells206. In addition, all 
major cell types in the brain have been shown to express a range of chemokine 
receptors and possess the ability to produce a number of chemokines 
themselves207. This suggests there is an independent chemokine signalling circuit 
within the brain, indicating that their role within the CNS may extend beyond 
localised immune cell mobilisation.   
1.4.1 Development 
Appropriate cellular migration and organisation is essential for the developing 
CNS and relies upon a number of chemokines that have been shown to play a 
role in regulating such processes. The most prominent of these chemokines is 
CXCL12, and its receptor CXCR4, which have already been mentioned briefly. 
CXCL12, considered the primordial chemokine, is extensively expressed 
throughout the developing CNS208. Its importance is demonstrated in mice 
deficient for CXCL12 or CXCR4, which die perinatally and often present with 
developmental abnormalities of the brain, specifically disorganisation of the 
cerebellum. Cerebellar development in the normal embryo is an organised 
process of CXCL12-dependent migration and maturation of precursor cells which 
results in the formation of cerebellar granule neurons208. Without the guidance 
from this chemokine, migration is impaired and the granule neurons form 
ectopically. As well as regulating the migration of granule progenitors, CXCL12 is 
thought to hold them in a proliferative environment and facilitate their 
proliferation by interacting with a particular mitogen, Sonic hedgehog209. Thus, 
not only does the CXCL12-CXCR4 interaction ensure the appropriate organisation 
of the cerebellar granule neurons, they also regulate proliferation. In a similar 
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fashion, the granule layer of the dentate gyrus is impaired in CXCR4 KO mice and 
fails to develop properly210. These mice do possess dentate granule neurons; 
however they are fewer in number and can be found ectopically within the 
normal migratory stream, which extends from the dentate neuroepithelium. This 
suggests that the absence of CXCR4 has an effect on both the proliferation and 
migration of the precursor cells. Although heavily implicated in development, 
CXCL12 and CXCR4 continue to be expressed by granule neurons and precursor 
cells in adult animals, suggesting that the role of this chemotactic pair does not 
cease with development211.  
CXCR2 has also been implicated in spinal cord development by mediating the 
migration of oligodendrocyte precursors. These precursor cells originate in the 
ventricular zone and migrate to the white matter where they proliferate and 
differentiate212. Their arrest in the white matter is thought to be dependent on 
CXCL1 signalling through its receptor CXCR2 as the spinal cords of CXCR2 null 
mice exhibited a reduction in the number of oligodendrocytes, many of which 
were found abnormally clustered at the periphery213.   
1.4.2 Homeostasis 
The expression of certain chemokine receptors and ligands in the brain continues 
into adulthood irrespective of the presence of inflammatory stimuli, suggesting 
that these chemokines may have a role in maintaining certain brain processes in 
the steady state.  
A number of studies have suggested a role for chemokines in regulating several 
neuroendocrine functions such as feeding, temperature and water balance207, 214, 
215. A drawback of a lot of these studies is that they involved either injection of 
lipopolysaccharide (LPS) or injection of a chemokine directly and are therefore 
not ‘steady-state’. However, the fact that an inflammatory stimulus or an 
increase in expression can induce a change in these functions suggests that 
chemokines are homeostatic regulators. For example, CXCL8, CCL3, CCL4 and 
CCL5 have all been shown to induce hyperthermia216-219 and CXCL8, CXCL10, 
CCL2 and CCL5 can reduce short term food intake when injected 
intracerebroventricularly (i.c.v)220, 221.  
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It has also been suggested that certain chemokines could function as 
neurotransmitters. To help define neuropeptide ability as neurotransmitters, a 
list of five criteria was established to which they should comply. The list 
stipulates that they should be localised at nerve terminals, they should co-
localise with other neurotransmitters at the nerve terminal vesicles, they should 
show release following membrane depolarisation, they should exhibit 
electrophysiological effects and the receptors for the peptide should be 
expressed both pre- and post-synaptic222. Although chemokines do not adhere to 
all five of the stipulations, they do present a strong case for acting as 
neurotransmitters. It has been shown in rats that CXCL12 and CCL2 are able to 
co-localise with both cholinergic and dopaminergic neurons, depending on the 
brain region of interest223, 224. The spatial distribution of chemokine receptors in 
relation to the cells that synthesise their ligands suggests that they must be 
released by nerve endings or dendrites. For example, CX3CR1, located on 
neurons and microglia, is stimulated by its ligand CX3CL1, which is expressed 
only by neurons225. In cultured mouse hippocampal and hypothalamic neurons, 
Guyon et al showed that CXCL12 can directly modulate voltage-dependent 
membrane currents, the effects of which can be blocked using the CXCR4 
antagonist AMD3100226. In addition, patch-clamp recording of cultured rat spinal 
cord neurons showed that CCL2 could regulate neurophysiology by modulating 
GABAergic neurotransmission227. Together, these findings demonstrate that 
chemokines can have electrophysiological effects in the CNS. Chemokine 
receptors can be expressed on pre-synaptic neurons that also synthesise the 
ligand. Like classical neurotransmitters such as dopamine, the dual expression of 
both a ligand and its cognate receptor by the same neuron suggests some kind of 
autocrine function. Interestingly, Callewaere et al showed that, in rats, CXCL12 
not only co-localises with arginine vasopressin, but also inhibits its release from 
hypothalamic dendrites through autocrine mechanisms involving pre-synaptic 
CXCR4228.   
1.4.3 Infection and inflammation 
In the event of inflammation or disease, either within the CNS or in the 
periphery, the chemokine repertoire in the brain is altered. The primary role of 
chemokines during neuroinflammation is facilitating the transmigration of 
leukocytes across the physical barriers of the brain229. In this way, using the 
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process which is described in detail in section 1.5.1, certain inflammatory 
chemokines have been shown to induce the infiltration of certain leukocyte 
subsets. For example, CCL2, CCL3, CCL4 and CCL5 induce the activation and 
chemotaxis of T cells and monocytes230-232. In addition, blocking certain 
chemokines and receptors changes the leukocyte repertoire within the CNS231, 
233. Although to an extent chemokine involvement in CNS inflammation appears 
to differ between pathologies and may be specific to the nature of the insult, 
there is a degree of overlap and certain conditions have provided a generalised 
insight into chemokine involvement in neuroinflammation.  
Michlmayr et al have used models of viral encephalitis to show that many, but 
not all, inflammatory chemokines are upregulated in the brains of treated 
mice234. They report that, 7 days following infection with Semliki forest virus 
(SFV), inflammatory chemokine ligands, in particular CCL2, CCL5, CXCL9 and 
CXCL10, are significantly upregulated, in some cases with a 90-fold increase. 
This expression pattern coincides with the influx of a number of leukocyte cell 
types into the brain, including NK cells, myeloid cells, B cells and, most notably, 
CD3+ T cells. Using a series of chemokine receptor blockers, they showed that 
this cellular migration into the CNS was mainly reliant on the actions of CCR5, 
CCR2 and CXCR3. Others have reported, both in vivo and in vitro, that at earlier 
time points following infection, inflammatory chemokines are secreted by 
activated, or virally infected, cells in the CNS including astrocytes, microglia and 
endothelial cells235, 236. Moreover, neutrophil infiltration is said to occur in 
several viral models through the CXCR2/CXCL1 axis237, 238. This reportedly 
heightens CNS inflammation by increasing the permeability of the BBB239.     
It is well documented that leukocyte infiltration is a pivotal event in the 
pathogenesis of MS. Several chemokines have been shown to help mediate this 
process through their expression on the vascular endothelial lumen240. Studies 
have reported the incidence of CCR7+ cells in MS lesions, which are likely 
infiltrating in response to the ligands CCL19 and CCL21241. There is still some 
debate regarding the phenotype of these cells; however 90% of leukocytes in the 
CSF of MS patients are thought to be CCR7-expressing central memory T cells. 
Elevated levels of CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CXCL1, CXCL9 and 
CXCL10 have been described in MS, and the corresponding mouse model 
experimental autoimmune encephalomyelitis240. The expression pattern of these 
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proteins is thought to differ temporally and spatially adding to the complicated 
nature of the disease. With regards to EAE specifically, CCL2 is thought to be of 
particular importance. One of the major cellular infiltrates in EAE is monocytes, 
which are recruited into the CNS in a CCR2-dependent manner, and which are 
able to differentiate into microglia242. Many studies have confirmed the 
involvement of CCR2 and CCL2 using KO mice136, 243-245. However, reports have 
suggested that depleting monocyte infiltration is compensated for by 
supplementary neutrophil infiltration, indicating that chemokines work in 
concert to ensure that a range of leukocyte subsets can access the brain 
parenchyma136.    
Although very little has been done to investigate the chemokine repertoire in 
the CNS in response to peripheral inflammation, D’Mello et al have reported that 
monocytes are recruited into the brain during hepatic inflammation. They have 
shown that cerebral microglia, activated by peripherally induced TNFα, recruit 
monocytes in a CCL2:CCR2-dependent fashion230.  
Together, reports suggest that CNS inflammation, and perhaps also peripheral 
inflammation, leads to increased expression of many chemokines and cytokines 
which can mediate cellular influx into the brain. Chemokines and their receptors 
are therefore potential therapeutic targets for the regulation of inflammatory 
pathologies of the CNS. 
1.5 Routes of immune-to-brain communication 
Under homeostatic conditions, the barriers described in section 1.3.2 are 
sufficient to ensure that the CNS environment is protected and maintained. 
However, it must be possible for the CNS to respond to inflammation in the 
periphery, otherwise the manifestation of sickness behaviours in response to 
systemic infection would not occur. There are many different routes by which 
the immune system can communicate with the brain6. Most, at least on some 
level, can be mediated by inflammatory cytokines and the secondary mediators 
that they induce5, 246. The different methods of communication will be described 
below.   
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1.5.1 Leukocyte infiltration 
Inflammation normally requires the extravasation of leukocytes from the blood 
into the tissue through the endothelial cell barrier, which occurs via a multi-step 
process called the leukocyte adhesion cascade247. Inflammatory cytokines, 
including IL-1β and TNFα, LPS and histamine activate the endothelium resulting 
in the release of selectins51. The prototypical interaction is between P-selectin, 
which is released from Wiebel-Palade bodies and platelet granules, and the 
carbohydrate structure P-selectin glycoprotein 1 (PSGL-1) found on activated 
leukocytes. This interaction leads to the rolling of leukocytes along the surface 
of the endothelium. Immobilised chemokines expressed on the surface of the 
endothelium will bind leukocytes that express the corresponding receptor, 
initiating an intracellular signalling cascade which results in a conformational 
change and the activation of integrins. These cell-surface integrins will bind to 
cell adhesion molecules expressed by endothelial cells, including intracellular 
adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1), 
and will result in the firm adhesion of selected leukocytes.  Finally, these 
leukocytes will undergo diapedesis and will transmigrate across the endothelium 
into the tissues, either directly through the cells or through the junctions 
between them. Entry into the CNS normally relies on transcellular migration 
alone due to the tight junctions found between the endothelial cells of the 
BBB248.   
Under steady state conditions, this process is tightly regulated by the BBB and 
BCSFB and few leukocytes are able to enter the parenchyma. However, in the 
event of peripheral or central inflammation, this selection process becomes 
more relaxed. Leukocyte infiltration and BBB disruption are classic hallmarks of 
many inflammatory conditions of the CNS including MS, stoke, traumatic brain 
injury (TBI) and viral encephalitis249-252. Mechanisms regulating BBB permeability 
and cellular infiltration are incompletely understood, but are thought to involve 
the effects of inflammatory cytokines and chemokines on BBB endothelial cells.  
Many of the findings regarding leukocyte infiltration into the brain have 
implicated factors involved in normal cellular migration, suggesting an increase 
in activity rather than a change in mechanism. In the steady state, the adhesion 
molecules ICAM-1 and VCAM-1 are barely detectable in normal brain cells; 
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however they are upregulated on endothelial cells and glia under a number of 
inflammatory conditions including stroke, LPS challenge and TBI253, 254. In vivo 
and in vitro studies using ICAM-1-deficient mice have shown a definitive role for 
ICAM-1 in facilitating leukocyte migration into the CNS following TBI255. It is 
thought that ICAM-1 signalling induces cytoskeletal alterations in brain 
endothelial cells that facilitate a change in the BBB permeability. In a mouse 
model of acute cytokine-induced meningitis, increased BBB permeability and 
leukocyte accumulation in the CSF are seen. However, both of these phenotypes 
are almost completely abolished when the model is applied to mice doubly 
deficient in P- and E-selectin256. The upregulation of cellular adhesion molecules 
on brain endothelium and trafficking leukocytes appears to be induced by 
inflammatory agents and cytokines directly. Wong et al have used primary 
cultures of human brain microvessel endothelial cells to show that treatment 
with LPS or inflammatory cytokines upregulated ICAM-1 in a concentration- and 
time-dependent manner257. Similarly, Roe et al used cultures of human brain 
microvascular endothelial cells to show that infection with West Nile virus (WNV) 
upregulated ICAM-1, VCAM-1 and E-selectin expression and enhanced leukocyte 
adhesion252. In MS, Th1 inflammatory cytokines, including IFNγ, TNFα, IL-1β and 
IL-6, are involved in the pathogenesis of the disease and can activate the 
expression of endothelial cell adhesion molecules258. Together, these findings 
suggest that inflammatory components promote the interaction of leukocytes 
with brain endothelium by inducing elevated adhesion molecule expression.  
Some studies have suggested that changes in BBB permeability and facilitated 
leukocyte transmigration may involve alterations in tight junction integrity259, 
260. Indeed, the breakdown of tight junctions has been noted in the vicinity of MS 
lesions249, and in vitro studies have shown that stimulation of cultured 
endothelial cells with serum isolated from relapsing MS patients provokes a 
downregulation of occludin and VE-cadherin, proteins that are important for 
tight junction integrity261. 
Whatever the mechanism, there is a plethora of literature indicating that 
leukocyte infiltration into the CNS is a key process during many inflammatory 
conditions. The consequence of this appears to differ depending on the nature of 
the insult. A model of TBI in Wistar rats found T cell infiltration and microglia 
activation to be indicative of the acute response and were capable of 
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contributing to the classic brain oedema often seen following such injury262. In 
stroke, there is mounting evidence to suggest that post-ischemic tissue damage 
in the brain is mediated by infiltrating leukocytes, including neutrophils263, 
macrophages (and activated microglia)264 and T cells265, 266. However, Fassbender 
et al have shown that infiltrating cells may not actually influence infarct size 
following transient occlusion of the middle cerebral artery267. Using histology 
and flow cytometry, these cell types were shown to have differing temporal 
recruitment patterns268, 269 which may explain the conflicting data concerning 
their effects if timing is a crucial variable. Determining whether or not leukocyte 
infiltration is beneficial or detrimental in stroke is difficult since, although these 
cell types have a damaging effect to the local tissue, immune cells are also 
important for the removal of dead neurons from the ischemic core and for 
promoting astrocytosis250.         
1.5.2 Cytokine transport 
The BBB provides a physical barrier between the brain and the periphery and is 
characterised by its highly selective nature. Under steady state conditions, the 
BBB uses specialised transport mechanisms to mediate the transendothelial 
migration of certain proteins and peptides, ensuring that the CNS is not flooded 
by humoral neurotransmitters and blood elements179.  
During CNS inflammation, cytokines can be directly secreted in the CNS by TLR 
activation in an array of cell types. However, it is also possible for cytokines 
circulating in the periphery, including those produced by cells at the CVOs and 
choroid plexus, to enter the brain by active transport. This has been 
demonstrated in a number of studies using radiolabelled inflammatory cytokines 
that have been induced in the periphery270-273. Their active transport across the 
BBB into the parenchyma occurs without disruption of the BBB itself, 
demonstrating that this mechanism of transport does not rely on a loss of 
structure. Peripheral administration of large quantities of unlabelled cytokine 
leads to the rapid saturation of this transport system, suggesting that this 
cytokine-specific transport mechanism is not the only route of communication 
between the periphery and the brain273.     
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Inflammation can influence the permeability of the BBB, with leukocyte influx 
being a characteristic of many CNS pathologies. Breakdown of BBB integrity, 
perhaps mediated through astrocytic activation, is thought to aid in the 
pathogenesis and progression of many neurological diseases, including seizure 
disorders274, Alzheimer’s disease (AD)275 and MS174. The function of active 
cytokine transporters, which normally operate at low levels, can also be altered 
by pathological conditions. Interestingly, stroke and spinal cord injury both lead 
to an increase in activity of the TNFα transporter272, 273.  
1.5.3 Humoral pathway  
The humoral pathway of communication is slower than the neural pathway and 
involves cells found within the CVOs and brain endothelial cells. Blood-borne 
proteins, including inflammatory cytokines, are able to activate brain 
endothelium directly to relay information across the BBB, or they can activate 
specific brain regions independently of the BBB, namely the CVOs276.  
Circulating cytokines are able to activate cells found within the BBB, specifically 
brain endothelial cells and perivascular macrophages (PVMs)277. Stimulation of 
these cells by inflammatory agents will lead to the release of secondary 
mediators such as PGE2, which are able to diffuse freely across the BBB278. In 
addition to activating BBB components, circulating proteins are able to enter 
into the parenchyma at areas lacking an intact BBB, namely the CVOs. As 
discussed previously (section 1.3.2.3), hormones which are capable of activating 
the hypothalamic-pituitary-adrenal (HPA) axis may come into direct contact with 
neurons and microglia due to the fenestrated nature of the endothelium181. The 
activation of neurons at the CVOs can be confirmed by c-Fos induction279, 280. In 
addition to neuronal activation, activated microglia can initiate a wave of 
stimulation to neighbouring structures, spreading the response throughout the 
brain parenchyma281. 
1.5.4 Neural pathway and the cholinergic anti-inflammatory 
pathway 
Immunity is coordinated by neural circuits that operate reflexively. The afferent 
arc, consisting of nerves that sense injury or inflammation, activates the 
efferent neural circuits that modulate immune responses and the progression of 
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inflammatory disease282.  The vagus nerve is the main nerve of the 
parasympathetic division of the autonomic nervous system which regulates 
metabolic homeostasis. The vagus nerve exits the brain from the medulla 
oblongata and descends vertically within the carotid sheath postlateral to the 
carotid arteries. From there, the branches of the vagus nerve innervate the gut 
and peripheral organs including the lungs, spleen, kidneys and liver. It controls 
heart rate, gastrointestinal motility and secretion, hepatic glucose production 
and other visceral functions283. It is also a major constituent of the inflammatory 
reflex; a physiological mechanism that functions on the path between immunity 
and metabolism. Recent evidence has shown that the efferent vagus nerve can 
control local and systemic inflammatory responses using a process termed “the 
cholinergic anti-inflammatory pathway”284. 
The vagus nerve can be activated by inflammatory cytokines. In addition, the 
afferent branches of the vagus nerve contain macrophages and DCs in the 
perineural sheath that express TLRs and can be activated by PAMPs282. Much of 
the information regarding the role of the vagus nerves in immune-to-brain 
transmission comes from vagotomy experiments. Many people have used rodent 
models to show that intraperitoneal injections of LPS can stimulate c-fos 
expression in neurons285. However, when vagotomys are performed under the 
diaphragm, so as not to disturb cardiac and pulmonary function, expression of 
this early activation gene is attenuated. This has also been shown by Marvel et al 
in a model of reversible inactivation of the vagus nerve using anaesthetic. They 
found that non-responsiveness of the dorsal vagus complex blocked the social 
withdrawal and c-fos upregulation normally seen in LPS injected rats286. These 
findings suggest that the neuronal activation of the brainstem, the hypothalamus 
and limbic structures that normally follows peripheral intraperitoneal LPS 
stimulation is dependent on vagus nerve transmission287. In addition, surgical 
transection of the vagus nerve in rodents, preventing immune signalling at 
peripheral nerve endings, is able to attenuate sickness behaviours caused by 
peripheral immune stimulation56, 288, 289. However, this suppression is thought to 
be dose-dependent and can be overcome with the administration of a large dose 
of IL-1β290. In this manner, the administration of cytokine can induce fever and 
sickness behaviour by bypassing neural circuitry and acting through the CVOs via 
the humoral pathway.  
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The actions of the neural pathway are thought to be mediated through the 
production of acetylcholine (ACh) from the stimulated afferent arm291. 
Acetylcholine, an important neurotransmitter and neuromodulator, signals 
through two different kinds of receptor; muscarinic and nicotinic292. RNA analysis 
of these receptors shows that they are expressed on mixed populations of 
lymphocytes as well as other cytokine producing cell types, most of which are 
also capable of producing acetylcholine293. Via post-transcriptional mechanisms, 
acetylcholine can suppress the production of a number of pro-inflammatory 
cytokines, including TNF and IL-1β, by LPS- stimulated human macrophage 
cultures294.       
Although this is clearly an important mechanism of immune-to-brain 
communication, it seems to be more essential for some processes than for 
others. For example, vagotomised LPS- or IL-1β- injected rodents may have 
attenuated sickness behaviours, but they do still present with a fever 
response295. These results confirm that the neural pathway is not the only 
communication pathway between the immune system and the brain. It seems 
likely that the afferent arc is particularly important for relaying information to 
the brain in response to mild to moderate peripheral inflammation. 
1.6 CNS responses to peripheral stimulus 
The major routes of immune-to-brain communication have been highlighted in 
the previous section and demonstrate that peripheral components of the 
immune system, namely inflammatory cytokines, are able to stimulate the CNS. 
There are a number of ways in which the brain will respond to such stimuli, 
activating a central response to try to eliminate the threat; however there are 
also several routes through which peripheral stimulation can mediate 
behavioural changes which may, in severe cases, result in the onset of 
neuropsychiatric disorders. The routes implicated, although presented as 
independent pathways, likely work in parallel and will be discussed in detail.      
1.6.1 The HPA axis 
The hypothalamic-pituitary-adrenal axis is a major part of the neuroendocrine 
system and is based on the feedback interactions of three endocrine glands; the 
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hypothalamus, the pituitary gland and the adrenal glands296. The HPA axis 
regulates many essential processes such as energy exchange, the immune 
system, digestion and mood. In addition, the HPA axis is responsible for directing 
the response to stress through the production of glucocorticoids (GCs)222. The 
stress system is always active and is characterised by circadian variations, but in 
circumstances where physical or emotional stressors exceed a critical threshold, 
the activities of the stress system intensify. This response is necessary to try and 
reinstate homeostasis by instigating behavioural adaptations, the redistribution 
of energy and inhibition of the inflammatory response. Being able to 
appropriately and efficiently respond to stress confers a survival advantage by 
controlling the ‘fight or flight’ response297. 
As shown diagrammatically in Figure 1-4, when physical or psychological stress is 
experienced, corticotropin-releasing hormone (CRH) is produced by the 
paraventricular nucleus (PVN) of the hypothalamus. This acts on the anterior 
pituitary gland, stimulating the production and release of adrenocorticotrophic 
hormone (ACTH), which in turn activates the adrenal glands. The adrenal glands 
subsequently release GCs (cortisol in humans or corticosterone in rodents), as 
well as stimulating the production of other stress hormones including 
noradrenaline and adrenaline222. GCs bind glucocorticoid receptors (GCRs) which 
are ubiquitously expressed throughout many tissues and on almost all immune 
cell subsets. As well as controlling growth and metabolism, GCs can act as 
neuromodulators and exert inhibitory effects on the immune system298. For 
example, through either direct inhibition or inhibition of key transcription 
factors, GCs can interfere with the production of a number of inflammatory 
cytokines, including IL-1β and IL-6299. Glucocorticoids not only inhibit 
inflammatory cytokines, but they also upregulate the synthesis of anti-
inflammatory cytokines including IL-10. In addition, it has been shown that GCs 
can increase the phagocytic potential of macrophages to stimulate the clearance 
of debris and other harmful elements300. The combined actions of the HPA axis 
result in a potent anti-inflammatory response that aims to return the body to its 
homeostatic state. Should the HPA axis become impaired in some way and 
homeostasis lost, a chronic stress response may ensue leading to the onset of 
neuropsychiatric symptoms. This is often indicated in patients suffering from 
depression, who present with raised levels of cortisol301. 
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Whilst the HPA axis works to control inflammatory responses by modulating 
cytokine production, this system itself is sensitive to a number of inflammatory 
cytokines. This is interesting as long-term sufferers of MDD have elevated levels 
of inflammatory cytokines, which may be the driving force behind chronic HPA 
axis activation302, 303. Several studies have demonstrated an important role for 
inflammatory cytokines in the hyper-activation of the HPA axis and the severity 
of MDD5, 304. Moreover, using either direct administration of Il-1 into rats or by 
using viral infection, studies have shown that IL-1 is able to stimulate the 
production of CRH, which in turn will upregulate ACTH305. Andreis et al have 
shown that this effect is mediated through the direct action of IL-1β on the 
adrenal gland306.   
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Figure 1-4 The HPA axis 
Stress induces the production of CRH from the PVN of the hypothalamus. This, in turn, stimulates 
the release of ACTH from the pituitary gland which activates the adrenal glands of the kidneys to 
produce glucocorticoids. The HPA axis works as a negative feedback loop, whereby 
glucocorticoids suppress further production of CRH and PVN by the hypothalamus and pituitary, 
respectively. 
 
1.6.2 Neurotransmitter modulation  
The monoamine neurotransmitters dopamine, serotonin (5-HT) and 
noradrenaline (NA) are released from neurons in the CNS and the periphery222. 
They are thought to be involved in a wide range of physiological and homeostatic 
functions including learning and memory, concentration and attention and blood 
pressure regulation. The relationship between monoamines and depressive 
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disorders were seen with the use of a monoamine oxidase inhibitor, which was 
originally developed for other purposes, but was quickly found to have anti-
depressive effects and, as such, drugs that augment the effects of monoamines 
are often used in the treatment of psychiatric conditions. The current treatment 
for MDD is the use of selective serotonin reuptake inhibitors (SSRIs). However, 
30% of patients do not respond to each given treatment which suggests that 
monoamines alone do not explain the pathogenesis of MDD307.   
Tryptophan (Trp) is a circulating essential amino acid that serves as the 
precursor to many metabolic pathways308. Trp may be used for the synthesis of 
5-HT, although around 90-95% of it is metabolised via the kynurenine (KYN) 
pathway (KP). This pathway facilitates the oxidative degradation of Trp into 
KYN, which is able to cross the BBB and enter the parenchyma where it can be 
metabolised by microglia, astrocytes and perivascular macrophages309. 
Metabolism of KYN is compartmentalised depending on the cell type and can 
lead to the production of both neurotoxic and neuroprotective substances. 
Kynurenic acid (KA), which is favoured by astrocytes, is thought to be 
neuroprotective, whereas quinolinic acid (QA), the preference of microglia, 
causes oxidative stress and is thought to be neurotoxic310. Microglia and 
infiltrating macrophages are the only cell types in the CNS that possess all the 
necessary enzymes for QA production311, and studies have suggested that QA 
production is the favoured path in patients suffering neuropsychiatric 
disorders312, 313 or acute inflammation314. The oxidation of Trp which is the 
initiating step in the KP is catalysed by the enzyme idoleamine 2,3-dioxygenase 
(IDO). IDO can therefore control the levels of 5-HT and stimulate the production 
of neuromodulators, both positive and negative315. 
Trp, as an essential amino acid, is important for the survival of many infectious 
microbes and its consumption is frequently seen during infection. Therefore the 
breakdown of Trp is actually a variant of the antimicrobial response which 
restricts its availability for infectious agents316. It has been shown that a number 
of factors involved in immunity can influence the levels of IDO. Pro-
inflammatory cytokines including, IL-2, IFNγ and TNFα, as well as secondary 
mediators such as PGE2, are potent activators of IDO, whereas the cytokines IL-4 
and IL-10 inhibit IDO317. Regulatory DCs and macrophages, which favour 
tolerance, express IDO as an immunosuppressive mechanism to catabolise Trp 
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degradation318. IDO expression is thought to be induced by IFNγ produced by 
activated T cells, which subsequently induces IDO-dependent arrest or apoptosis 
of T cells in a negative feedback fashion319. Patients suffering from MDD 
metabolise Trp at a higher rate than non-depressed controls, and a number of 
inflammatory conditions have been linked with higher expression of IDO320.    
 
Figure 1-5 The kynurenine pathway of tryptophan degradation 
IDO, which is upregulated by a number of inflammatory cytokines, is an enzyme which catalyses 
the oxidation of TRP into KYN. KYN is then further metabolised into either KA, which exhibits 
neuroprotective properties, or QA which is neurotoxic.  This pathway, initialised by the actions of 
IDO, prevents TRP from facilitating the production of serotonin, an important neurotransmitter.    
  
1.6.3 Peripheral inflammation and behavioural changes 
There is now an abundance of literature that links inflammation with changes in 
behaviour. These findings come from both human and animal studies and involve 
a number of arms of the inflammatory response. Along with human clinical data, 
in which chronic inflammatory diseases are associated with the onset of 
neuropsychiatric conditions including depression and anxiety, there are also 
rodent studies which have shown the same correlation using administration of 
immune stimuli and assessment of sickness behaviours5, 55, 246, 321, 322. Numerous 
behavioural tests for rodents have been developed and, although a degree of 
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scepticism will always remain with regards to the interpretation of the ‘mood’ of 
rodents, these have allowed us to specifically test the effects of inflammation 
on behavioural changes.  
It is now broadly accepted that rodents receiving inflammatory stimuli 
experience the onset of sickness behaviours, which serve as an ‘immunological’ 
model of MDD. The peripheral administration of recombinant cytokines or 
inflammatory cytokine inducers, such as LPS, triggers the classic symptoms of 
sickness including fever, reduction in food intake and activation of the HPA axis7, 
55, 56. Set-point body temperature is controlled by neurons in the preoptic 
hypothalamus; however pyrogenic cytokines can mediate changes to instigate a 
fever response. To do this, cytokines, which cannot freely pass through the BBB, 
must be able to communicate with the brain. I have already highlighted the 
numerous methods of communication between the periphery and the CNS 
(Section 1.5), be it neural, humoral or via the activation of the HPA axis, which 
could mediate the behavioural adaptations presented with immune modulation.        
With regards to human clinical data, there are a number of non-CNS diseases in 
which cytokine administration or cytokine blockage is used as a form of 
treatment. This has provided scientists with a suitable cohort for studying the 
effects of inflammatory cytokines on neurological wellbeing. The treatment of 
Hepatitis C patients with IFNα has implicated cytokine therapy in the onset of 
neuropsychiatric disorders including depression, anxiety and anger/hostility323. 
Kraus et al found that 35% of patients receiving IFNα treatment experienced the 
onset of clinically relevant depressive symptoms using the well-validated 
Hospital Anxiety and Depression Scale (HADS)324. They found that this was 
exacerbated when treatment was combined with the anti-viral drug Ribavirin, 
although a more recent evaluation by Udina et al showed a lower depression 
onset rate of 1 in 4325. These neuropsychiatric symptoms described by Kraus et al 
subsided in 15% of patients 4 weeks after IFNα treatment was terminated324. 
However, other studies have reported the incidence of interferon-induced 
depression as being anywhere between 0% and 90%326, 327. Similar findings have 
been reported in a double-blind study involving IFN-α treatment of patients with 
malignant melanoma, whereby the authors suggest that different mechanisms 
may govern the different manifestations that fall under the ‘umbrella’ of 
cytokine-induced sickness behaviours328. Psoriasis is another peripheral disease 
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that is commonly associated with the onset of neuropsychiatric symptoms such 
as depression, as well as substance abuse and suicidality. Published in The 
Lancet in 2006, Tyring et al noted some interesting findings from a phase III 
clinical trial involving the treatment of psoriasis patients for a 12 week period 
with the anti-TNF drug Etanercept329. 50% of patients experienced an 
improvement in their secondary symptoms of depression, measured using the 
Hamilton rating scale for depression (Ham-D) and the Beck depression inventory 
(BDI)329. These improvements in depressive symptoms did not significantly 
correlate with an improvement in psoriatic disease score as measured using the 
psoriasis area and severity index score (PASI). This suggests that TNFα is, on 
some level, associated with the neurological symptoms that are often presented 
by psoriasis patients. In addition to the knowledge gained from specific diseases, 
Reichenberg et al have performed studies in which humans were injected with 
endotoxin. Administration of LPS or Salmonella was found to induce depressive 
mood, anxiety, reduced food consumption and mild fever, phenotypes that were 
directly proportional to the levels of circulating inflammatory cytokines322, 330.  
1.6.4 Neurogenesis and plasticity 
Adult neurogenesis, which was identified in human tissue for the first time in 
1998141, occurs primarily at two specific sites within the brain. These are the 
subgranular layer of the dentate gyrus of the hippocampus and the 
subventricular zone of the lateral ventricle, although recent reports have 
suggested there may be new neuron formation in other areas142. In mice, it takes 
several days to weeks for new cells in the granule layer of the dentate gyrus to 
be fully incorporated into hippocampal circuitry and express mature neuronal 
markers, going through a four stage process of proliferation, migration, 
differentiation and survival331. This process is thought to take significantly longer 
in humans and non-human primates. There is still some debate regarding the 
function and necessity of new neurons but, due to their increased plasticity in 
comparison with mature neurons, they are thought to have a role in maintaining 
brain regions by replacing dead or dying cells. Furthermore, neurogenesis is 
positively correlated with increased cognition, memory and spatial learning332, 
333. Specifically, mice with increased levels of neurogenesis were found to excel 
in pattern separation tasks332. However, very recent publications have suggested 
that increased neurogenesis erodes memory, likened to the phenomenon of 
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infantile amnesia, which coincides, with the highest period of neuronal 
turnover334, 335.   
1.6.4.1 Inflammation and neurogenesis 
Several studies have shown that peripheral inflammation, MDD, ageing and 
neurodegenerative diseases can have a negative impact on the degree of adult 
neurogenesis336, which can be evaluated using either BrdU or doublecortin (DCX) 
immunostaining. Interestingly, a proportion of sufferers of MDD or other 
psychiatric conditions present with reduced hippocampal volume, measured 
using magnetic resonance imaging (MRI)337, 338. This reduction in volume is 
thought to inhibit neurogenesis and restrict neuronal plasticity. In agreement, 
Malberg et al have reported that long term anti-depressant treatment of rodents 
leads to a significant increase in adult neurogenesis in the hippocampus339 as 
does voluntary exercise, running and environmental stimulation340, 341. Sufferers 
of chronic depression also have reduced levels of brain derived neurotrophic 
factor (BDNF), an important factor in the regulation of synaptic plasticity342, 
which is rescuable with anti-depressant treatment343. It is thought that BDNF is 
particularly important during the stress response as it confers cognitive 
flexibility and the ability to adapt to environmental change344. Microglia can be 
both supportive and harmful to neurogenesis depending on their activation 
state345. In steady state conditions, ramified microglia ingest dying neurons in a 
manner that avoids the release of DAMPS, preserving brain homeostasis346. In 
addition, microglia are thought to release several factors that promote the 
proliferation and survival of new neurons. However, central or peripheral 
administration of LPS leads to microglial activation and a decrease in new 
neuron survival347. The survival of neurons negatively correlated with the 
number of activated microglia, an effect that could be blocked with the 
administration of the microglial inhibitor, minocycline348.  
Together, these findings highlight just how much of an effect immune-mediated 
processes can have on adult neurogenesis, an event that appears to be important 
for cognitive function, memory and plasticity.  
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1.7 Peripheral inflammation and the CNS 
There are unquestionable correlations between long term sufferers of chronic 
inflammatory illnesses of the periphery and a decline in mental health and 
quality of life. However, it has been very difficult to identify the biological 
mechanisms of these symptoms due to the outdated assumption that the CNS is 
devoid of influence from the periphery. As mentioned previously, the use of 
cytokine therapy has now provided solid evidence that certain diseases normally 
associated with the periphery can have a measurable and reversible biological 
effect on an individuals’ psyche.  
1.7.1 Psoriasis 
Although there are many chronic inflammatory diseases associated with the 
onset of neuropsychiatric conditions, psoriasis is of particular relevance to this 
thesis and will be focused on as a representative peripheral disorder with a 
negative correlation with MDD.  
Psoriasis is a debilitating, recurrent skin disease that affects around 2% of the 
Caucasian population. The most common type of psoriasis is characterised by 
silver plaque-like formations on the skin that are variform, sharply demarcated, 
raised and itchy. A strong genetic risk factor for psoriasis has been identified349-
352 and it is thought that the disease responds to a number of triggers including 
stress, infections, smoking and injury. The immune component of psoriasis was 
first noted with the success of treatment with general immunosuppressive drugs 
including cyclosporine and methotrexate and it was subsequently thought that 
psoriasis was driven by IFNγ-producing Th1 cells. However, it was later found 
that DCs and keratinocytes in psoriatic lesions overproduced IL-23353, which in 
turn implicated Th17 cells as the main drivers of the disease. IL-23 is considered 
the “master regulator” of the Th17 pathway and is essential for the survival and 
proliferation of these cells. As such, it is now known that T-cell mediated 
hyperproliferation of keratinocytes, thought to be driven primarily by IL-23-
dependent Th17 cell-produced IL-17 and IL-22, induces the classic pathology 
seen in psoriasis354. Recently, a new subset of T cells has emerged which, like 
Th17 cells, produce IL-22, but they do not produce IL-17 or IFNγ41. These cells, 
subsequently name Th22 cells, are found in high levels in inflammatory skin 
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lesions and are characterised by their expression of homeostatic chemokine 
receptors, CCR4 and CCR640, 355. IL-22 induces keratinocyte proliferation and 
epidermal hyperplasia and promotes the production of antimicrobial 
mediators356. As such, Th22 cells are now defined as pivotal in the pathology of 
psoriasis and are a new potential target in this, and many other, inflammatory 
skin diseases.  
In addition to the effects of psoriasis itself, there is also a high risk association 
between psoriasis and other inflammatory conditions including arthritis and 
inflammatory bowel diseases (IBD)357. More than 10% of psoriasis patients also 
present with arthritis. As mentioned, psoriasis is one of many chronic 
inflammatory disorders that are strongly associated with debilitating 
neurological side effects. It is therefore an interesting disease to study with 
regards to co-morbid associations and neurological correlations.   
1.7.2 Animal models of peripheral inflammation 
There are very few successful animal models of chronic peripheral inflammation 
that exhibit a true reflection of a human disease. Of the models that have been 
developed, most are of course used to study the pathology itself and thus focus 
on the affected tissue, and perhaps the response in the periphery, rather than 
the response in the CNS. Most of the peripheral inflammation models that have 
been used to study the CNS response have relied upon the systemic injection of 
inflammatory agents and have failed to reflect a specific disease state. Rather, 
they utilise the ability to activate the systemic immune system by introducing 
bacterial components directly into the blood. Although this allows us to visualise 
the response in the CNS, it is not as applicable to discerning the relationship 
between peripheral diseases and neuropsychiatric disorders in humans, as these 
comorbidities are often presented with tissue-specific chronic disorders.     
1.7.2.1 The Aldara model of skin inflammation 
Aldara cream is a prescription drug that is used topically for the treatment of 
actinic keratosis358, genital warts359 and superficial basal cell carcinoma360. 
Aldara cream contains 5% imiquimod (IMQ) as its active component, which 
activates TLR8 in humans and TLR7 in rodents. Over a short period of time, its 
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application to the skin causes a localised skin inflammation361, 362, and can 
trigger flare-ups in psoriasis patients363, and it has now been developed by 
scientists into a commonly used rodent model of psoriasis-like skin inflammation.  
The earlier animal models of psoriasis relied on either transgenic mice or 
xenotransplantation, both of which are costly and time consuming364. The mouse 
model of IMQ induced psoriasis on the other hand is favoured for its simplicity 
and is characterised by epidermal hyperplasia, acanthosis and leukocyte 
infiltration that are thought to be mediated through the IL-23/ IL-17 axis365. 
Mirroring human psoriasis, IL-23 and Th17 cell-associated cytokines are 
upregulated in lesions in the skin, and blockade of IL-23 is able to supress the 
inflammation366. Plasmacytoid DCs (pDCs), which express high levels of TLR7367 
and infiltrate the skin in a CCL2-dependent manner following IMQ application368, 
are considered by some to represent the main source of the type I IFN response 
seen in this model369, 370. However, others have reported that pDCs are 
dispensable for the localised effects to IMQ371. The initial skin response is 
associated with the upregulation of inflammatory cytokines in the skin, including 
IL-1β and IL-6, along with neutrophil infiltration and keratinocyte activation372. 
Interestingly, Aldara cream contains another active component in addition to the 
TLR7/8 ligand IMQ. Isostearic acid, which is present in the vehicle, has been 
shown to activate the inflammasome via NALP3 pathway independently of IMQ 
and can induce the production of the inflammatory cytokines IL-1β and IL-18372. 
Although some of the early effects of Aldara are thought to involve both active 
components, the requirement for TLR7 ligation and MyD88 signalling suggests a 
primary role for IMQ in driving the full response371, 372.   
This model provides a pathology very similar to that seen in human psoriasis, and 
allows us to investigate the effects of peripheral, tissue-based inflammation on 
brain biology to try to identify possible mechanisms that underpin the 
relationship between chronic inflammatory conditions and neuropsychiatric 
disorders.  
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1.8 Justification and thesis aims 
Having ruled out the previous misconception that the brain is isolated and 
protected from the periphery, it is clear that immune activation outwith the CNS 
can have a profound effect on the brain. The importance of this relationship has 
been highlighted in a number of studies in which the inflammatory cytokine 
profile has been manipulated. As such, it is clear that inflammation originating 
in the periphery can have a very fundamental effect on the neuropsychological 
state of patients. However, much remains to be elucidated with regards to the 
biological mechanisms underpinning this relationship. Using a well-characterised 
animal model of psoriasis-like skin inflammation, it is hoped that we can 
increase our understanding of how the immune system and the central nervous 
system are linked. Developments in this field have the potential to allow for 
better directed treatment that will improve both chronic inflammatory illness 
and neurological wellbeing.   
As such, the primary aim of this thesis is: 
• To investigate the effect of peripheral inflammation on the brain using a 
well characterised model of psoriasis-like skin inflammation. 
As this thesis progressed, further specific aims were established. Once we had 
identified the distinct transcriptional response in the brains of treated mice, we 
sought to determine, in more detail, the mechanisms driving the response to 
skin-based inflammation. This was done using a range of peripheral inflammatory 
models, both TLR-dependent and TLR-independent, or ‘sterile’. We also aimed 
to determine whether transcriptional chemokine expression in the brain could 
induce immune cell recruitment and we sought to evaluate what role, if any, 
atypical chemokine receptor ACKR2 had in the brain response to cutaneous 
inflammation (using ACKR2 knock-out mice). Finally, we wanted to understand 
whether peripheral inflammation could induce a functional output. The two 
parameters we chose to examine were behaviour, due to the well-described 
relationship between inflammation and sickness behaviour, and neurogenesis. 
Neurogenesis is sensitive to many other inflammatory insults and this, along with 
the much-localised expression of ACKR2 at known sites of adult neurogenesis, 
highlighted neurogenesis as an interesting function to assess in our studies.  
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2 Materials and Methods 
2.1 General materials & reagents 
Plastics: All plastics were purchased from Gibco (Invitrogen, Paisley UK) or BD 
Biosciences (Oxford, UK) unless stated otherwise. 
Tips: All tips were sterile filter tips purchased from Starlab 
EDTA: 186.1g ethylenediaminetetraacetic acid (EDTA) (Sigma Aldrich) and 20g 
sodium hydroxide (NaOH, Sigma Aldrich) was dissolved in 900ml distilled H20 
(dH20), and adjusted to pH8 using hydrochloric acid (HCl, Sigma Aldrich). This 
was subsequently made up to 1 litre (L) using dH20. 
1% acid alcohol: 1% concentrated HCl was added to 100ml of 70% Ethanol (EtOH) 
Citrate buffer (0.1 M): 2.1g citric acid monohydrate (Sigma Aldrich) was 
dissolved in 700 ml dH2O. 2M NaOH was added to adjust the solution to pH6. The 
total volume was made up to 1L of buffer with addition H2O. 
Eosin Y solution: 1% Eosin Y (Cell Path) was added to tap water 
ELISA wash buffer: 1x Phosphate buffered saline (PBS) (Invitrogen) was mixed 
with 0.5% Tween 20 (Sigma Aldrich) 
Tris-acetate EDTA (TAE) Buffer: A 50x stock solution of TAE buffer was made by 
dissolving 242g Tris base (Sigma Aldrich) in 750ml dH20. 57.1ml glacial acetic 
acid (Sigma Aldrich) and 100ml 0.5M EDTA was then added and the buffer was 
made up to 1L with dH20. Before use, stock buffer was diluted 1:50 in dH20. 
Scott’s tap water: 3.5g sodium hydrogen carbonate (NaHCO3) and 20g 
magnesium sulphate (MgSO4) were added to 1L of distilled H2O. Thymol (Sigma) 
was added to prevent mould formation.  
10x Tris Buffered Saline with Tween 20 (TBST): For 1L of buffer, 24.23g Tris 
base (200mM), 87.66g sodium chloride (NaCl, 1.5 M) and 10ml Tween® 20 (1%) 
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were added to 800ml of distilled H2O. The solution was adjusted to pH 7.6 using 
concentrated HCl and diluted 1/10 to obtain 1x TBST. 
2.2 In Vivo Procedures 
2.2.1 Animals 
C57BL/6 WT mice were either bred at the Central Research Facility at the 
University of Glasgow or purchased from Harlan Laboratories. GGDKB mice 
(ACKR2 KO mice) were bred at the Biological Services Unit at the Beatson 
Institute, University of Glasgow and were transferred to the Central Research 
Facility prior to being put on procedure. All mice were given at least one week 
to acclimatise to the facility before being used and were maintained in specific 
pathogen free conditions. Mice were age and sex matched and used between 6 – 
9 weeks of age. All experiments received ethical approval and were performed 
under the authority of UK Home Office Licences.  
2.2.2 Induction of Peripheral Inflammation 
2.2.2.1 Aldara Model 
C57BL/6 female mice were shaved on their dorsal skin. 24 hours later mice were 
treated with either Aldara cream (MEDA, 5%v:v Imiquimod, 1/3 of a sachet per 
mouse, 80mg) or aqueous control cream (Boots, UK, Liquid paraffin B.P. 6% w/w, 
White Soft Paraffin B.P. 15% w/w, Purified Water, Emulsifying Wax, Chlorocresol 
0.1% w/w) of the same quantity which was applied to the area of shaved skin. 
Treatment was repeated every 24 hours for 5 days. Mice were weighed after 
each application. Mice were euthanised 24 hours after the final application by 
CO2 inhalation. 
2.2.2.2 Aldara Timecourse Model 
C57BL/6 female mice were were treated with Aldara cream as described. Mice 
were euthanised by CO2 inhalation 24 hours following the first, third or fifth 
application of Aldara depending on their group (D1, D3 and D5, respectively).  
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2.2.2.3 TPA Model 
C57BL/6 female mice were shaved on their dorsal skin. 24 hours later mice were 
treated with either 12-O-Tetradecanoylphorbol-13-acetate (TPA) (Sigma, 150µl 
100µM per mouse) or equivalent volume acetone (VWR International) which was 
applied to the area of shaved skin. Treatment was repeated every 24 hours for 5 
days. Mice were weighed after each application. Mice were euthanised 24 hours 
after the final application by CO2 inhalation. 
2.2.2.4 TPA Timecourse Model 
C57BL/6 female mice were treated with TPA (150µl 100µM per mouse) as 
described. Mice were euthanised by CO2 overdose 24 hours following the first, 
third or fifth TPA application depending on their group (D1, D3 and D5, 
repectively). 
2.2.2.5 Soluble Imiquimod Model 
C57BL/6 female mice were injected intraperitoneally (I.P) with either soluble 
Imiquimod (Source Bioscience, 100µl 1mg/ml per mouse) or equivalent volume 
PBS. Treatment was repeated every 24 hours for 5 days. Mice were weighed 
after each application. Mice were euthanised 24 hours after the final application 
by CO2 inhalation. 
2.2.2.6 Topical Imiquimod Model 
C57BL/6 female mice were shaved on their dorsal skin. 24 hours later they were 
treated with 80mg aqueous control cream supplemented with 5% v:v soluble 
Imiquimod, or equivalent volume aqueous control cream alone. Treatment was 
repeated every 24 hours for 5 days and mice were weighed after each 
application. Mice were euthanised 24 hours following the final application by 
CO2 inhalation.  
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2.3 Tissue Isolation following In Vivo Models 
2.3.1 Perfusion 
The right atrium of the heart was cut to allow blood to drain into the chest 
cavity without compromising the circulation. Perfusions were performed by 
injecting 20ml of PBS, warmed to 37°C, into the left ventricle of the beating 
heart using a 23G needle.  
2.3.2 Isolation of plasma from peripheral blood 
Mice were culled by CO2 inhalation. An incision was made in the right atrium and 
blood was collected in a 1ml syringe flushed with EDTA. Blood was immediately 
transferred to a 1.5ml eppendorf tube containing 20µl EDTA. Plasma was 
isolated by centrifugation at 300g for 10 mins. Taking care not to disturb the 
pellet, plasma was transferred to a fresh 1.5ml eppendorf tube before being 
centrifuged again at 10,000g for 5 mins. Platelet-free plasma (supernatant) was 
collected and was stored in a fresh 1.5ml eppendorf tube at -80°C. 
2.3.3 Isolation of leukocytes from peripheral blood 
Mice were culled by CO2 overdose; a recognised schedule 1 technique. An 
incision was made in the right atrium and blood was collected in a 1ml syringe 
flushed with EDTA. Blood was immediately transferred to a 1.5ml eppendorf 
tube containing 20µl EDTA. After the removal of the plasma, cells were 
incubated in a 15ml falcon tube in 5ml of 1X red cell lysis buffer (Miltenyi) for 10 
mins at room temperature. Tubes were centrifuged for 10 mins at 300g to allow 
the cells to pellet, and the supernatant was poured off. Cells were washed with 
10ml PBS, centrifuged as before and then transferred to a fresh 1.5ml eppendorf 
tube. Cells were washed for a final time with 500µl PBS and centrifuged at 600g 
for 3 mins. The supernatant was poured off and the pellet was resuspended in 
350µl of RLT buffer. PBL samples were stored at -80°C until they were processed 
for RNA purification.      
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2.3.4 Brain Dissection 
Following perfusion, mice were decapitated and the skin on the head was cut 
back to reveal the skull. Scissors were carefully inserted under the 
interhemispheric fissure and the skull was cut open. Forceps were used to pull 
the skull apart allowing for the brain to be dissected out. The olfactory bulb, 
brainstem and the meninges were carefully removed. Dissected brains were 
either submerged in formalin for 24 hours prior to processing or were ‘snap-
frozen’ in liquid nitrogen and stored at -80°C. 
2.3.5 Skin Dissection 
Following perfusion, an incision was made along the base of the shaved and 
treated area of the dorsal skin of the mice. Skin was gently lifted away from the 
underlying muscle and the patch of treated skin was cut off. This area was cut in 
two and one half was ‘snap-frozen’ in liquid nitrogen and stored at -80°C. The 
other half was laid out flat on filter paper (epidermis-side up) to prevent it from 
folding, and was then inserted into a bijoux containing 10% neutral buffered 
formalin. Tissue was fixed overnight in formalin before being processed, as 
described later.   
2.3.6 Recovery of Spleens 
The spleens of perfused mice were extracted and were stored in PBS on ice. 
Subsequently, spleens were weighed and photographed. 
2.4  Gene Expression Analysis 
2.4.1 Lysate preparation and phase separation of animal tissue 
Tissue samples were homogenised in 1ml of QIAzol Lysis Reagent (Qiagen) using a 
TissueLyser LT (Qiagen) homogeniser for 10 minutes. Lysate was then incubated 
for 5 minutes at room temperature before 0.2ml chloroform was added. Tube 
was shaken vigorously by hand, incubated for 2-3 minutes and then centrifuged 
at 12,000g for 15 minutes at 4°C. The colourless upper phase (containing the 
RNA) was transferred to a fresh eppendorf tube prior to RNA extraction.   
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Cells were lysed in 350µl (>1 x 105 cells) of RLT buffer and stored at -80°C until 
required. Prior to RNA purification, cells were thawed and were passed through 
a QIAshredder (Qiagen) by centrifugation at full speed for 1min. 
2.4.2 RNA extraction using silica-gel membrane technology 
RNA was extracted following the RNeasy Mini Kit protocol (Qiagen) as described 
in the manufacturer’s handbook. RNA was precipitated by adding 1 volume of 
70% EtOH in RNase-free H2O. RNA from each sample was collected by 
centrifugation through an RNeasy spin column (Mini Kit). Genomic DNA was 
digested on-column as described in the protocol. Briefly, a stock solution of 
DNase I enzyme (in buffer RDD, diluted 1/8) was prepared and 80µl was added to 
each sample and incubated for 15mins. Spin columns were washed several times 
to remove any protein impurities and then air dried. RNA was eluted from the 
columns in30- 50µl RNase-free H2O. 
2.4.3 Assessment of RNA Integrity 
The quality of RNA was assessed by the University of Glasgow Polyomics Facility 
using a Bioanalyzer 2100 (Agilent) on a Nano chip in accordance with 
manufacturer’s instructions. All chips and reagents used were supplied in the 
RNA 6000 Nano kit (Agilent). Nuclease-free H2O was used to dilute the RNA to 
the following concentration:  
Nano chip  
Total RNA   5-500 ng/ml  
mRNA   25-250 ng/ml 
To prime the chip, the micro-channels were filled with a sieving polymer matric 
and fluorescent dye. Pressure was applied using a priming syringe (supplied) to 
disperse the gel-dye mix throughout the microfluidics of the chip. 9µl was also 
applied to an additional 2 wells as described in the protocol.  
After priming, 5µl of RNA 6000 marker was applied to each of the wells. 
Subsequently, 1µl of RNA 6000 nano-ladder was pipetted into the ladder well 
and 1µl of each diluted RNA sample was added to each of the sample wells. 
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Chips were vortexed briefly to mix contents and then RNA was separated in a 
microchannel according to size using the Bioanalyzer 2100. 
 
2.4.4 Affymetrix GeneChip Arrays 
Microarray assays were performed by the Sir Henry Wellcome Functional 
Genomics Centre at the University of Glasgow. The quality of total RNA samples 
was assessed using an Agilent 2100 Bioanalyzer in accordance with 
manufacturer’s instructions. 1µg of purified total RNA was amplified by in vitro 
transcription and converted to sense-strand cDNA using a WT Expression kit 
(Ambion).  cDNA was then fragmented and labelled using an Affymetrix 
GeneChip WT Terminal Labelling kit. Fragmented cDNA samples were quality-
checked using the 2100 Bioanalyzer and then hybridized to Affymetrix GeneChip 
Mouse Gene 1.0 ST Arrays. Procedures were carried out as described by the 
manufacturers. 
Data were pre-processed and analysed using GeneSpring GX software and were 
normalised using RMA 16. Prior to analysis, background correction was 
performed. Background correction is arguably the most important step in probe 
level processing and is a non-linear correction performed on a chip-by-chip 
basis. Background signal may be caused by non-specific binding and optical noise 
and needs to be accounted for in order to determine the true signal intensity. 
The Affymetrix GeneChip array used in this study utilises an innovative design 
and includes 17,000 generic background probes that cover the full range of GC 
content.  The modified GC-RMA algorithm was selected as the favoured method 
to correct this array for background noise. Using the signal intensity from the 
17,000 anti-genomic probes to determine the background, the GC-RMA algorithm 
corrects for it using three sequential steps: 
1. Optical background correction: to account for optical noise introduced by 
the scanner that measures the hybridisation efficiency 
2. Adjustment of probe intensity through non-specific binding using the 
background probe signal intensities 
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3. Adjustment of probe intensity through gene-specific binding where the 
signal intensities are corrected for the effect of PM probe affinities. 
Essentially, by following these three steps, the median signal intensity of the 
background probes possessing an equal GC content is subtracted from the signal 
intensity of the probe set. This provides what is considered to be the true signal 
intensity.     
Normalised and corrected data was subsequently analysed using unpaired t-tests 
to determine the significance of each gene in Aldara-treated mice compared to 
control mice. P-values were adjusted for multiple comparisons using the 
Benjamini Hochberg multiple comparison method. Microarray profiling data were 
deposited in the National Center for Biotechnology Information Gene Expression 
Omnibus database with the series entry identifier GSE72214. Functional 
clustering was performed using the Database for Annotation, Visualization and 
Integrated Discovery (DAVID) v6.7.  
2.4.5 cDNA Synthesis from RNA 
RNA was converted to complementary DNA (cDNA) using Precision nanoScript RT 
kit (Primerdesign). Following quantification using a Nanodrop (ThermoFisher), 
RNA was diluted to equal concentrations (100-2000ng, depending on experiment) 
with RNase-free H2O. The following components were added to 200µl thin-walled 
PCR tubes and incubated at 65°C for 5 minutes: 
RNA (100-2000ng)    9µl 
Oligo DT Primer Mix    1µl 
Total Reaction Volume   10µl 
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The reactions were cooled to room temperature, allowing the primers to anneal 
to the RNA. The following components were added from a master mix: 
10X Reaction Buffer   2µl 
dNTP mix (25mM each dNTP)  1µl 
100mM DTT     2µl 
dH2O      4µl 
Reverse Transcriptase    1µl 
Total Reaction Volume   20µl 
A ‘-RT’ control was included during cDNA synthesis in which the reverse 
transcriptase enzyme was substituted with 1µl of nuclease- free H2O. Reactions 
were incubated for 10 minutes at 25°C to extend the primers then for 20 
minutes at 65°C to synthesise cDNA. The reactions were then terminated by 
incubating at 75°C for 15 minutes. cDNA was diluted 1/10 with distilled H2O and 
stored at -20°C. 
2.4.6 Polymerase chain reactions 
Polymerase chain reactions (PCRs) were performed using pre-made red PCR 
master mix (Rovalab) as described below: 
Red PCR mastermix  45µl 
Forward primer   0.5µl 
Reverse primer   0.5µl 
Template cDNA   1-2µl 
Nuclease-free H2O* 
Total Volume   50µl 
*Reaction made up to 10µl in H20. 
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PCR reactions were run in a thermocycler set for the following programme: 
1. 95°C 3 minutes 
2. 95°C 15 seconds 
3. 60°C 15 seconds   35-40 cycles 
4. 72°C 45 seconds 
5. 72°C 5 minutes 
6. 4°C forever 
2.4.6.1 Gel electrophoresis of PCR products 
Following PCR reactions, products were separated on a 2% agarose gel containing 
ethidium bromide. To make the gel, the appropriate quantity of agarose (Sigma) 
was weighed out and dissolved in TAE buffer by heating in a microwave. 
Ethidium bromide was added to the solution before it was poured into a gel 
cassette. ‘Combs’ were used to create wells of an appropriate size and the gel 
was left to set. Once samples were loaded, the gel was left to run in TAE buffer 
for approximately 1hr at 100 volts. PCR products were visualised under 
ultraviolet (UV) light using an Alpha 2200 Digital UV-Visphoto Imager (Alpha 
Innotech). In order to verify the size of the products, samples were run alongside 
one of two DNA ladders; Hyperladder I for products <10 kilo bases (kb) or 
Hyperladder IV (both Bioline) for products <1000 base pairs (bp).  
2.4.7 Quantitative Real-Time PCR 
2.4.7.1 Primer design 
In order to detect and quantify genes of interest using SYBR green quantitative 
real- time PCR (qRT-PCR), two sets of primers were designed. ‘Inner’ primers, or 
QPCR primers, were necessary for the amplification of the target gene whereas 
the ‘outer’ primers (Table 2-2) were designed to function as standard templates. 
Standard primers flank the amplicon targeted by the qRT-PCR primers, along 
with 20bp’s either side, amplifying this region. Primers were designed using 
Primer3 Input software version 4.0.0 (http://primer3.ut.ee/), adhering to the 
following conditions to ensure their specificity and efficiency.    
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Specification for QPCR primers: 
Primer size      18 to 24 bp (20bp optimal) 
Melting temperature (Tm)   59.5°C to 61°C (60°C optimal) 
GC content      40% to 65% (50% optimal) 
Max self-complementarity   3 (≤2 optimal) 
Max 3’ complementarity    1  
Amplicon size     ≤150bp  
Standard primers were designed to the same stringent criteria, however the 
amplicon size could range from 100bp to 2000bp and, if need be, the self- 
complementarity could be increased to 5.  
2.4.7.2 Primers preparation for quantitative PCR 
Primers were synthesised by Integrated DNA Technologies (IDT, Belgium) by 
standard DNA synthesis and desalination, to remove any impurities. Standard and 
QPCR primers were resuspended in nuclease- free H2O to a concentration of 
100µM and forward and reverse primers were subsequently mixed 1:1 to obtain a 
final primer concentration of 50µM. The specificity of the primer sequences was 
assessed using Basic Local Alignment Search Tool (http://blast.ncbi.nlm.nih.gov/ 
Blast.cgi), before being confirmed by PCR using cDNA known to contain the 
region of interest. All reconstituted primer pairs were stored at -20°C 
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Table 2-1 Primer sequences used for RT-PCR 
Gene Forward Sequence Reverse Sequence 
TBP 5’ TGC TGT TGG TGA TTG TTG GT 3’ 5’ AAC TGG CTT GTG TGG GAA AG 3’ 
CXCL10 5’ GCT CAA GTG GCT GGG ATG 3’ 5’ GAG GAC AAG GAG GGT GTG G 3’ 
Gbp2 5’ CCA AGC GAG ATG CCT TTA TC 3’ 5’ TTC TTC TTC CAG GGG TCC A 3’ 
Gbp3 5’ ACC CAT TTG TCT GGT GGA AA 3’ 5’ GAG GCT GTG CTA TCT GCT CAA 3’ 
Gbp4 5’ CCT CTT CCT CTT TCT TCT TCC TTT 3’ 5’ GTG TTT CTA TGG GGG TGT GG 3’ 
Gbp6 5’ AAA CAC ACT CCC TCT CCC AGT 3’ 5’ TGA AGC CAG TCA ACA TCC AG 3’ 
Ifit1 5’ ACC ATG GGA GAG AAT GCT GAT GGT 3’ 5’ TGA TGT CAA GGA ACT GGA CCT GCT 3’ 
Ifitm3 5’ CGC TCC ATC CTT TGC CCT TCA GTG 3’ 5’ GCC CCC ATC TCA GCC ACC TCA T 3’ 
Igrm1 5’ AGT TCA GCA GGT AGC CCA GA 3’ 5’ TCA GCC TCA GTT TCC AGT CC 3’ 
Irf7 5’ GAA GAG GCT GGA AGA CCA ACT 3’ 5’ AGA TAA AAC GCC CTG TGC TG 3’ 
Lgals3bp 5’ ATT CCT GTG TCC CCT CCT TC 3’ 5’ GTG AGT GCT GGC TGA AAC CT 3’ 
Oasl2 5’ AGA AAG GGA TGG GAA CAG GTG GCT 3’ 5’ GGGTCGGGGACTAAGCAGGGTT3’ 
Rtp4 5’ GCA TCT TTG GGT GAG AAG GT 3’ 5’ ATG GGG AGG AAC TCT TTG GT 3’ 
Sp100 5’ CAT CAT TTT CCT TGG CTG GT 3’ 5’ CAT TTT GGT TGG TCC TTG CT 3’ 
Stat1 5’ GAA AAA CGC TGG GAA CAG AA 3’ 5’ CGA CAG GAA GAG AGG TGG TC 3’ 
CCL3 5' CAG CCA GGT GTC ATT TTC CT 3' 
5' CAG GCA TTC AGT TCC AGG TC 3' 
 
CCL5 5' CTG CTG CTT TGC CTA CCT CT 3' 5' ACA CAC TTG GCG GTT CCT T 3' 
 
CCL9 5' CTC ACA ACC ACG GAC CTA CA 3' 5' CAC TGG GGA AGA CCA AAG AA 3'  
CXCL13 5' CAT ACC CAA CCC ACA TCC TT 3' 
5' GCC TGT TCT CAA ATA GCC TTT C 3' 
 
CXCL16 5' TGC TGA CCC TTT GCC TCT AC 3' 5' GGC TGG CTT GGA CTA AAT AAC A 3' 
 
CCR5 5' TTT GTT CCT GCC TTC AGA CC 3' 5' TTG GTG CTC TTT CCT CAT CTC 3'  
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Table 2-2 Standard sequences used for RT-PCR 
Gene Forward Sequence Reverse Sequence 
TBP 5’ GAG TTG CTT GCT CTG TGT GCT G 3’ 5’ ATA CTG GGA AGG CGG AAT GT 3’ 
CXCL10 5' CGA TGG ATG GAC AGC AGA GAG CCT 3' 5' GAC AAG GAG GGT GTG GGG AGC A 3' 
Gbp2 5’ TTT GTG GGC TTC TTT CCA AC 3’ 5’ CTT TGC TGC CTC TGT GAG TG 3’ 
Gbp3 5’ CCC CAG AGA GGA CAA AGT GA 3’ 5’ ACC CCC CAG GAA CAG AGA AAG 3’ 
Gbp4 5’ TTG GTT TTG TGA GGG CAT TT 3’ 5’ ATC CAG TAA GGG GAG GCA GT 3’ 
Gbp6 5’ GTC TTC TCT TCC CCC ACC TC 3’ 5’ GGC TCC CAA TAA AAC CGC AC 3’ 
Ifit1 5’ GCA AGA GAG CAG AGA GTC AAG GCA 3’ 5’ GCA GGG TTC ATT TCC CCA GTG AGC 3’ 
Ifitm3 5’ TCT GAG AAA CCG AAA CTG CCG CA 3’ 5’ TGT AGG GAG GGG CAA GGA GGG A 3’ 
Igrm1 5’ CTG CTC CAC TAC TCC CAA C 3’ 5’ CTC TCC AGC CCA AAA ACA AA 3’ 
Irf7 5’ CTG TGA CCC TCA ACA CCC TAA 3’ 5’ GAG CCC AGC ATT TTC TCT TG 3’ 
Lgals3bp 5’ TGG TCA TAC GCC CCT TCT AC 3’ 5’ CAC AGG AAA TCC CAC AGG AC 3’ 
Oasl2 5’ AGA AAG GGA TGG GAA CAG GTG GCT 3’ 5’ GGG TCG GGG ACT AAG CAG GGT T 3’ 
Rtp4 5’ AGA CAG TGC TTG GCA GGT TC 3’ 5’ CTA TGG GGA AGG GCA TTT TT 3’ 
Sp100 5’ CCG AAT GGG TCA TCC TTA GA 3’ 5’ TCT TTT TCT GCG TCG TTG TG 3’ 
Stat1 5’ CCT ATG AGC CCG ACC CTA TT 3’ 5’ GGA AGC AGG TTG TCT GTG GT 3’ 
CCL3 5' CCA CGC CAA TTC ATC GTT 3' 5' TAT GCA GGT GGC AGG AAT GT 3' 
CCL5 5' CCC TCA CCA TCA TCC TCA CT 3' 5' TCA GAA TCA AGA GGC CCT CTA TCC 3' 
CCL9 5' GCC CTC TCC TTC CTC ATT CT 3' 5' GCC CTC TCC TTC CTC ATT CT 3' 
CXCL13 5' AAC GCT GCT TCT CCT CCT G 3' 5' CCA TCT CGC AAA CCT CTT GT 3' 
CXCL16 5' CGC CTA CAG CAA GAG TGG A 3' 5' AAG AGT GTT CCC CAA GAG CA 3' 
CCR5 5' ACC CAT TGA GGA AAC AGC AA 3' 5' CCT CTG AGG GGC ACA ACA AC 3' 
 
2.4.7.3 Generation of standard templates 
The expression levels of target genes can be quantified by comparing them 
against a standard curve. This was generated by performing a PCR reaction 
(described in section 2.4.6) using cDNA known to contain the target amplicon, 
the products of which were separated using gel electrophoresis (2.4.6.1). The 
relevant band, whose size corresponded with that of the desired product, was 
subsequently cut from the gel using a scalpel. The bands were then purified 
using a QIAquick Gel Extraction Kit (Qiagen) in accordance with the 
manufacturer’s instructions and the quantity of DNA was assessed using the 
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Nanodrop 1000. The following calculation was used to assess the absolute 
number of amplicon copies:  
Copies (per µl) =  (Concentration (g/µl) X Avogadro’s Constant)  
    Molecular weight of amplicon  
where the molecular weight of the amplicon is equal to the size of the amplicon 
in base pairs, multiplied by 660 Daltons, the average molecular weight of one 
base paired nucleotide. Purified standards were diluted in 1 X 10-2 TE buffer and 
stored at -20°C until use. 
2.4.7.4 Quantitative real-time PCR 
qRT-PCR was performed using a Prism® 7900HT Sequence Detection System 
(Applied Biosystems) in accordance with manufacturer’s guidelines. qRT-PCR 
amplifications were performed in triplicate within wells of a 96-well or 384-well 
PCR plate (both StarLab). Along with biological samples, each plate was 
performed with the addition of a –RT (2.4.5) and non- template control (NTC). 
NTCs were void of cDNA, substituting nuclease- free H2O in its place. Each 
reaction contained the following: 
      96-Well  384-Well 
SYBR® Green FastMix1   7.5µl   5µl 
RNase-free H2O    5.7µl   3.85µl 
Forward Primer2    0.15µl   0.075µlReverse 
Primer2     0.15µl   0.075µl 
cDNA (from a 1/10 dilution3)  1.5µl   1µl 
  
                                         
1 Purchased from Quanta Bioscience 
2 Primers listed in Table 2-1 
3 Diluted in nuclease-free H2O prior to experiment 
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2.4.9 Determining relative gene expression 
QPCR results were analysed using Sequence Detection System 2.4 software, 
whereby an absolute copy number for each target gene was generated based on 
the values of the standard curve. Comparative studies were previously 
performed in our lab to evaluate housekeeping gene expression across different 
tissues and found that tata binding protein (TBP) was the most consistent within 
the brain. Therefore, to eliminate variations caused by differences in starting 
RNA concentrations, the absolute copy numbers were normalised against TBP as 
follows: 
Normalised Copy Number = Target Gene Copy Number ÷ TBP Copy Number   
Subsequently, the normalised copy number was then used to calculate 
magnitudes of fold change by comparing treatment groups against relevant 
control groups.  
2.5 Protein Expression Analysis 
2.5.1 Enzyme-linked immunosorbent assay 
Cytokine levels in murine plasma were analysed using Duoset enzyme- linked 
immunosorbent assay (ELISA) Development System kits (R&D Systems). Frozen 
samples were thawed thoroughly before use, and were diluted appropriately 
using the relevant reagent diluent. The protocol was followed as outlined in the 
manufacturers’ handbook using half volume plates (Costar, Corning 
International), so all sample and reagent volumes used were half of that outlined 
in the protocol. Plates were read using a TECAN plate reader to provide optical 
density (O.D) readouts which were then converted to protein concentration 
values based on the standard curve of known quantities. 
2.5.2 Histology 
2.5.2.1 Tissue Preparation 
Samples for histological analysis were dissected as previously described. Samples 
were immediately submerged in formalin and kept at room temperature for 24 
hours before being processed. 
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2.5.2.2 Tissue Processing 
Following fixation in neutral buffered formalin for 24 hours, tissues were 
processed using an automated Shandon Citadel 1000 processor (ThermoFisher), 
whereby they were dehydrated over increasing concentrations of ethanol, 
submerged in xylene and infiltrated with paraffin wax (see details below).  
1. 70% Ethanol   1 hour 
2. 90% Ethanol   1 hour 
3. 95% Ethanol   1 hour 
4. 100% Ethanol   1x 1 hour, 1x 2 hours, 1x 2.5 hours 
5. Xylene   2x 1 hour and 1x 1.5 hours 
6. Molten paraffin wax 2x 4 hours (60-65°C)  
Following processing, samples were inserted into metal moulds and embedded in 
paraffin wax using a Shandon Histocentre 3 (ThermoFisher). Wax blocks were 
subsequently cooled on an integrated cold plate until set hard, and were stored 
at room temperature until use.  
2.5.2.3 Tissue Sectioning 
Sections of skin and brain, at 5µm and 7µm thickness respectively, were cut 
using a Shandon Finesse 325 microtome (ThermoFisher). Cut sections were 
floated onto a water bath at a temperature of 40°C to smooth out wrinkles 
before being adhered to Microslide Superfrost Plus slides (VWR International). 
Slides were left on a Raymond A Lamb Hotplate (ThermoFisher) set to 55°C for 
approximately 1 hour to dry. Slides were stored at room temperature until use. 
2.5.2.4 Haematoxylin & eosin (H&E) staining 
Tissue sections were deparaffinised by being submerged in absolute xylene (VWR 
International) for 3 minutes before being rehydrated across a gradient of 100% 
and 70% ethanol solutions for 20 seconds each. Sections were rinsed in running 
water for 2 minutes before being transferred to Haematoxylin Z Stain (CellPath) 
for 6 minutes. Sections were rinsed under running water for 2 minutes, 
differentiated in 1% acid alcohol for 30 seconds and then rinsed again. Sections 
were immersed in Scott’s tap water for 2 minutes and were then rinsed, prior to 
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being counterstained in Putt’s Eosin (CellPath, diluted 1:4 with dH2O) for 6 
minutes. Sections were rinsed for a final 2 minutes and were then dehydrated 
along a gradient of 70%, 90% and 100% ethanol solutions for 20 seconds each. 
Finally, sections were placed in absolute xylene for 3 minutes before being 
mounted in DPX (Leica Biosystems).   
2.5.2.5 Doublecortin (DCX) Fluorescent Staining 
Brains were cut sequentially along the midsaggital plane (from the inside to the 
outside) to 7µm thick sections. Sections were deparaffinised in absolute xylene 
for 5 minutes before being dehydrated across a gradient of 100%, 90% and 70% 
ethanol solutions for 2 x 3 minutes each. Sections were rehydrated in H2O for 5 
minutes before being washed in TBST for 5 minutes. Antigen retrieval was 
performed using citrate buffer, in which the sections were boiled for 8 minutes. 
Slides were left to cool for 15 minutes at room temperature, before being 
washed in H2O and TBST for 5 minutes each. Sections were blocked for 1 hour at 
room temperature using 20% normal horse serum (Vector Laboratories) in TBST 
containing 4 drops of Avidin (Vector Laboratories) block, before being washed 
again in TBST. Primary antibody (Polyclonal goat anti-mouse DCX (Santa Cruz 
Biotechnology) 1:100/ 2.5% normal horse serum/ 2.5% mouse serum (Invitrogen) 
in DAKO diluent (DAKO) + 4 drops Biotin (Vector Laboratories) block/ml) or 
isotype (Goat IgG (Vector Laboratories) 1:2500/ 2.5% normal horse serum/ 2.5% 
mouse serum in DAKO)/ negative control was added to the slides and incubated 
overnight at 4°C. The following day, slides were brought to room temperature, 
washed twice in TBST and were incubated with the secondary antibody (Horse 
anti-goat IgG 1:200/ 2.5% normal horse serum/ 2.5% mouse serum in DAKO) for 
30 minutes at room temperature. Cells were washed in TBST, incubated with 
FITC-Avidin D (1:500 in PBS, pH 8.0) (Vector Laboratories) for 40 minutes in the 
dark at room temperature, washed once again and then mounted with 2 drops of 
Vectashield Hardset containing DAPI (Vector Laboratories).  
2.5.3 Luminex 
Plasma samples from skin inflammation models were isolated as described 
previously, and were stored at -80°C until use. The mouse cytokine 20-plex 
panel was used, along with the extracellular protein buffer reagent kit (Life 
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Technologies), to determine the concentration of 20 cytokines in the plasma 
samples (Table 2-3). Assay was carried out in accordance with the 
manufacturer’s instructions. Briefly, samples were diluted 1:4 with assay diluent 
and were added in triplicate to a 96-well filter plate coated with premixed 
beads, along with an appropriate standard curve and blanks. Plates were 
wrapped in tin foil and were left on a plate shaker at room temperature for 2 
hours. Subsequently, plates were washed, Biotinylated Antibody mix was added 
and the plates were incubated for 1 hour at RT. Following another wash step, 
Streptavidin-RPE was added and plates were left shaking at room temperature 
for 30 minutes. Plates were washed for a final time before results were read 
using a Bio-Rad Bio-Plex machine and analysed with Bio-Plex Manager 4.1 
software. 
Table 2-3 Cytokines and chemokines analysed using Luminex 
 
2.6 Behavioural Models 
2.6.1 Burrowing Model with Aldara Treatment 
Burrowing tubes were commissioned to a local model maker who constructed 
twenty identical tubes to the dimensions and specification outlined in the Nature 
Protocol373 and shown in Figure 2-1. 200g of normal food pellets were deposited 
into each tube, which were then placed individually into large cages, against the 
back right corner. Mice were acclimatised overnight in group cages, whereby one 
burrowing tube containing 200g of food was left in a cage of 5 mice overnight. 
The tubes were removed the following morning. Baseline tests were carried out 
at for a 2hr and a 24hr time-point. To do so, mice were individually caged and 
left between 2pm and 4pm. At 4pm the contents of each tube was weighed and 
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returned to the respective tube. Mice were then left overnight in their single 
cages until the next morning when the remaining food pellets were weighed 
again. Baseline texts were carried out 48hrs prior to mice being put on 
procedure. Mice were put on procedure and treated in the morning with either 
80mg Aldara cream or equivalent control cream as described in section 2.2.2.1. 
Four hours later, coinciding with the 2hr baseline time period, burrowing tests 
were performed over 2hrs. Again, mice were caged individually in the same cage 
they had been in for the baseline tests and the remaining food was weighed at 
the end of the 2hr window. Mice were then returned to their group cages. 
Individual cages were cleared of burrowed food pellets between each test. Both 
the treatment and the burrowing tests were repeated for a total of 3 
consecutive days to coincide with the peak of the Aldara treatment.  
Figure 2-1 Burrowing Tubes 
Behavioural analysis of treated mice was performed using a burrowing model of anhedonia. This 
required the use of burrowing tubes of a particular dimension and specificity, as shown.  
  
2.6.1.1 Compound 21   
CXCR3 Blocker, or Compound 21, a kind gift from Amgen Inc. (Thousand Oaks, 
CA, US), was first prepared as a stock solution by being dissolved in 100% DMSO 
to a concentration of 7.9mg/ml. This was stored at -20°C until further use. 500µl 
of 50% PEG400 (Sigma) and 500µl of dH2O were added to 1ml of the Compound 
21 stock solution. Water was added very slowly to prevent the compound from 
falling out of solution. Mice were injected subcutaneously (s.c) with 50µl 
(10mg/kg) of Compound 21 for four consecutive days, starting one day prior to 
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the initiation of Aldara treatment (24hrs after baseline tests). Control mice were 
treated with the vehicle minus Compound 21 at the same concentration. 
2.6.1.2 Use of DAPTA 
D-ala-peptide T-amide (DAPTA), a CCR5 antagonist, was dissolved in H2O to a 
concentration of 1mg/ml. Mice were injected s.c with 200µl (1mg/kg) of DAPTA 
daily for four consecutive days, starting one day prior to the initiation of Aldara 
treatment (24hrs after baseline tests).   
2.7 Statistical Analysis 
Data were analysed using GraphPad Prism software (San Diego, CA). Depending 
on the experiment, analysis was performed using a Student’s unpaired t test or a 
one- or two- way ANOVA with Bonferroni post-tests, as outlined in figure 
legends. A probability value (p-value) of p<0.05 was considered statistically 
significant.  
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3 Transcriptional profiling of the brain following 
cutaneous inflammation induction with Aldara  
3.1 Introduction 
It is clear that events in the periphery can have a profound effect on the CNS. 
However, the mechanisms by which peripheral inflammation can influence the 
brain remain to be fully understood. Evidence suggests that immune 
components, particularly inflammatory cytokines, may mediate some of the 
neurological conditions that are often presented alongside chronic inflammatory 
diseases5, 55, 302, 322. These conditions include major depressive disorder, anxiety 
and schizophrenia321, 374. Trying to understand the relationship between 
inflammation and mood disorders in the human brain is difficult due to the 
obvious ethical and practical restrictions and for this reason many have turned 
to animal models. Animal models have helped confirm this correlation and have 
shown that immune activation in the periphery can induce a set of depressive-
like behaviours called ‘sickness behaviours’55, 56, 375. These behaviours are a way 
of conserving energy and are often short lived, coinciding with the duration of 
illness. However it is thought that in some cases, inflammation fails to resolve 
and these behaviours become chronic, resulting in the emergence of long term 
mood disorders. Generally speaking however, animal models used to try to 
further our understanding in this respect have relied on rather crude methods of 
instigating large scale systemic inflammation, rather than focusing on disease 
models that are arguably more reflective of human conditions. This makes it 
difficult to gauge just how relevant these studies are with regards to the 
relationship that exists between the immune/inflammatory system and the CNS 
in humans. In addition, the models that have been studied have so far failed to 
reveal the underlying mechanisms of this co-morbid relationship and as such, 
further investigation is required.  
The aim of this thesis was to investigate the effects of peripheral inflammation 
on the brain using a tissue- specific model of peripheral inflammatory disease 
that reflects the human disease, psoriasis. Aldara cream, described in detail in 
section 1.6.2.1, has been shown to induce psoriasis- like skin inflammation when 
applied repeatedly to the dorsal skin of mice363. Extensive reviews of this model 
suggest that it is one of the most accurate mouse models of human psoriasis as it 
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functions through the IL-17/ IL-23 axis366, 376. This, along with its simplicity and 
reproducibility, made it an appropriate model to use for this study. The aim of 
this chapter was to investigate if and how the Aldara model of psoriasis-like skin 
inflammation affects the brain in control and Aldara treated mice. To do so, 
Affymetrix GeneChip arrays were used to derive a full transcriptional profile of 
the brain. In addition, a basic behavioural test was performed to determine 
whether or not Aldara treatment can induce a functional CNS phenotype.     
3.2 The Aldara model of skin inflammation 
To induce the psoriasis-like pathology, Aldara cream was applied daily to the 
shaved dorsal skin of 6-8 week old female c57BL/6 mice. This was repeated over 
5 consecutive days. Alternatively, age and sex matched mice were treated with 
a water based control cream. Mice were terminally anaesthetised 24 hours after 
the final application and tissues harvested for analysis.     
3.2.1 Model Validation 
Prior to carrying out microarray analyses, the suitability of Aldara as an inducer 
of reproducible skin inflammation was confirmed. To do this, mice treated with 
Aldara cream, or control cream, every 24 hours were weighed following each 
application. In addition, spleens were collected, weighed and measured. Dorsal 
skin samples from the area of application were removed from the mice after the 
final application, sectioned and stained with H&E. Consistently, mice treated 
with Aldara cream lost a significant amount of weight compared with control 
cream treated mice (Figure 3-1A). This loss was apparent 24 hours following the 
first treatment and was most pronounced between the third and fifth 
treatments. Between the fourth and fifth applications, the Aldara treated mice 
showed signs of recovery; however their weight remained lower than the control 
group. The spleens of the treated mice were consistently larger than those of 
the control mice, often more than twice the weight and size (Figure 3-1B-C). 
Finally, H&E staining of the skin sections revealed a psoriasis-like skin 
inflammation in mice treated with Aldara. This was characterised by epidermal 
hyperplasia, dermal thickening and inflammation and flaking of the skin (Figure 
3-1D). These results demonstrate that, in agreement with the literature, Aldara 
cream induced a psoriasis- like skin inflammation at the site of application. The 
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corresponding weight loss and splenomegaly suggest that this model is also 
associated with a systemic response. To investigate this, 24hr after the fifth 
application of Aldara cream, plasma was isolated from mouse whole blood 
obtained by cardiac puncture. ELISA was used to assess the protein expression of 
three prominent inflammatory cytokines, IL-1β, IL-6 and TNFα (Figure 3-2A-C). 
Plasma from LPS- treated mice was used as a positive control (Figure 3-2D). 
After the fifth application of Aldara, none of the cytokines were present in 
measurable concentrations in the plasma as all fell below the minimum 
detection level of the kits. The positive controls confirmed that the assay 
worked. However, the lack of cytokine induction seen in the periphery may be 
due to the timing of the analysis.  
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Figure 3-1 Evaluation of the phenotypic response to Aldara- induced skin inflammation 
Mice treated with ~80mg Aldara cream, or equivalent volume control cream, were weighed 
following each application (A). In addition, spleens were removed and were weighed (B) and 
photographed (C). H&E staining was performed using 5µm thick sections of Aldara- or control- 
treated skin which were visualised at 200X magnification (D). (A & B) n = 10/ group from two 
independent experiments (C & D) n = 5/ group. Significance was measured using two-way ANOVA 
with Bonferroni multiple comparison post-tests *** = p ≤ 0.001.   
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Figure 3-2 Expression of inflammatory cytokines in the plasma of Aldara-treated mice  
Plasma was isolated from mice treated with ~80mg Aldara cream, or equivalent volume control 
cream, 24hrs after the fifth application. ELISAs were used to assess the expression of three key 
inflammatory cytokines, IL-1β (A), IL-6 (B) and TNF-α (C). To ensure the integrity of the assay, 
plasma from LPS- injected mice was included as a positive control. Group size of n = 5 for Control 
cream and Aldara- treated mice, n = 3 for LPS- treated mice. Minimum level of detection 
represents the lowest sensitivity for each kit. 
  
3.2.2 Processing of RNA samples 
RNA was extracted from the right hemisphere of brains taken from mice 24 hours 
after the fifth, and final, application of Aldara cream. Before microarray 
analysis could be performed, the integrity of the RNA samples was assessed. This 
analysis, which was performed by the University of Glasgow Polyomics facility, 
was done using an Agilent 2100 Bioanalyser, which assesses nucleotide fragments 
separated by size and evaluates them quantitatively on microfluidic chips via 
laser induced fluorescent detection (fluorescent units, FU). Screening each 
sample generates an electropherogram that allows RNA integrity to be visually 
assessed. In addition, using a mathematical algorithm, an RNA integrity number 
(RIN) can be generated. RIN is a software tool that has been designed to 
estimate RNA integrity based on the presence or absence of degraded RNA 
products and the ratio of 28S:18S ribosomal ‘RNA species’. RIN values are 
between 1 and 10, where 1 is a completely degraded sample and 10 is a 
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perfectly intact sample. RIN software algorithm ensures repeatability of 
electropherogram interpretation by removing user-dependent visual 
interpretation. An example of an electropherogram from a completely intact 
RNA sample with an RIN of 10 is shown in Figure 3-3A. This eletropherogram 
contains three peaks which represent the RNA marker (1), the 18S rRNA (2) and 
the 28S rRNA (3). Very little background signal should be present outwith these 
three peaks as this would indicate the presence of RNA degradation products. 
The integrity of the RNA from each brain sample was assessed. One 
representative electropherogram of RNA integrity from control mice (B) and one 
from Aldara treated mice (C) are shown. The RIN of each sample is shown in 
Table 3-1. An RIN of 8 or above is considered sufficient for performing 
microarray analysis, thus all samples met the requirement. In addition, Table 3-1 
shows the ratio of 28S to 18S rRNA species in each sample. In the mouse, a ratio 
>2 is considered good quality RNA, with an optimal ratio of 2.5. Therefore, the 
28S:18S ratio, high RIN, low background and clear peaks demonstrate that all 
RNA samples were of high enough quality to proceed to microarray analysis.      
Having confirmed the integrity of the RNA, samples were amplified by in vitro 
transcription and reverse-transcribed to generate sense-strand cDNA. This was 
then fluorescently labelled and fragmented. The Agilent 2100 Bioanalyzer can 
measure the efficiency of cDNA fragmentation using a DNA chip, which generates 
an electropherogram by measuring the fluorescence intensity over time.  
Figure 3-3(D-E) show representative fragment electropherograms from control 
mice (D) and Aldara treated mice (E). Each shows one peak next to the DNA 
marker, denoted on the electropherogram by the number 1, indicating that the 
DNA fragments in each sample were of similar size. The speed with which they 
passed through the investigative electrophoretic microchannel suggested that 
the fragments were relatively small and together these data indicate that the 
RNA samples were of high quality and were successfully fragmented. 
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Figure 3-3 Electropherograms to show RNA integrity  
RNA isolated from Aldara-treated brains and control cream-treated brains was prepared for 
microarray analysis. Prior to the array, RNA integrity and the efficiency of sense-strand DNA 
fragmentation were measured using an Agilent 2100 Bioanalyzer. An electropherogram was 
generated for each sample. This was used to assign an RIN value between 1 and 10. Data are 
shown as Fluorescent units (FU) over time. (A) Representative high integrity RNA sample with RIN 
of 10. (B-C) Integrity of whole brain RNA from; (B) control mice and (C) Aldara treated mice. (D-E) 
Fragmented DNA samples from (D) control mice and (E) Aldara treated mice. (B-E) Data are 
shown as one representative from each group. n=5/ group.   
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Table 3-1 RNA integrity of brain samples  
Sample ID RIN Value Ribosomal 28s:18S ratio 
Control 1 9 2.5 
Control 2 8.9 2.5 
Control 3 9.1 2.5 
Control 4 9.1 2.5 
Control 5 9.1 2.5 
Treatment 1 8.8 2.5 
Treatment 2 8.9 2.4 
Treatment 3 9.0 2.4 
Treatment 4 9.0 2.2 
Treatment 5 8.9 2.4 
  
 
3.3 Determining the effect of Aldara treatment on the 
transcriptional profile of the brain 
To determine the transcriptional effect of cutaneous Aldara treatment on the 
brain, the transcriptional profiles of the brains from 5 Aldara treated mice were 
compared with those from the brains from 5 control cream treated mice. The 
Affymetrix GeneChip Mouse Gene 1.0 Array has been extensively validated and 
was selected for this transcriptomic analysis. This array provides a 
comprehensive expression profile, using 770,317 distinct probes distributed 
across the full length of about 28,853 specific coding transcripts.      
3.3.1 Pre-processing of Affymetrix chip data using GeneSpring  
Microarray experiments were carried out by the Glasgow Polyomics facility 
(http://www.polyomics.gla.ac.uk), a core University facility. In order to control 
the effects of systematic error from dye efficiencies, uneven hybridisation or 
other extraneous factors, whilst still retaining biological variance, the quality of 
the raw data was assessed and pre-processed with the following steps:   
• Background correction: this is to adjust for the hybridisation effects that 
are not directly related to the interactions between the probes and the 
DNA. The details of this step are outlined in Section 2.4.4. 
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• Normalisation: this allows multiple chips to be compared with one another 
by removing systematic error and bias. This unifies the distribution of the 
perfect match values across the different chips, assuming that they have 
approximately the same distribution. 
• Perfect match probe correction and summarisation: this summarises the 
11 perfect match (PM) probe intensity values providing a normalised value 
of RNA expression for each gene. 
Agilent GeneSpring GX software was used for pre-processing and data analysis, 
utilising a modified version of Robust Multi-array Analysis (RMA), RMA 16, for the 
normalisation and summarisation of probe-level intensity measurements. 
3.3.2 Signal histogram of normalised data 
Following data normalisation and prior to formal analysis of the array, sample 
hybridisation was monitored for differences in efficiency. This was to check for 
variations between the chips that may affect the quality and reproducibility of 
the array, which can result from user error or differences in chip manufacturing. 
To do so, fragmented cDNA is first added to a hybridisation control cocktail 
containing a set of 4 control transcripts; BioB, BioC, BioD and cre. These control 
transcripts are prepared to staggered standard concentrations of 1.5pM, 5pM, 
25pM and 100pM, respectively. To ensure consistency of hybridisation efficiency 
between chips, the signal intensities of the four hybridisation control transcripts 
on each of the 10 GeneChips used in this study are plotted on the histogram 
shown in Figure 3-4, where the red lines represent the treatment samples and 
the green lines represent the control samples. The similar intensity values for 
the four hybridisation controls would suggest that there is little variation in 
hybridisation efficiency between each chip.       
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Figure 3-4 Signal histogram showing normalisation of microarray data  
To determine the transcriptional response in the brain following Aldara treatment and control cream 
treatment, microarray analysis was performed. Labelled sense-strand cDNA, generated from 
amplified RNA samples as described, was hybridised to 10 different chips along with 4 control 
transcripts at known standard concentrations. Signal histograms were generated for sample and 
control hybridisation, allowing the signal intensities to be compared. The histogram shown here 
depicts the normalised signal intensities of the hybridization controls; bioB, bioC, bioD and cre. 
Each line on the histogram represents an individual GeneChip, where the red lines are the 
treatment samples and the green lines are the control samples.  
 
3.3.3 Principle component analysis 
Principle component analysis (PCA) is a level of analysis that identifies patterns 
in the observed differential transcriptomic data. PCA uses a mathematical 
method that allows multidimensional data from the array to be transformed into 
a lower dimensional output using a minimal set of variables, called principle 
components (PC). The resulting PCA graph allows for visual analysis to be 
performed so that trends in the data, and outlying samples, can be identified.  
Figure 3-5 shows the PCA map of the normalised microarray data from this study. 
Each circle represents one sample and each colour represents a different group, 
where green is the control group and red is the Aldara treated group. The graph 
shows variation between samples within the same group, indicated by the lack 
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of tight clustering, which suggests that there are slight differences in the 
transcriptomic profile of the brains of both groups. None of the samples was 
identified as an outlier and thus all samples were included for subsequent 
analysis. The PCA graph shows a separation between the control and treatment 
groups, suggesting a differential gene response to the two different stimuli.   
 
Figure 3-5 Principle component analysis mapping of microarray samples 
To determine the transcriptional response in the brain following Aldara treatment and control cream 
treatment, microarray analysis was performed. Principle component analysis (PCA) was performed 
on normalised data from all samples included in the microarray study to identify trends in the data. 
Samples clustered in the same area are considered to be genetically similar. Each circle 
represents one sample and the different colours represent the different groups; where green is the 
control group and red is the Aldara treated group. n=5/group. 
 
3.3.4 Analysis of Affymetrix GeneChip data 
The various steps of quality control outlined above were applied to the GeneChip 
arrays to rule out sources of variation from differences in RNA quality, 
background signal noise and efficiency of hybridisation. As such, it can be 
assumed that any subsequent differences in signal intensity are representative of 
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differences in the transcriptional profile of the samples. In order to focus our 
investigation and to determine the biological relevance of transcriptional 
changes, differentially expressed genes had to be identified by order of 
significance. Thus, normalised signal intensities from the GeneChip array, 
generated using the GCRMA algorithm, were subject to statistical analysis. 
3.3.4.1 Filtering entities on expression 
Pre-processing the array chips using the RMA16 algorithm assigns the 28,853 
entities with a normalised signal intensity value. As an additional control, and to 
remove background, each entity had to have a signal intensity value between 
20% and 100%. By ensuring the entities outwith the upper 80% of all chip values 
were removed, background signal was eliminated. In addition, each entity had to 
satisfy this parameter in all five samples of each group in order to pass quality 
control and be included for analysis. The entities that remained following the 
filtration on gene expression are shown in the profile plot in Figure 3-6. This 
graph shows the normalised signal intensity of the entity, where the signal is 
normalised to the median value of that entity across all the samples, and allows 
entities with very high or very low signal values to be visualised on the same 
graph. The normalised signal intensity value of each entity is shown for both 
control samples and Aldara-treated samples. It is clear from the plot that the 
relative expression of many of the entities is much higher in the Aldara-treated 
samples, indicative of gene induction in these samples.   
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Figure 3-6 Profile plot showing normalised intensity values of entities following filtration 
This graph shows the change in the signal intensity value of each entity in control samples (left 
hand side) and treatment samples (right hand side). Each line represents one entity and the colour 
of the line denotes the signal intensity of that entity in the treatment group, ranging from -0.3 to 2.1, 
as outlined in the legend. 
 
3.3.4.2 Genes identified by GeneSpring as being differentially expressed in 
the brains of Aldara treated mice 
Differentially expressed genes were identified using a paired t-test along with 
Benjamini-Hochberg multiple testing correction (MTC) with a false discovery rate 
(FDR) of 0.1.  
MTC should be performed where possible in order to reduce the number of false 
positive results. Statistical analysis performed on large scale arrays like this one 
will use one test per entity. With many thousands of variables, and thus many 
thousands of tests being performed, the number of random events falsely being 
determined significant will increase. The p-value is the likelihood or probability 
of the null hypothesis being true and the more often the p-value is calculated 
from a single dataset, the higher the frequency of false positive results. For 
example, to analyse 1000 genes, 1000 statistical tests would be performed. If 
each has a p-value of 0.05, 50 of these genes would be considered false positives 
(0.05*1000). MTC is a statistical method that reduces the rate of error by taking 
into consideration the number of genes being tested, subsequently calculating a 
corrected p-value. Whilst MTC reduce the occurrence of false positives, they 
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also increase the chance of false negatives, thus the least stringent, Benjamini-
Hochberg, MTC method was ideal for this relatively small study.  
This method of statistical analysis generated a list of genes that were 
differentially expressed in the brains of the treatment group compared to the 
control group which satisfied a p-value ≤ 0.05. 7381 entities fell into this 
category; therefore a stringent fold change cut off ≥ 3 was applied to the 
dataset. The full list of genes that were differentially expressed in the brains of 
the treatment group, and which satisfied a p-value ≤ 0.05 and a fold change cut 
off ≥ 3 are listed in Appendix 1. In line with these criteria, 210 differentially 
expressed entities were found to be upregulated in the brains of the treatment 
group, which are shown in the volcano plot in Figure 3-7. In this plot, entities in 
red and green satisfied a p-value ≤ 0.05 and, in addition, the green samples 
were upregulated with a fold change ≥ 3. Since it was not feasible to validate all 
210 genes, we next categorised them according to gene ontology.   
 
Figure 3-7 Volcano plot of microarray data 
To determine the transcriptional response in the brain following Aldara treatment and control cream 
treatment, microarray analysis was performed. All of the entities evaluated in this array were 
plotted on a volcano plot that was generated using GeneSpring GX software. Red and green plots 
satisfy a p value ≤ 0.05 and, in addition, green plots adhere to a fold change cut off of 3 or above. 
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3.3.5 Gene ontology clustering using the Database for annotation, 
visualisation and integrated discovery (DAVID) 
Following the statistical, and fold change, analysis of the brain samples, further 
analysis was performed to functionally group the genes which were differentially 
expressed in the treatment brains. This analysis can help define patterns in the 
differentially expressed genes by grouping them according to their function. 
Often, this type of analysis is more informative than studying each gene 
individually and may provide insight into the mechanisms involved in the brain 
response to Aldara treatment. 
To apply biological relevance to the dataset of differentially expressed genes 
and to identify which groups of functionally related genes were enriched, gene 
ontology was assigned using the Database for Annotation, Visualization and 
Integrated Discovery (DAVID) Bioinformatics Resources. This publicly available 
software tool allows the visualisation of significantly enriched biological 
pathways based on the upregulated gene profile obtained from the microarray 
analysis. DAVID software uses a modified Fisher‘s exact test and Benjamini-
Hochberg MTC to determine which groups of functionally related genes are 
enriched, and groups with a p value < 0.05 were considered to be specifically 
associated with the gene list. DAVID analysis takes into consideration that each 
gene is represented by more than one probe on the Affymetrix GeneChip and 
will only analyse each gene once, irrespective of how many times it appears in 
the gene list.  
The most enriched pathways are shown in Figure 3-8, amongst which are 
‘Chemokine signalling pathway’, ‘Inflammation mediated by chemokine and 
cytokine signalling pathway’ and ‘Leukocyte transendothelial migration’. This 
strongly associates chemokines with the brain response and suggests that 
leukocyte migration into the brain may be mediating the distal response to 
Aldara treatment. In addition, the third most enriched process is ‘Toll-like 
receptor signalling pathway’, which may be the result of the TLR ligand, 
Imiquimod, directly stimulating cells in the brain.  
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Figure 3-8 Top 10 enriched biological processes identified using DAVID software 
Following microarray analysis, the list of differentially expressed genes in the brain were uploaded 
into DAVID software in order to identify enriched biological pathways. This figure shows the ten 
most enriched pathways in order of significance of the - log of their p-value. 
 
3.3.6 Comparing the brain response in models of TLR-induced 
peripheral inflammation 
Statistical analysis of the microarray dataset identified 210 differentially 
expressed genes in the brains of Aldara-treated mice that satisfied a p-value ≤ 
0.05 and a fold change cut-off ≥ 3. As it was not feasible to validate this number 
of genes using individual QPCR, a subset of target genes had to be identified. 
Since ‘Toll-like receptor signalling pathway’ was one of the pathways found to 
be enriched in the brains of Aldara-treated mice, we compared our data set to 
that of other models of peripherally induced TLR stimuli. LPS challenge has been 
studied extensively in the context of the brain response to peripheral 
inflammation. In one such study by Thomson et al, microarray analysis was 
performed following I.P. LPS administration, which allowed for the identification 
of a panel of 24 differentially expressed genes in the brains of treated mice377. 
Upon comparing our dataset with theirs, we found that 23 out of the 24 genes 
were also induced following Aldara treatment (Figure 3-9), a number of which 
were ISGs. Since both TLR4 and TLR7 signalling can induce an IFN response, the 
ISGs were an appropriate focus for our investigation. Figure 3-10 shows the 15 
ISGs in order of their fold change induction in the brain following Aldara 
treatment, presented as a heatmap which was generated using GeneSpring GX 
software. The fold change and p-value for each of the ISGs is shown in Table 3-2.    
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Figure 3-9 Venn diagram showing common genes between LPS and Aldara models 
Differentially expressed genes identified in the brain following an LPS model of systemic 
inflammation were compared to the list of differentially expressed genes generated following 
microarray analysis of brains from Aldara treated mice. Interestingly, 23 out of the 24 genes 
identified in the LPS model were also upregulated following the Aldara model, providing a focus for 
investigation in this chapter.  
 
 
Figure 3-10 Heatmap of differentially expressed ISGs identified by microarray analysis 
Microarray analysis was performed using RNA from brains of Aldara treated and control mice. 
Following statistical analysis, the list of differentially expressed genes was compared to the list of 
genes identified in the brain following systemic LPS stimulation. A heatmap was generated using 
GeneSpring GX software to depict the 15 differentially expressed ISGs in Aldara treated and 
control brains that were identified previously in an LPS model of systemic inflammation. The five 
treatment samples are shown in red and the five control samples in green. 
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Table 3-2 A list of the 15 ISGs that were upregulated in the Aldara model  
 Symbol Gene name Fold change p-value 
Oasl2 2'-5' oligoadenylate synthetase-like 2 14.91 1.68E-08 
Ifit1 interferon-induced protein with tetratricopeptide repeats 1 14.15 2.26E-07 
Irf7 interferon regulatory factor 7 13.70 3.23E-08 
Ifitm3 interferon induced transmembrane protein 3 7.91 6.25E-09 
Rtp4 receptor transporter protein 4 7.32 3.52E-07 
Ctsc cathepsin C 7.22 2.65E-10 
Irgm1 immunity-related GTPase family M member 1 6.98 4.35E-07 
Gbp3 guanylate binding protein 3 6.91 3.71E-06 
Gbp2 guanylate binding protein 2 6.51 3.34E-06 
Stat1 signal transducer and activator of transcription 1 5.20 2.13E-06 
Gbp4 guanylate binding protein 4 4.33 1.37E-06 
CXCL10 chemokine (C-X-C motif) ligand 10 4.25 1.27E-04 
Gbp6 guanylate binding protein 6 4.08 1.01E-05 
Lgals3bp lectin, galactoside-binding, soluble, 3 binding protein 4.06 3.03E-06 
Sp100 Sp100 nuclear antigen 3.67 4.49E-07 
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3.5 QPCR analysis of the transcriptional profile in 
response to Aldara treatment  
Microarray analysis provided the data set of genes that were differentially 
expressed in the brains of Aldara treated mice. To confirm the upregulation of 
these genes, individual SYBR Green QPCR was performed using RNA from an 
independent model of Aldara-induced skin inflammation. To focus our 
investigation, this was restricted to the 15 ISGs of interest that have been shown 
to be induced in the brains of mice challenged with systemic LPS, the majority 
of which were identified in the microarray.   
3.5.1 QPCR validation of differentially expressed genes in the 
brain 
Specific primer pairs were designed for each gene as described in section 
2.4.7.1. SYBR Green QPCR was performed using RNA from brains from an 
independent Aldara model. With the exception of Gbp4, all of the ISGs evaluated 
were significantly elevated in the brains of Aldara treated mice compared with 
the brains of control mice (Figure 3-11). With regards to the significant genes, 
the upregulation ranged from around 2- to >60 fold induction, with CXCL10 
exhibiting the greatest induction of 64-fold. 
3.5.2 QPCR validation of the peripheral blood response 
To determine whether or not the ISG response was induced systemically, the ISG 
induction in the brain was compared with induction in peripheral blood 
leukocytes (PBL) using SYBR Green QPCR. If an ISG response was identified in the 
PBL, it may be that the expression seen in the brain was the result of a 
contaminating signal from the blood. Therefore, this part of the study would 
ensure that blood contamination was not a factor in the brain response. PBL 
were harvested from Aldara treated and control mice 24 hours following the 
fifth Aldara application. The results show that none of the ISGs assessed was 
significantly elevated in the PBL of the treatment group. The only genes to show 
an upward trend in the PBL were Gbp3, IFITm3 and Oasl2, although the 
induction is very slight and not significant. Of note, several genes appeared to 
be downregulated in the PBL (Figure 3-11).  
  113 
3.5.3 Comparison of central brain response with peripheral blood 
response 
Having established the differential expression of the ISGs in the brain and the 
PBL by comparing them to control tissues using individual student’s t tests, we 
next sought to determine the significance of the fold change induction when 
comparing between the two tissues. This was done using two-way ANOVA with 
Bonferroni multiple comparison post-tests. The fold change induction in the 
brain was significantly greater than the fold change induction in the PBL for all 
15 ISGs examined (Figure 3-11), highlighting the differential response between 
the periphery and the brain.   
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Figure 3-11 QPCR analysis of ISGs in brains and PBL 
Mice were treated with 80mg Aldara cream or control cream every 24hrs for 5 consecutive days. 
Mice were euthanised 24hrs after the final application. Cardiac puncture was performed to retrieve 
PBLs and perfused brains were extracted. RNA was isolated from both tissues. QPCR analysis of 
the target ISG genes identified in the microarray was performed for both tissues (A-O). n= 5 mice 
per group. Significance was measured using individual students t test or two-way ANOVA with 
Bonferroni multiple comparison post-tests *** (+++) = p ≤ 0.001 **(++) = p ≤ 0.01 *(+) = p ≤ 0.05 
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3.6 Assessment of burrowing behaviour 
Having identified a number of transcriptional changes in the brains of Aldara 
treated mice, it was important to determine what, if any, functional effect 
these transcripts may mediate. Neuroinflammatory components are key 
candidates for triggering the behavioural changes often presented in tandem 
with chronic inflammatory disorders of the periphery. To determine whether or 
not topical Aldara treatment could induce a functional output, a simple 
behavioural model was employed. This model used custom made burrowing 
tubes to assess the extent to which mice burrow during a 2 hour period following 
treatment373. Burrowing is an instinctive and natural behaviour in rodents. To 
test this behaviour, mice were first acclimatised to the presence of a burrowing 
tube overnight prior to baseline tests being carried out. The groups were then 
divided to ensure that the best, and worst, burrowers were split evenly between 
the two groups. Mice were treated at the same time each morning with 80mg of 
either Aldara cream or control cream as described previously and were then 
single housed for the testing period 4 hours later. Each single cage contained 
one burrowing tube prefilled with a fixed weight of food pellets. The mice were 
then left undisturbed to burrow at their leisure for a two hour period, before 
being returned to group cages. The weight of food remaining in each tube was 
recorded. Figure 3-12(A) shows the setup of the burrowing tube containing 200g 
of food pellets in a large cage before and after the burrowing test period. The 
weight of food left in the tube was significantly lower in the control group than 
the Aldara treated group, meaning that control mice ‘burrowed’ more of the 
contents than the Aldara treated mice (B). Both groups showed a range of 
burrowing activity during the baseline tests, however even after the first 
application, the activity of Aldara treated mice was significantly reduced. This 
trend continued over the three testing days with some mice failing to burrow at 
all after only one treatment. In contrast, control mice appeared to burrow more 
with time suggesting an improvement in this behaviour. When presented as a 
percentage of the baseline activity for each individual mouse, where the 
baseline burrowing is considered 100%, it is apparent that some of the Aldara 
treated mice do display enhanced burrowing activity. However, the burrowing 
activity of Aldara treated mice is increased to a lesser extent than that of the 
control mice (C). Similarly, one out of the five mice in the control group 
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burrowed less on day 3 than it did in the baseline tests; however the trend lines 
show a clear separation between the two groups. These results show that 
burrowing behaviour was impaired in Aldara treated mice, an effect that could 
be seen after only one treatment. The motor functions of these mice did not 
appear to be a factor as they displayed normal activity levels and the burrowing 
tubes were large enough that they did not come into contact with, and 
potentially irritate, the affected area of skin. However, motor functions were 
not directly tested.     
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Figure 3-12 Burrowing activity of Aldara treated mice 
Aldara treated or control treated mice were assessed for burrowing activity on three consecutive 
days. Four hours following treatment application, mice were single caged with a burrowing tube 
containing 200g of food pellets for 2 hours. At the end of this time point, mice were caged again in 
groups and the remaining weight of food pellets in the tubes was recorded. (A) shows the setup of 
the burrowing tubes before and after burrowing activity. The weight left in the tube following the 2 
hour period is shown (B) or presented as a percentage of baseline tests, where baseline readings 
were considered 100% (C). n=5 per group. Significance was measured using two-way ANOVA with 
Bonferroni posttests *** = p ≤ 0.001 *= p ≤ 0.05.     
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3.7 Discussion 
In order to determine the effect of peripheral, tissue-specific inflammation on 
the brain, the Aldara model of psoriasis-like skin inflammation was used362. This 
model, in which mice were treated with a daily dose of cutaneous Aldara cream, 
was first validated to ensure its reproducibility before microarray analysis of the 
brains was performed. This study identified a large number of differentially 
expressed genes in the brains of the treatment group, which satisfied a p-value ≤ 
0.05 and a fold-change cut off of 3. Amongst the upregulated genes was a 
distinct panel of ISGs that have previously been identified in the brain in a 
model of peripheral LPS injection377. To determine the likelihood that this ISG 
response is a generic consequence of TLR driven peripheral inflammation, these 
ISGs served as the focus of this chapter. These genes of interest were validated 
in an independent Aldara model to confirm their induction in the brain and, in 
order to determine whether the response was systemic, the transcriptional 
profile of the PBL was also assessed. A basic behavioural model was used to 
determine whether, or not, Aldara treatment was sufficient to induce impaired 
burrowing activity, a behaviour that is instinctive to rodents.  
QPCR analyses confirmed that all 15 ISGs, which were commonly upregulated in 
response to Aldara and LPS, were significantly induced in the brains of the 
Aldara treatment group. In addition, the fold change induction in the brain was 
significantly greater than the fold change induction in the PBL for all genes. This 
suggests that the response in the PBL differs in kinetics and magnitude to the 
response in the brain. Importantly, this also rules out the possibility of blood 
contamination in the brain being responsible for the transcriptional changes 
observed.  
CXCL10 is the gene that exhibits the greatest fold change induction in the brain 
when analysed using QPCR. With an upregulation of almost 64-fold, its 
expression change is significant, allowing it the potential to play a prominent 
role in the CNS response to peripheral inflammation. CXCL10 is a classic ISG that 
is commonly expressed in the brain in response to a range of inflammatory 
stimuli, including traumatic brain injury (TBI)251, EAE and MS243, 378-380, and a 
number of viral infections234, 381-383. CXCL10 binds to the receptor CXCR3 and can 
mediate the migration of receptor expressing leukocytes. This mechanism has 
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been shown to induce the influx of leukocytes into the brain during 
inflammation. It is possible that, with such a strong induction in response to 
Aldara treatment, CXCL10 could be mediating the recruitment of leukocytes into 
the brain in this model. This is supported by the DAVID analysis which identified 
‘Chemokine signalling pathway’, ‘Inflammation mediated by chemokine and 
cytokine signalling pathway’ and ‘Leukocyte transendothelial migration’ as 
significantly enriched biological pathways in the brain. Therefore, leukocyte 
infiltration into the CNS, as a consequence of Aldara-mediated peripheral 
inflammation, is plausible.  
In addition to the transcriptional response, Aldara treatment also induced a 
functional response in the brain, in the form of impaired behaviour. Although 
this cannot be directly associated with the increased ISG production, the 
burrowing model has been shown to be sensitive to a number of treatments in 
which the inflammatory profile of the brain has been altered384, 385.  
The specific actions of Aldara cream, through which this brain response is 
mediated, remain unknown. However, Aldara cream works as a therapeutic 
agent due to its active component, IMQ, which binds to TLR7/8 and stimulates 
an IFN-driven anti-viral response.TLR7/8, which recognise single-stranded RNA, 
can signal canonically through MyD88 to activate the transcription factor NF-κB 
and lead to the production of inflammatory cytokines. In addition, it can also 
signal through an independent, IRF7-mediated pathway leading to the activation 
ISRE7 and the production of IFNα. These signalling pathways drive a specific 
anti-viral immune response that is characterised by the production of type I IFNs 
and is amplified by the transcription of ISGs386. This response has been described 
in a number of publications reporting human, primate and rodent studies, both 
in vitro and in vivo, and using natural as well as synthetic agonists387-390.  
It is therefore predictable that we see an IFN stimulated response following 
TLR7-mediated immune stimulation. However, what is surprising about the data 
from this study is that the ISG response appears to be localised in the brain, 
independently of an ISG response in the PBL. Furthermore, there was no 
evidence of an overt inflammatory cytokine response in the plasma. The 
presence of such a pronounced transcriptional response in the brain 24 hours 
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after the fifth application of Aldara suggests that the response in the brain is 
long-lived and perhaps ensues beyond the response in the periphery.   
To our knowledge, the CNS response to topical Aldara treatment has not been 
examined before. However its active component, IMQ, has been used to 
investigate the brain response following various different routes of 
administration. Butchi et al. have shown that intracerebroventricular inoculation 
with Imiquimod in developing mice leads to microglia and astrocyte 
activation391. They have reported that protein levels of certain proinflammatory 
cytokines are upregulated in response to TLR7 ligation, along with a strong IFNβ 
response. Damm et al. used IMQ to investigate how TLR ligation, and different 
routes of administration, can cause the manifestation of inflammation at distant 
sites, including the brain7. They found that a high dose of peripherally 
administered IMQ (subcutaneous and intraperitoneal) induced a milder brain-
controlled illness response than other TLR ligands have been shown to, but did 
induce a moderate fever, peripheral and hypothalamic cytokine induction and 
inflammatory transcription factor activation. Although there was a marked 
upregulation of IFNs in the periphery, they reported no change in the levels of 
IFN in the brain. However, topical application to the skin was not investigated in 
either of these studies, nor did they evaluate the expression of ISGs, thus it is 
difficult to make direct comparisons with the analysis performed in this thesis.  
In addition to the IMQ-based studies, others have shown an ISG response in the 
brain following different inflammatory stimuli; however the route of 
administration used in these studies is more direct, either through the nasal 
cavity or by intracranial injection. Wacher et al used intranasal West Nile Virus 
(WNV) and intracranial lymphocytic choriomeningitis virus (LCMV) to show the 
upregulation of several ISGs in the brain at different time-points392.  Similarly, 
van der Pol et al used the intranasal administration of vesicular stomatitis virus 
(VSV) and cytomegalovirus (CMV) to demonstrate the upregulation of ISGs at four 
distinct sites throughout the brain, highlighting the long-range of IFN signalling. 
In addition, they showed that viral RNA was below the level of detection in some 
of the distant brain regions, indicating that the ISG response was not dependent 
on the localised presence of viral stimuli393. Analysis was also performed 
following the intravenous injection of VSV. Here, an ISG response was found in 
all tissues examined, including the brain, irrespective of the presence of virus 
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RNA. However it should be noted that only two ISGs, OAS and IFIT2, were 
analysed as being representative of the ISG response. The work by Thomson et 
al377, upon which our selection of target ISGs was based, showed the induction of 
a distinct panel of ISGs in the brain in response to both acute and chronic LPS 
stimulation. In addition, this response was not mimicked in the PBL and could 
not be induced with the administration of inflammatory cytokines directly, or 
with an alternative TLR ligand, lipoteichoic acid (LTA). Interestingly, a 
commonality between Aldara and LPS is that their receptors, TLR7 and TLR4, 
respectively, both have an alternative, non-canonical, signalling pathway that 
can lead to the production of type I IFNs. It is therefore possible that the brain 
response we see in both of these models is the result of NF-κB-independent 
downstream signalling. There is considerable evidence linking type I IFNs to 
psychiatric disorders, including sequencing data that showed a significant 
association between MDD and genes involved in the IFN α/β signalling pathway394 
and the onset of MDD in patients with Hepatitis C and cancer following IFN 
treatment323, 327, 328, 395-397. Therefore, we hypothesise that TLR-mediated type I 
IFN production could lead to a distinct ISG response in the brain and the 
subsequent onset of behavioural deficits.  
Although it is clear from the results that topical, cutaneous Aldara treatment 
can induce a distinct brain response, the mechanisms by which this response is 
mediated remain to be established. It may be possible that, provided IMQ was 
able to cross the BBB, the IFN response is induced by the direct activation of 
glial cells within the brain parenchyma. To our knowledge, no one has looked 
specifically at whether or not IMQ is able to do so, however the microarray did 
not show any evidence of an upregulated expression of IFN itself. If IMQ is not 
able to traverse the BBB, the response must be initiated first in the periphery, 
whereby peripherally-induced IFNs could be travelling to, and interacting, with 
the brain.  
In summary, through studies described in this chapter we have identified a 
transcriptional profile in the brain in response to Aldara treatment. In addition, 
this treatment induces a behavioural abnormality that is associated with 
impaired neurological well-being. However, the mechanisms by which this 
response is driven remain to be established. We have yet to determine whether 
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this response is TLR-dependent, or what the role of the initial localised skin 
response is. Thus further investigation is required.    
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Defining the mechanism of the brain response to 
peripheral cutaneous inflammation 
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4 Defining the mechanism of the brain response 
to peripheral cutaneous inflammation 
4.1 Introduction 
The results in Chapter 3 identified a brain response to peripherally induced 
cutaneous inflammation in the Aldara model of skin inflammation. However, the 
mechanisms involved in establishing this response remain unclear and many 
questions remain unanswered. For example, although the ISG response was 
consistent across two TLR-mediated models, LPS and Aldara, it is not clear if the 
brain response was TLR-dependent. During this study in 2013, Walter et al 
published a Nature Communications article showing that Aldara cream could also 
activate a TLR7-independent cutaneous immune response372. It was reported 
that isostearic acid alone, a component of the vehicle, could induce 
keratinocyte cell death and inflammasome activation. They concluded that the 
full immune response required both IMQ and isostearic acid, however, the 
systemic response was largely dependent on TLR7 and type I IFN signalling. 
These findings highlighted the importance of determining the separate 
contributions of IMQ and isostearic acid in generating the brain response 
described in Chapter 3.  
The QPCR analysis of the PBL, and the ELISA analysis of the plasma, in Chapter 3 
suggested that the brain response was occurring independently of a peripheral 
inflammatory response; however this was only analysed following 5 repeated 
applications of Aldara cream, which may be considered quite late in the 
response. Therefore, it may be that a peripheral response has driven the CNS 
response but that it is generated at a much earlier time point. 
This Chapter set out to address these issues in an attempt to understand more 
about the mechanisms of the brain response to cutaneous inflammation. To do 
so, the TPA model of skin inflammation was first used398. TPA is a chemical 
irritant which activates protein kinase C (PKC) and, when applied repeatedly to 
the dorsal skin, induces a similar psoriasis-like phenotype to Aldara398, 399. 
However, TPA does not function through TLRs and is therefore considered a 
‘sterile’ model of inflammation. Thus, using this model, we hoped to determine 
the involvement of TLR stimulation in the generation of the brain response. In 
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addition, to determine whether or not the brain ISG response could be the result 
of an ISG response in the periphery, present at an earlier time-point, a time 
course model of both Aldara and TPA was assessed. Finally, to understand the 
individual contribution of IMQ, an additional two IMQ models were analysed.  
4.2 The TPA model of skin inflammation 
To induce peripheral skin-specific inflammation, 12-O-Tetradecanoylphorbol-13-
acetate (TPA) was applied daily to the shaved dorsal skin of 6-8 week old female 
c57BL/6 mice. This application was repeated over 5 consecutive days. As a 
control, age and sex matched mice were treated in a similar way with acetone 
vehicle. Mice were terminally anaesthetised 24 hours after the final application. 
4.2.1 Model Validation 
In order to compare the TPA response to the Aldara response examined in 
Chapter 3, the same parameters were assessed as a method of validating the 
model. Mouse weights were recorded following each application, spleens were 
collected to be weighed and photographed and H&E stained sections from the 
treated dorsal skin were analysed. Unlike Aldara treated mice, TPA treated mice 
did not lose any weight over the course of the treatment and in fact, like control 
mice, gained weight (Figure 4-1A). The mice did however show signs of 
splenomegaly as the spleens from the treated group were significantly bigger 
than the spleens from the control group and weighed almost twice as much 
(Figure 4-1B+C). When the H&E staining of the control and treated areas of skin 
was analysed, it was clear that TPA induced an inflammatory response 
characterised by epidermal hyperplasia, dermal expansion, erythema and 
inflamed lesions (Figure 4-1D). Again, ELISA analysis was used to assess the 
plasma concentrations of three key inflammatory cytokines, IL-1β, IL-6 and TNFα 
(Figure 4-2A, B+C, respectively). All samples fell below the minimum level of 
detection of the ELISA kits for each of the three cytokines. To ensure the 
robustness of the assays, plasma from LPS-treated mice was included on each 
plate as a positive control (Figure 4-2D).   
     
   
  127 
 
 
 
Figure 4-1 Evaluation of the phenotypic response to TPA induced skin inflammation 
Mice treated with 150µl 100µM TPA, or equivalent volume acetone, were weighed following each 
application (A). In addition, spleens were photographed (B) and weighed (C). H&E staining was 
performed using 5µm thick sections of TPA- or acetone- treated skin which were visualised at 200X 
magnification. n = 5/group. Significance was measured using two-way ANOVA or student’s t test. 
*** = p ≤ 0.001. 
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Figure 4-2 Expression of inflammatory cytokines in the plasma of TPA-treated mice 
Plasma was isolated from mice treated with 150µl 100µM TPA, or equivalent volume acetone, 
24hrs after the fifth application. ELISAs were used to assess the expression of three key 
inflammatory cytokines, IL-1β (A), IL-6 (B) and TNF-α (C). To ensure the integrity of the assay, 
plasma from LPS- injected mice was included as a positive control. Group size of n = 5 for 
TPA/acetone treated mice, n = 3 for LPS- treated mice. Minimum level of detection represents the 
lowest sensitivity for each kit. 
 
4.2.2 QPCR analysis of ISG expression in response to TPA 
treatment  
To determine the expression of the 15 target ISGs (described in Chapter 3) 
following TPA treatment, QPCR analysis was performed using RNA from brains 
and PBL isolated 24 hours after the final TPA treatment. Expression of each gene 
was normalised to the housekeeping gene, TBP, and each treatment group was 
compared to the corresponding control group, values from which were 
normalised to a fold change value of 1. The fold change induction of each gene 
in the brain and PBL is shown in Figure 4-3.   
4.2.2.1 QPCR analysis of ISG response in the brain 
The results of the QPCR analysis show that none of the ISGs was significantly 
upregulated in the brain in response to TPA treatment. All genes exhibited a fold 
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change induction of 1 or below. Four of the genes, Ctsc, Gbp2, Gbp6 and Stat1, 
showed a significant downregulation of expression in the brains of TPA treated 
mice compared with the control brains. However, the CT values of some of the 
samples were high and close to what would be considered the level of detection, 
therefore it is difficult to determine if the downregulation was real or if it was 
the result of inaccuracy resulting from low expression. This inaccuracy could also 
account for the high standard deviation present in many of the groups. 
Regardless, it is clear that cutaneous TPA treatment fails to induce a similar ISG 
brain response to cutaneous Aldara treatment.     
4.2.2.2 QPCR analysis of the ISG response in the peripheral blood  
To determine whether or not TPA treatment induces a transcriptional response 
in the periphery, QPCR analysis was performed using RNA from the PBL. This 
comparison also ensured that the expression levels in the brain were not the 
result of blood contamination. Again, none of the ISGs were significantly induced 
in the PBL of the treatment group. Some of the genes, for example Rtp4, 
showed a difference, however these did not reach significance and the variation 
within these groups is high, again suggesting that the low expression levels have 
introduced inaccuracies. The expression of Gbp4 in the PBL is significantly 
reduced following TPA treatment, with a fold change of 0.5 (Figure 4-3).     
4.2.2.3 Comparison of brain response with the peripheral blood response 
When comparing between the two tissues, it is obvious that neither exhibits a 
significant ISG induction following cutaneous TPA treatment. Only three genes 
are significantly differentially expressed between the brain and PBL; Gbp2, Rtp4 
and Stat1 (Figure 4-3). With only very minimal fluctuations in expression and 
high standard deviation, it was apparent that the response to TPA treatment is 
minimal in comparison with the response to Aldara treatment described in 
Chapter 3.  
  130 
 
  131 
 
Figure 4-3 QPCR analysis of ISGs in brains and PBL following TPA treatment 
Mice were treated with 150µl 100µM TPA, or equivalent volume of acetone, every 24hrs for 5 
consecutive days. Mice were euthanised 24hrs after the final application. Cardiac puncture was 
performed to retrieve PBLs and perfused brains were extracted. RNA was isolated from both 
tissues. QPCR analysis of the 15 target ISG genes was performed for both tissues (A-O). n= 5 
mice per group. Significance was measured using individual unpaired students t tests for individual 
tissues (control vs treated) or two-way ANOVA with Bonferroni multiple comparison post-tests for 
comparisons between tissues (PBL vs brain). *** (+++) = p ≤ 0.001 **(++) = p ≤ 0.01 *(+) = p ≤ 0.05 
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4.3 Temporal response following cutaneous Aldara 
treatment 
Work described in Chapter 3 established that repeated treatment with Aldara 
cream induces a brain ISG response. This appears to be independent of an overt 
inflammatory response in the periphery. However, it may be that the brain 
response is driven by a peripheral response which is initiated at a much earlier 
time point and which has dissipated by the fifth application. To investigate this, 
a time course of Aldara treatment was used. 80mg of Aldara cream was applied 
daily to the shaved dorsal skin of 6-8 week old female c57BL/6 mice for 1, 3 or 5 
applications. As a control, age and sex matched mice were treated with an equal 
quantity of water based control cream. Mice were terminally anaesthetised 24 
hours after the final application.  
Consistent with previous results, the Aldara treated mice lost a significant 
amount of weight over the course of the treatment, with the most significant 
weight loss occurring between the third and fifth applications. The mice had 
regained some of their weight by the end of the treatment period; however they 
remained significantly lighter than the control mice (Figure 4-4A). Areas of the 
treated dorsal skin were sectioned and H&E stained. The control skin remained 
uninflamed throughout the five day period; however the Aldara treated mice 
showed epidermal thickening even after one application. The skin inflammation 
was most pronounced after the third and fifth applications, where distinct 
epidermal hyperplasia was evident (Figure 4-4B).     
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Figure 4-4 Model validation of Aldara time course  
Mice were treated with 80mg of Aldara, or an equivalent quantity of control cream, for 1, 3 or 5 
consecutive applications. Mice were weighed following each application (A). H&E staining was 
performed using 5µm thick sections of Aldara- or control cream- treated skin from each time point 
and sections were visualised at 200X magnification (B). n = 4/group. Significance was measured 
using two-way ANOVA *** = p ≤ 0.001 * = p ≤ 0.05 
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4.3.1 QPCR analysis of the transcriptional ISG profile at different 
time points in response to Aldara treatment  
To assess the time course of the ISG response to Aldara treatment, SYBR Green 
QPCR analysis was performed using RNA from brains and PBL isolated 24 hours 
after 1, 3 or 5 treatments. Each gene was normalised to the housekeeping gene, 
TBP, and each treatment group was compared to the corresponding control 
group, which were normalised to a fold change value of 1. The fold change 
induction of each gene in the brain and PBL is shown in Figure 4-5 
4.3.1.1 QPCR analysis of ISG response in the brain 
The results of the QPCR analysis of the control and Aldara-treated brains show 
that all 15 genes are induced in the brain at day 3 following Aldara treatment 
when compared with the control brains. Although the response at day 1 was less 
pronounced than the other time points, six of the ISGs, Gbp2, IFIT1, IFITm3, 
IRF7, Sp100 and Stat1, were significantly induced (Figure 4-5C,G,H,J,N and O, 
respectively). It is evident from the results that day 3 is the peak of the ISG 
response in the brain following cutaneous Aldara treatment, as all 15 ISGs were 
significantly induced. This ranged from a 20-fold induction to a striking 1000-fold 
induction for CXCL10, which was the most highly induced (Figure 4-5B). By day 
5, all of the genes remained elevated in the brain and, with the exception of 
IFIT1, Gbp2 and CXCL10; the expression levels were statistically significant 
compared with the controls. These data show that the brain response to Aldara 
treatment is initiated during the early stages of the model and persists 
throughout the time-course; however this response appears to peak after the 
third treatment before beginning to diminish. With the exception of Sp100, the 
induction at day 3 is significantly higher than it is at day 5, confirming that the 
response dissipated beyond day 3.       
4.3.1.2 QPCR analysis of the ISG response in the peripheral blood  
The QPCR analysis of the PBL from both Aldara-treated and control mice 
indicated the presence of an ISG response in the periphery at the earlier time 
points. 11 out of the 15 genes were significantly induced in the PBL of the 
treatment group compared with the control group at day 1. None of the ISGs 
expressed in the PBL was induced more than 20-fold. By day 3, only 4 genes 
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remained significantly induced; Ctsc, CXCL10, Rtp4 and Stat1, and by day 5 this 
was down to only one gene; IFITm3. However, IFITm3 was not significantly 
induced on day 3 and appeared to have fluctuated in the PBL over the time 
course. These data suggest that an early ISG response is induced in the PBL after 
the first treatment; however this response dissipates over time, and is minimal 
by day 5. 
4.3.1.3 Comparison of central brain response with the peripheral blood 
response following Aldara treatment 
When comparing the brain and PBL in Aldara-treated mice, there is a clear 
separation in the magnitude and temporal pattern of the two responses. The 
response in the brain is much stronger than in the PBL, with fold-change 
inductions in the hundreds or even thousands. Although there appears to be an 
initial PBL response at day 1, only with Ctsc is the fold change induction in the 
PBL higher than in the brain. Using statistical analysis, the induction of all 15 
ISGs is significantly higher in the brain than in the PBL at day 3. By day 5, 
although all genes still show a fold change induction, this is only significant in 
comparison with the PBL for two of the genes; Ctsc and Stat1. By comparing 
these two tissues, it would appear that the PBL response differs in magnitude 
and temporal pattern to the brain response. This indicates that the strong 
response which lingers in the brain following cutaneous Aldara treatment cannot 
be attributed to the ISG response in the PBL.    
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Figure 4-5 QPCR analysis of ISGs in the brain and PBL during the Aldara time course 
Mice were treated with 80mg of Aldara cream, or an equivalent volume of control cream, every 
24hrs for 1, 3 or 5 days. RNA was then isolated from the brain and PBL 24hrs after the final 
treatment. Gene expression analysis of (A) Ctsc, (B) Cxcl10, (C) Gbp2, (D) Gbp3, (E) Gbp4, (F) 
Gbp6 (G) Ifit1, (H) Ifitm3, (I) Irgm1, (J) Irf7, (K) Lgals3bp, (L) Oasl2, (M) Rtp4, (N) Sp100 and (O) 
Stat1 was performed using QPCR and was normalised to TBP. Data are expressed as fold change 
induction, relative to the controls, which have a fold change value of 1. Data represent the mean +/- 
SD. Significance was calculated for individual tissues (control vs treated, d1 vs d3 vs d5), between 
tissues (treated only, PBL vs brain) and between time-points (treated only, d1 vs d3 vs d5) using 
two-way ANOVA with Bonferroni multiple comparison post-test. *** p ≤ 0.001. ** p ≤ 0.01, * p ≤ 
0.05. n = 4/group 
 
4.3.2 Luminex analysis of the temporal response following Aldara 
treatment  
Luminex analysis was performed in order to determine the cytokine response in 
the plasma at the different time points following cutaneous Aldara treatment. 
The mouse 20-plex panel covered a range of key cytokines (Figure 4-6), 
chemokines and growth factors (Figure 4-7). In order to include the appropriate 
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number of technical replicates, where each sample was analysed in triplicate, 
samples were diluted 1:4 prior to analysis. However, as a result, many of the 
readings were below the level of detection of the assay. To enable statistical 
analysis, any sample which failed to obtain an expression value was assigned a 
concentration equal to the minimum level of detection for each protein. Three 
of the proteins failed to obtain a value for any of the samples included on the 
assay; therefore IL-1α, IL-10 and IFNγ were omitted from further analysis. 
8 out of the 17 remaining proteins were significantly induced in the treated 
group when compared with the control group at day 1. These included 4 
cytokines; IL-2, IL-5, IL-6, IL-12 (Figure 4-6B, D, E, F) and 4 chemokines; CCL2, 
CXCL1, CXCL9 and CXCL10 (Figure 4-7A, C, D, E). Several of these were highly 
expressed, at around 1000 pg/ml, including all four chemokines. By day 3, the 
expression of the cytokines failed to reach significance when compared to the 
controls, however CXCL1, CXCL9, CXCL10, VEGF and GM-CSF were significantly 
induced in the Aldara treated mice compared with control mice (Figure 4-7). At 
day 5, IL-1β and IL-17 levels were significantly higher in the control group 
compared with the treated group, indicating a downregulation following 
cutaneous Aldara treatment. The only proteins significantly induced in the 
Aldara treated mice at day 5 were VEGF and GM-CSF, the expression of which 
appeared to be higher than the control mice at the later time points in this 
model. Interestingly, IL-1β, IL-6 and TNFα were detected at day 5 in this assay 
despite being below the level of detection when investigated using ELISA earlier 
in this thesis. This was perhaps due to the increased sensitivity of the Luminex 
assay. In summary, the results of the Luminex analysis suggest that topical 
Aldara treatment can induce an early peripheral inflammatory response, 
characterised by the expression of cytokines and chemokines, which dissipates 
over the course of the treatment. This response appears to be temporally 
different to the central response.  
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Figure 4-6 Cytokine expression in the plasma 1, 3 or 5 days following Aldara treatment 
Mice were treated with 80mg of Aldara cream, or an equivalent volume of control cream, every 
24hrs for 1, 3 or 5 days. Plasma was isolated 24hrs after the final treatment. Luminex analysis of 
(A) IL-1β, (B) IL-2, (C) IL-4, (D) IL-5, (E) IL-6, (F) IL-12 (G) IL-13, (H) IL-17 and (I) TNFα was 
performed. Data are expressed as concentration in pg/ml. Data represent the mean +/- SEM. 
Significance was calculated using two-way ANOVA with Bonferroni multiple comparison post-tests: 
*** p ≤ 0.001. ** p ≤ 0.01, * p ≤ 0.05. n = 4/group 
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Figure 4-7 Chemokine/ growth factor expression in the plasma 1, 3 or 5 days following 
Aldara treatment 
Mice were treated with 80mg of Aldara cream, or an equivalent volume of control cream, every 
24hrs for 1, 3 or 5 days. Plasma was isolated 24hrs after the final treatment. Luminex analysis of 
(A) CCL2, (B) CCL3, (C) CXCL1, (D) CXCL9, (E) CXCL10, (F) VEGF (G) FGF-Basic and (H) GM-
CSF was performed. Data are expressed as concentration in pg/ml. Data represent the mean +/- 
SEM. Significance was calculated using two-way ANOVA with Bonferroni multiple comparison 
post-tests: *** p ≤ 0.001. ** p ≤ 0.01, * p ≤ 0.05. n = 4/group 
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4.4 Temporal response following TPA treatment 
Analysis of the temporal response to Aldara treatment, described in Section 4.3, 
showed that topical Aldara treatment induced an early peripheral cytokine 
response, skin inflammation that worsened over the course of the treatment and 
a brain ISG response that peaked at day 3. Conversely, the TPA model of 
cutaneous inflammation failed to induce an ISG response in the brain after 5 
applications. To determine whether or not the TPA model can induce a brain ISG 
response at earlier time-points, a time-course was set up. TPA was applied daily 
to the shaved dorsal skin of c57BL/6 mice for 1, 3 or 5 days. As a control, age 
and sex matched mice were treated with an equal quantity of acetone. Mice 
were terminally anaesthetised 24hrs following the final application and plasma 
and perfused tissues collected.  
Mice did not lose any weight over the course of the treatment and, like acetone-
treated control mice, TPA-treated mice gained weight with time (Figure 4-8A). 
H&E analysis of the treated dorsal skin sections showed that TPA treatment 
induced skin inflammation following just one application, indicated by epidermal 
hyperplasia, which worsened with repeated doses. Skin inflammation was most 
pronounced after the third and fifth treatments (Figure 4-8B).  
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Figure 4-8 Model validation of TPA time-course 
Mice were treated with 150µl 100µM TPA, or equivalent volume acetone, for 1, 3 or 5 consecutive 
applications. Mice were weighed following each application (A). H&E staining was performed using 
5µm thick sections of TPA- or acetone- treated skin from each time point and sections were 
visualised at 200X magnification (B). n = 4/group. Significance was measured using two-way 
ANOVA 
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4.4.1 QPCR analysis of temporal ISG expression following TPA 
treatment  
To assess the time course of the ISG response to TPA treatment, QPCR analysis 
was performed using RNA from brains and PBL isolated 24 hours after 1, 3 or 5 
treatments. Each gene was normalised to the housekeeping gene, TBP, and each 
treatment group was compared to the corresponding control group, which were 
normalised to a fold change value of 1. The fold change induction of each gene 
in the brain and PBL is shown in Figure 4-9.  
4.4.1.1 QPCR analysis of ISG expression in the brain 
The results of the QPCR analysis of ISG expression in control and TPA-treated 
brains showed that this treatment failed to induce an ISG response in the brain 
at any of the time points examined. Only one gene, Gbp3, was significantly 
induced in the brains of the treated group and this was only at day 3. Several 
other genes, including Irgm, Lgals3bp, Stat1, IFITm3 and CTSC, were 
downregulated in the brain in response to TPA treatment at various time points, 
but particularly at day 5. It is clear from these data that the brain ISG response 
following TPA treatment is minimal and, in fact, many of the genes appear to be 
downregulated. This is in stark contrast to the distinct ISG response seen 
following Aldara treatment.        
4.4.1.2 QPCR analysis of the ISG response in the peripheral blood  
The QPCR analysis of the PBL from both TPA-treated and control mice indicated 
the presence of a mild ISG response in the periphery (Figure 4-9). Only one gene, 
Gbp4, was significantly induced at day 1, however by day 3, 10 out of the 15 
ISGs were significantly induced in the PBL of the treatment group compared with 
the control group (CTSC, Gbp2, Gbp3, IFITm3, IFIT1, IRF7, Lgals3bp, Oasl2, Rtp4 
and Stat1). This response was considered mild as none of the ISGs expressed in 
the PBL was induced more than 4-fold. By day 5, only one gene remained 
significantly induced; Sp100. These data suggest that TPA treatment can induce 
a moderate ISG response in the PBL, particularly at day 3; however the response 
is short lived. 
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4.4.1.3 Comparison of central brain response with the peripheral blood 
response following TPA treatment 
When comparing the brain and PBL from TPA-treated mice, the ISG response 
appeared to be greater in the PBL than in the brain (Figure 4-9). The fold change 
induction of six of the genes; CTSC, Gbp2, IFITm3, Oasl2, Rtp4 and Stat1, is 
significantly greater in the PBL than in the brain at day 3. Although the induction 
of ISGs in the PBL is not particularly strong, with fold-change inductions of 4 or 
less, many of the ISGs were downregulated in the brain, highlighting the 
difference between the peripheral and central response. Much of the ISG 
response in both tissues had dissipated by day 5, however two ISGs, Stat1 and 
Sp100, were significantly induced in the PBL compared with the brain. By 
comparing these two tissues, it appeared that the PBL response to TPA is 
stronger than the brain response to TPA, when evaluated using ISG induction. 
These findings are in contrast to the response following Aldara treatment, for 
which the opposite is true.   
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Figure 4-9 QPCR analysis of ISGs in the brain and PBL during the TPA time-course 
Mice were treated with 150µl 100µM TPA, or equivalent volume of acetone, every 24hrs for 1, 3 or 
5 days. RNA was then isolated from the brain and PBL 24hrs after the final treatment. Gene 
expression analysis of (A) Ctsc, (B) Cxcl10, (C) Gbp2, (D) Gbp3, (E) Gbp4, (F) Gbp6 (G) Ifit1, (H) 
Ifitm3, (I) Irgm1, (J) Irf7, (K) Lgals3bp, (L) Oasl2, (M) Rtp4, (N) Sp100 and (O) Stat1 was performed 
using QPCR and was normalised to TBP. Data are expressed as fold change induction, relative to 
the controls, which have a fold change value of 1. Data represent the mean +/- SD. Significance 
was calculated for individual tissues (control vs treated, d1 vs d3 vs d5), between tissues (treated 
only, PBL vs brain) and between time-points (treated only, d1 vs d3 vs d5) using two-way ANOVA 
with Bonferroni multiple comparison post-test. *** p ≤ 0.001. ** p ≤ 0.01, * p ≤ 0.05. n = 4/group 
 
4.4.2 Luminex analysis of the temporal cytokine response 
following TPA treatment 
Luminex analysis was again performed to determine the cytokine levels in the 
plasma at the different time points following TPA treatment. As before, samples 
were diluted 1:4 prior to use in the assay. As a result, many of the cytokines 
were below the level of detection of the assay and in this case, IL-1α, IL-6, IL-
10, IFNγ and GM-CSF were omitted from further analysis. The remaining eight 
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cytokines, five chemokines and two growth factors are shown in Figure 4-10 and 
Figure 4-11, respectively.   
Only two of the cytokines, IL-5 and IL-13, were significantly induced following 
TPA treatment. The expression of IL-5 was significantly higher in the treatment 
group than in the control group at day 1 (Figure 4-10D), whereas the expression 
of IL-13 was significantly higher at both day 1 and day 3 (Figure 4-10F). None of 
the other cytokines was found to be significantly induced at any other time-
point. TNFα was found to be significantly downregulated in the treatment group 
at day 5 when compared with the control group. With regards to the chemokines 
and growth factors, only CCL2 (Figure 4-11A) and CXCL10 (Figure 4-11E) were 
significantly induced at day 1 and day 3, respectively. CCL2 showed the highest 
induction following TPA treatment with an expression of around 200pg/ml after 
day 1. Together, these data suggest that TPA treatment does not induce a strong 
inflammatory response in the periphery. Although the expression of certain 
cytokines and chemokines at the earlier time points indicates a response, this 
appears to be mild and short-lived.     
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Figure 4-10 Cytokine expression in the plasma 1, 3 or 5 days following TPA treatment 
Mice were treated with 150µl 100µM TPA, or an equivalent volume of acetone control, every 24hrs 
for 1, 3 or 5 days. Plasma was isolated 24hrs after the final treatment. Luminex analysis of (A) IL-
1β, (B) IL-2, (C) IL-4, (D) IL-5, (E) IL-12 (F) IL-13, (G) IL-17 and (H) TNFα was performed. Data are 
expressed as concentration in pg/ml. Data represent the mean +/- SEM. Significance was 
calculated using two-way ANOVA with Bonferroni multiple comparison post-tests: *** p ≤ 0.001. ** 
p ≤ 0.01, * p ≤ 0.05. n = 4/group 
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Figure 4-11 Chemokine/ growth factor expression in the plasma 1, 3 or 5 days following TPA 
treatment 
Mice were treated with 150µl 100µM TPA, or an equivalent volume of acetone control, every 24hrs 
for 1, 3 or 5 days. Plasma was isolated 24hrs after the final treatment. Luminex analysis of (A) 
CCL2, (B) CCL3, (C) CXCL1, (D) CXCL9, (E) CXCL10, (F) VEGF and (G) FGF-Basic was 
performed. Data are expressed as concentration in pg/ml. Data represent the mean +/- SEM. 
Significance was calculated using two-way ANOVA with Bonferroni multiple comparison post-tests: 
*** p ≤ 0.001. ** p ≤ 0.01, * p ≤ 0.05. n = 4/group 
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4.5 The response to systemic Imiquimod 
Cutaneous Aldara treatment leads to the expression of a distinct, brain 
transcriptional ISG response. This response appears to peak after the third 
application and is induced independently of an overt inflammatory profile in the 
periphery. In addition, it has been shown that this response cannot be induced in 
the brain following a sterile, non-TLR-mediated, model of skin inflammation, 
TPA. Together, these findings suggest that the ISG response is TLR7-dependent 
as it is only induced following treatment with Aldara, which contains the TLR7 
antagonist, Imiquimod. However, as mentioned above, studies have suggested 
that Aldara can mediate an immune response in a TLR7-independent manner, 
through the actions of isostearic acid372. Therefore, it is difficult to establish 
whether the brain response is generated as a result of the stimulation of TLR7 by 
IMQ or the activation of the inflammasome by isostearic acid. In an attempt to 
understand the effect of IMQ treatment alone, c57BL/6 mice were injected I.P 
with soluble IMQ every 24 hours for five consecutive days. Alternatively, control 
mice were injected I.P with an equal volume of saline. As before, the model was 
characterised by monitoring mouse weights throughout the treatment and 
evaluating spleen size 24 hours after the final administration.  
Mice treated with I.P IMQ did not lose any weight over the course of the 
treatment and, consistent with the control mice, appeared to gain weight over 
time (Figure 4-12A). Although there was a slight difference in the spleen 
weights, this did not reach significance, and the administration of IMQ via this 
route did not cause splenomegaly (Figure 4-12B + C).    
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Figure 4-12 Evaluation of the phenotypic response following intraperitoneally administered 
Imiquimod 
Mice were treated with 100µl 1mg/ml IMQ, or equivalent volume of PBS, every 24hrs for five 
consecutive days. Mice were weighed following each application (A). In addition, spleens were 
removed and were weighed (B) and photographed (C). n = 5/group. Significance was measured 
using two-way ANOVA (weights) or student’s t test (spleens). 
 
4.5.1 QPCR analysis of ISG expression in response to 
intraperitoneal Imiquimod  
To determine whether or not I.P administration of IMQ could stimulate the 
expression of ISGs in the brain and the periphery, QPCR was performed using 
brains and PBL isolated 24 hours after the final injection. Each of the 15 ISGs 
was normalised to the housekeeping gene, TBP, and each treatment group was 
compared to the corresponding control group, which were normalised to a fold 
change value of 1. The fold change induction of each gene in the brain and PBL 
is shown in Figure 4-13.   
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4.5.1.1 QPCR analysis of the ISG response in the brain 
The results of the QPCR revealed that only 6 out of the 15 ISGs were significantly 
induced in the brain following I.P IMQ administration. Gbp3, IFIT1, IFITm3, IRF7, 
Lgals3bp and Rtp4 were all significantly induced in the brains of treated mice 
compared with the control brains; however the fold change induction was low in 
comparison to the induction following Aldara treatment and the maximum 
induction was 3-fold. Unlike the brain response following TPA, none of the genes 
was found to be downregulated in the brain following IMQ treatment. The brain 
response to I.P. IMQ appears to lie somewhere between the response to Aldara, 
where a strong ISG profile is seen, and the response to TPA, in which none of the 
ISGs was induced in the brain. It would appear from these results that I.P. IMQ 
treatment induced only a moderate ISG response in the brain.     
4.5.1.2 QPCR analysis of the ISG response in the peripheral blood  
With regards to the peripheral ISG response to IMQ treatment, 9 out of the 15 
ISGs were significantly induced in the PBL, including many of the genes which 
were also induced in the brain. Gbp6, IFIT1, IFITm3, Irgm, IRF7, Lgals3bp, Oasl2, 
Rtp4 and Sp100 were all significantly induced in the PBL of the treated group 
when compared with the control group. Again, none of the ISGs was significantly 
downregulated in the PBL following IMQ treatment.     
4.5.1.3 Comparison of central brain response with the peripheral blood 
response 
Two-way ANOVA was performed to determine the significance of the differential 
expression of the ISGs between the brain and the PBL. 7 genes were significantly 
differentially expressed between the brain and the PBL; Gbp3, Gbp6, IFIT1, 
Irgm, IRF7, Oasl2 and Sp100. With the exception of Gbp3, all of these genes 
were induced to a greater extent in the PBL than in the brain, suggesting that 
the peripheral ISG response to I.P. IMQ is greater than the central ISG response. 
Together, the results of the QPCR suggest that treatment with I.P. IMQ fails to 
induce an ISG response in the brain. This is in contrast to the data which show 
that treatment with topical Aldara, which contains IMQ as its active component, 
leads to a strong and distinct ISG response in the brain. It may suggest that the 
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transcriptional response is driven by IMQ-independent mechanisms, or that it is 
reliant on a cutaneous route of administration.      
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Figure 4-13 QPCR analysis of ISGs in brains and PBL following IMQ injections 
Mice were treated with 100µl 1mg/ml IMQ, or equivalent volume of saline, every 24hrs for 5 
consecutive days. Mice were euthanised 24hrs after the final application. Cardiac puncture was 
performed to retrieve PBLs and perfused brains were extracted. RNA was isolated from both 
tissues. QPCR analysis of the 15 target ISG genes was performed for both tissues (A-O). n= 5 
mice per group. Significance was measured using individual unpaired students t tests for individual 
tissues (control vs treated) or two-way ANOVA with Bonferroni multiple comparison post-tests for 
comparisons between tissues (PBL vs brain). *** (+++) = p ≤ 0.001 **(++) = p ≤ 0.01 *(+) = p ≤ 0.05 
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4.5.2 Luminex analysis following intraperitoneal Imiquimod 
treatment 
The results of the QPCR analysis showed that I.P. IMQ treatment leads to a 
higher ISG response in the PBL than in the brain and a higher PBL response when 
compared with the PBL response following topical Aldara application. To see if 
this was a direct result of a general inflammatory response in the periphery, 
Luminex analysis was again performed to determine cytokine expression in the 
plasma. As with previous Luminex data presented in this thesis, the samples 
were diluted 1:4 prior to use and, as a result, many of the readings were below 
the level of detection of the assay. In this case, IL-1α, IL-6, IL-10, IL-13, IFNγ, 
CXCL1, CCL2 and GM-CSF were omitted from further analysis. Levels of the 
remaining seven cytokines, three chemokines and two growth factors are shown 
in Figure 4-14 and Figure 4-15, respectively.   
Interestingly, none of the cytokines examined was significantly induced in the 
plasma following I.P. IMQ treatment. Although certain cytokines, including IL-1β, 
IL-2 and IL-17 (Figure 4-14A, B + F), appeared to be increased in the treated 
group, there was a high degree of variability within the biological replicates, 
thus the inductions failed to reach significance. Two of the chemokines, CXCL9 
and CXCL10 (Figure 4-15B + C), were significantly induced in the plasma 
following IMQ treatment. CXCL10, in particular, was highly upregulated with an 
expression value of around 250pg/ml. The results would suggest that the ISG 
response in the PBL, identified using QPCR, is not a direct result of a general 
inflammatory profile in the periphery, although it may be possible that a 
peripheral cytokine response is present earlier in this model.     
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Figure 4-14 Cytokine expression in the plasma following intraperitoneal IMQ treatment 
Mice were treated with 100µl 1mg/ml IMQ, or equivalent volume of saline, every 24hrs for 5 
consecutive days. Plasma was isolated 24hrs after the final treatment. Luminex analysis of (A) IL-
1β, (B) IL-2, (C) IL-4, (D) IL-5, (E) IL-12, (F) IL-17 and (G) TNFα was performed. Data are 
expressed as concentration in pg/ml. Data represent the mean +/- SEM. Significance was 
calculated using unpaired student’s t tests: *** p ≤ 0.001. ** p ≤ 0.01, * p ≤ 0.05. n = 5/group 
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Figure 4-15 Chemokine/ growth factor expression in the plasma following intraperitoneal 
IMQ treatment 
Mice were treated with 100µl 1mg/ml IMQ, or equivalent volume of saline, every 24hrs for 5 
consecutive days. Plasma was isolated 24hrs after the final treatment. Luminex analysis of (A) 
CCL3, (B) CXCL9, (C) CXCL10, (D) VEGF and (E) FGF-Basic was performed. Data are expressed 
as concentration in pg/ml. Data represent the mean +/- SEM. Significance was calculated using 
unpaired student’s t tests: *** p ≤ 0.001. ** p ≤ 0.01, * p ≤ 0.05. n = 5/group 
 
4.6 Topically applied Imiquimod as a model of skin 
inflammation 
Results in Section 4.5.1, in which soluble IMQ was injected intraperitoneally, 
demonstrated that IMQ administered in this way was not sufficient to induce the 
brain ISG response that was seen following topical Aldara treatment. These 
results suggested that the central response may be driven by IMQ-independent 
mechanisms, perhaps via the actions of isostearic acid. However, using a 
different route of administration was not an ideal method of comparison, as the 
initial tissue response in the skin may be an important factor in the generation 
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of the remote response in the CNS. In order to test the importance of the local 
tissue response, soluble IMQ was first dissolved in PBS before being reconstituted 
into the water based, non isostearic acid containing, control cream. This was 
applied topically to the shaved dorsal skin of c57BL/6 mice daily for 5 
consecutive days. As a control, mice were treated with an equal volume of 
aqueous control cream alone. This model eliminated the potential actions of 
other components found in the Aldara vehicle, and meant that any response 
would be the result of IMQ-induced mechanisms.     
Mice were weighed daily following each application. Weights are shown as 
percentage of initial weight in Figure 4-16A, where the initial weight was 
considered 100%. IMQ treated mice lost a significant amount of weight, evident 
after the first application. Weight loss ceased and mice began to regain some of 
their weight after the third application, however they remained significantly 
lighter than the control mice. The IMQ- treated mice showed signs of 
splenomegaly, whereby their spleens weighed more than 2.5 times that of the 
control mice (Figure 4-16B + C). Surprisingly, the H&E analysis of the treated 
dorsal skin showed that topical IMQ failed to induce psoriasis-like skin 
inflammation.  
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Figure 4-16 Evaluation of the phenotypic response to IMQ induced skin inflammation 
Mice treated with 80mg IMQ cream (5% v:v in aqueous control cream), or equivalent volume 
control cream, were weighed following each application (A). In addition, spleens from IMQ-treated 
mice were photographed (B) and spleens from control and treated mice were weighed (C). H&E 
staining was performed using 5µm thick sections of IMQ- or control-treated skin which were imaged 
at 200X magnification. n = 5/group. Significance was measured using two-way ANOVA. *** = p ≤ 
0.001. 
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4.6.1 QPCR analysis of ISG expression in response to topical 
cutaneous Imiquimod  
To determine whether or not the topical administration of IMQ could stimulate 
the expression of ISGs in the brain and the periphery, QPCR was performed using 
RNA from brains and PBL isolated 24 hours after the final application. Each of 
the 15 ISGs were normalised to the housekeeping gene, TBP, and each treatment 
group was compared to the corresponding control group, which were normalised 
to a fold change value of 1. The fold change induction of each gene in the brain 
and PBL is shown in Figure 4-17.   
4.6.1.1 QPCR analysis of the ISG response in the brain 
To identify ISGs that were significantly induced in the brain following topical IMQ 
treatment, the brains from IMQ treated mice were compared with control 
brains. With the exception of Ctsc, all 15 ISGs were significantly upregulated in 
the brains of the IMQ treated group compared with the control group. The 
transcriptional induction in the brain was quite striking, with many of the genes 
exhibiting 10-100 fold change increases. Sp100 was of particular note, with a 
fold change increase in excess of 1000-fold (Figure 4-17N). It was clear from 
these results that topical IMQ treatment can lead to a strong ISG response in the 
brain, indistinguishable from the brain response following topical Aldara 
application.    
4.6.1.2 QPCR analysis of the ISG response in peripheral blood leukocytes  
In order to identify whether or not topical IMQ treatment could also induce an 
ISG response in the periphery, the expression of the genes in the PBL was 
evaluated for both the treated group and the control group. Interestingly, 9 out 
of the 15 ISGs were significantly downregulated in the PBL of the IMQ treated 
group compared with the PBL of the control group. Only two genes, Oasl2 and 
Rtp4 (Figure 4-17L + M), were significantly induced in the PBL following topical 
IMQ treatment with an approximately 8-fold increase. The remaining genes, 
Gbp3, IFIT1, Irgm and Lgals3bp, remained consistent between the control PBL 
and the treated PBL. These results indicated that topically applied IMQ did not 
induce a distinct ISG response in the periphery.  
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4.6.1.3 Comparison of central brain response with the peripheral blood 
response 
Two-way ANOVA was performed to determine the significance of the differential 
expression of the ISGs between the brain and the PBL. The fold-change induction 
of all 15 ISGs was significantly greater in the brain when compared with the PBL. 
With the exception of Ctsc, the differential expression between the ISGs in the 
brain and PBL was highly significant and satisfied a p-value <0.001. This 
confirmed that the ISG response in the brain was not the result of blood 
contamination. These findings also highlighted the differential nature of the 
peripheral response when compared with the central response, suggesting that 
ISG induction in the brain was not a general consequence of peripheral immune 
stimulation. 
When compared with the other models, the ISG response following topically 
applied IMQ is similar to the ISG response following topical Aldara treatment, 
both of which were characterised by a distinct brain response and a mild PBL 
response. This implies that the actions of the TLR7 ligand, IMQ, and the initial 
localised skin response are important for the generation of the brain ISG 
response.      
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Figure 4-17 QPCR analysis of ISGs in the brain and PBL following topical IMQ application 
Mice were treated with with 80mg IMQ cream (5% v:v in aqueous control cream), or equivalent 
volume control cream, every 24hrs for 5 consecutive days. Mice were euthanised 24hrs after the 
final application. Cardiac puncture was performed to retrieve PBLs and perfused brains were 
extracted. RNA was isolated from both tissues. QPCR analysis of the 15 target ISG genes was 
performed for both tissues (A-O). n= 5 mice per group. Significance was measured using individual 
unpaired students t tests for individual tissues (control vs treated) or two-way ANOVA with 
Bonferroni multiple comparison post-tests for comparisons between tissues (PBL vs brain). *** 
(+++) = p ≤ 0.001 **(++) = p ≤ 0.01 *(+) = p ≤ 0.05 
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4.7 Discussion 
The results presented in Chapter 3, in which transcriptional profiling techniques 
were used, identified a distinct ISG response in the brain following topical 
cutaneous Aldara application. However, the mechanisms of induction remained 
to be fully understood. It was widely assumed that the response to Aldara cream 
was mediated through the actions of the active component, IMQ, which binds to 
TLR7/8. One signalling pathway initiated by TLR7/8 ligation is the activation of 
IRF7 and the production of Type I IFNs. Therefore, this mechanism seemed a 
likely candidate for driving the production of an ISG response in the brain 
following treatment. Recently, however, Walter et al. published a report 
showing that Aldara cream can also function in a TLR-independent mechanism, 
through the actions of isostearic acid, which is a component of the vehicle372. 
They propose that some features of the response may be driven by the ability of 
isostearic acid to activate the inflammasome. Thus, it seemed important to 
establish the involvement of TLR stimulation in the generation of the brain ISG 
response and to determine the individual roles of IMQ and isostearic acid. The 
aims of this chapter were to investigate the mechanisms driving the brain 
response following cutaneous inflammation and to determine the importance of 
TLR stimulation using a number of different inflammatory models.  
Utilising a sterile model of skin inflammation, results suggested that TLR ligation 
was indispensable for the brain ISG response. Topical TPA administration induced 
a psoriasis-like skin inflammation consistent with that seen following Aldara 
application; however TPA failed to stimulate an ISG response. It has been shown 
that both Aldara and LPS administration377 lead to the induction of an ISG 
response in the brain. Both of these TLR ligands can signal in an NF-κB-
independent manner, leading to the production of Type I IFNs, thus making it a 
likely pathway in the generation of a downstream ISG response. This hypothesis 
is strengthened by results showing that a similar ISG response cannot be 
generated following sterile inflammation, in the form of TPA, or by the direct 
administration of inflammatory cytokines into the circulation377. Together, these 
results suggest that the ISG response following Aldara application is not simply a 
response to peripheral inflammation. 
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ISGs were not induced in the PBL following cutaneous Aldara or TPA stimulation; 
however these results were obtained following 5 consecutive applications. To 
better understand the temporal pattern of the responses, and to identify 
whether or not an ISG response is initiated in the periphery at an earlier time-
point, time course models of Aldara treatment and TPA treatment were 
performed. The Aldara time course experiment revealed that the ISG response 
peaked in the brain following the third treatment, although the genes remained 
elevated in the brain after the fifth treatment. The model also showed that the 
ISG response was not mimicked in the PBL at any of the time-points. With 
regards to the PBL, several ISGs were induced at day 1; however the PBL 
response was short-lived and had largely dissipated by day 3. This also allowed 
us to confirm that the brain response was not due to contamination with 
peripheral blood. In contrast to the Aldara model, the TPA time course model 
confirmed that this sterile model of skin inflammation failed to induce an ISG 
response in the brain, even at the earlier time-points. These data strengthened 
the hypothesis that TLR stimulation may be important for the generation of a 
brain ISG response following cutaneous inflammation and highlight the 
difference in expression kinetics between the brain and the PBL. To confirm the 
role of TLR stimulation, it would be preferable to run both models using TLR7-/- 
or MyD88-/- mice.    
To investigate the role of TLR stimulation further, and to rule out the effects of 
isostearic acid in the Aldara vehicle, two other inflammatory models were used. 
The first, which involved repeated intraperitoneal stimulation with IMQ, induced 
a relatively mild ISG response in the brain in comparison with the brain response 
to topical Aldara treatment. It did, however, cause a more pronounced response 
in the PBL, although there was a high degree of variability within the treated 
group. It is important to note that the dose of IMQ injected I.P was lower than 
the dose applied to the dorsal skin, which may be the reason we do not see a 
brain response with this model. It is also possible that IMQ could be sequestered 
in the gut, which would therefore prevent it from entering the circulation. The 
second model utilised soluble IMQ reconstituted into aqueous control cream as a 
vehicle, which was subsequently applied daily to the shaved dorsal skin of the 
mice. This model retained the route of administration used in previous models 
but eliminated any effects of isostearic acid. Following this treatment, a very 
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striking ISG response was seen in the brain, with fold-change inductions 
substantially greater than those seen following Aldara treatment. This response 
was not mimicked in the PBL, which showed a mixture of up- and down-
regulations in the treated group. Intriguingly, this treatment did not appear to 
induce an inflammatory phenotype in the skin suggesting that, as reported in the 
literature, the IMQ and isostearic acid may be responsible for different aspects 
of the response. Walter et al suggested that, in the absence of IMQ, treatment 
with vehicle cream induced inflammasome activation, keratinocyte cell death 
and IL-1 production372. In keeping with our findings, they report that the local 
effects on the skin are largely due to IMQ-independent mechanisms, as they too 
failed to induce the full skin phenotype in vivo following treatment with IMQ in 
‘softcream’. These findings would explain why, in Section 4.6, H&E analysis of 
skin treated with IMQ reconstituted in aqueous control cream showed few signs 
of inflammation.  
With such a potent brain response following topically administered IMQ; it would 
appear that the response was indeed TLR-driven. However, intraperitoneal 
administration of IMQ failed to induce an ISG response in the brain. Damm et al. 
used IMQ to investigate how TLR ligation, and different routes of administration, 
can cause the manifestation of inflammation at distant sites, including the 
brain7. They reported that a high dose of peripherally administered IMQ 
(subcutaneous and intraperitoneal) induced a moderate fever, peripheral and 
hypothalamic cytokine induction and inflammatory transcription factor 
activation. In keeping with our study, they found the response to be more 
pronounced with subcutaneous administration; however topical administration 
onto the dorsal skin was not investigated. Although an upregulation of 
inflammatory markers in the hypothalamus was reported, there was no change in 
brain levels of IFNs. It is difficult, however, to directly compare the results of 
their study to the results in this thesis as Damm et al focused on only one 
specific brain region at an earlier time point.  
The results from this Chapter would suggest that the ISG response is TLR-driven 
but also dependent on some component of the localised skin response. The 
problem with this hypothesis is that, as I have already mentioned, the localised 
skin response is predominantly reliant on the effects of isostearic acid and not 
IMQ. Therefore this makes it hard to establish what, if any, aspect of the skin 
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response is necessary for the generation of the brain ISG response. To better 
understand the role of each component in the generation of the brain ISGs, 
isostearic acid alone should be used to treat the mice, which would allow for a 
direct comparison of the two active components of Aldara cream. In addition, it 
would be interesting to inject soluble IMQ subcutaneously, as this, in theory, 
should stimulate a similar response in the skin to topical application.         
One proposed mechanism of peripheral immune signal transduction into the 
brain is via the activation of vascular endothelial cells by circulating cytokines, 
such as IL-1β and TNFα. To determine whether or not such cytokines were 
induced in the circulation following Aldara application, Luminex analysis was 
performed using plasma isolated from the time course model. According to the 
literature, TLR7 stimulation should lead to the production of inflammatory 
cytokines in the periphery, however it is also possible that cytokines, 
particularly IL-1β, could be produced as a result of inflammasome activation by 
isostearic acid. The Luminex data showed that four cytokines and four 
inflammatory chemokines were induced in the Aldara model following the first 
application; however IL-1β and TNFα were not detected. Luminex analysis was 
also performed using plasma from the TPA time course and the I.P. IMQ model, 
neither of which induced an ISG response in the brain. The Luminex results 
showed that the peripheral inflammatory cytokine response in both of these 
models was minimal, with very few cytokines being significantly induced. The 
lack of a peripheral cytokine response in a range of models, irrespective of their 
ability to induce an ISG response in the brain, indicated that the brain response 
was independent of the peripheral cytokine response and was driven by another 
mechanism. In addition, the expression of IFNγ was below the minimum level of 
detection of the kit in all of the models examined. This was interesting, since 
IFNs would normally be produced as a prerequisite to an ISG response. TLR7/8 
stimulation does, however, lead to the production of IFNα, which unfortunately 
was not included in the panel of cytokines on the kit used in this study. 
Therefore, the production of Type I IFNs in the periphery following Aldara 
treatment cannot be ruled out. It is important to bear in mind however, that 
some cytokine expression may have been diluted out in this assay, and firm 
conclusions would require the assay to be repeated using undiluted samples.   
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The absence of an overt peripheral cytokine response indicated that cytokines 
may not be driving the brain response following Aldara treatment. An alternative 
mechanism for generating the ISG response in the brain is through TLR7/8 
stimulation. This could occur in two ways; either by TLR ligation in the skin and 
the localised production of Type I IFNs that subsequently traffic to the brain and 
act in an endocrine fashion, or via the direct activation of TLR7/8 in the brain 
parenchyma or peripheral nerves. As mentioned, the ability of IMQ to cross the 
BBB is not known. Butchi et al have shown that intracerebroventricular 
inoculation of IMQ in developing mice leads to microglia and astrocyte 
activation391. They reported that protein levels of certain proinflammatory 
cytokines and chemokines, including CXCL10, IL-1β and IL-5, are upregulated in 
response to TLR7 ligation, as well as a strong IFNβ response. Their data suggest 
that, should IMQ be able to cross the BBB, it would induce a sufficiently strong 
inflammatory response to generate an ISG response. Interestingly, Damm et al 
have shown that, following IMQ administration, several transcription factors 
were activated in regions of the brain devoid of intact BBB, including the CVOs7. 
This suggests that areas protected by an intact BBB are less susceptible to IMQ, 
perhaps because it is not able to cross into the brain. According to the 
literature, dermal DCs, pDCs and Langerhans cells in the skin are activated 
following IMQ treatment and are the primary source of Type I IFN, specifically 
IFNα368, 400, 401. In addition, it has been reported that IFNα can mediate 
neurological effects by crossing the BBB by diffusion or by a facilitated saturable 
transport system402, 403. Therefore, if IMQ cannot cross the BBB, this would be a 
viable mechanism by which distal immune activation by Aldara/IMQ could 
mediate an ISG response in the brain. However, it does raise the question as to 
why an ISG response was not seen in the periphery if the response was induced 
by circulating Type I IFNs. As such, it may be the case that in this model, IFNs 
are produced directly in the brain. To test this hypothesis, QPCR and ELISA could 
be used to determine the expression of Type I IFNs in the brain at the various 
time-points following immune stimulation.  
In summary, both topical Aldara and topical IMQ application to the skin induced 
a distinct ISG response in the brain. This response appeared to be dependent on 
TLR stimulation, and differed in kinetics and magnitude to the PBL response. In 
addition, this response was generated independently of an inflammatory 
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cytokine profile in the periphery. The results suggest that the remote brain 
response may be driven by the production of TLR-dependent Type I IFNs, 
highlighting a potential mechanism of transcriptional regulation in the brain 
following peripheral immune stimulation.     
 
  
 
 
 
 
 
 
Chapter 5 
Transcriptional chemokine response in the brain 
following cutaneous immune stimulation 
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5 Transcriptional chemokine response in the brain 
following cutaneous immune stimulation  
5.1 Introduction 
The results in Chapter 3 provided a transcriptional profile of the brain response 
following topical Aldara treatment. Microarray analysis revealed a number of 
ISGs that were induced in the brain following treatment, which were validated 
and assessed in a range of inflammatory models. However, the microarray also 
identified a number of other genes as being differentially expressed in the brain 
but these were not further investigated. DAVID ontology analysis of the 
microarray dataset identified the most enriched biological pathways, amongst 
which were ‘Chemokine signalling pathway’, ‘Inflammation mediated by 
chemokine and cytokine signalling pathway’ and ‘Leukocyte transendothelial 
migration’. These pathways strongly implicated a chemokine response in the 
brain following Aldara treatment.  
Chemokines, described in detail in Chapter 1, regulate cellular migration and are 
thought to be involved in maintaining certain homeostatic and developmental 
processes in the brain109, 215. In many inflammatory models, both peripheral and 
central, chemokines are commonly upregulated in the brain. It is thought that 
this induction not only drives immune cell infiltration into the brain, but perhaps 
also disrupts key homeostatic functions. It is therefore possible that chemokine 
induction in the brain could be a prerequisite for chronic neuroinflammation and 
changes in brain biology that lead to the onset of neuropsychiatric phenotypes.  
To establish whether or not cutaneous Aldara treatment could lead to a 
chemokine response in the brain, the microarray dataset from Chapter 3 was 
revisited to identify the significantly induced chemokine genes. These genes 
were subsequently validated in the range of inflammatory models previously 
employed. Immunohistochemistry was performed to explore immune cell 
infiltration into the brain and finally, to try to correlate the chemokine response 
with a functional consequence, burrowing behaviour was investigated alongside 
the use of chemokine receptor antagonists.  
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5.2 Identifying the differential chemokine response in the 
brain following topical Aldara application 
Upon revisiting the microarray data detailed in Chapter 0, 7 chemokines and 1 
chemokine receptor were identified as being differentially expressed in the 
brains of the treatment group. GeneSpring GX software was used to generate a 
heat map showing the expression of the 8 genes, which is shown in Figure 5-1. 
The fold change induction and the p-value for each of the chemokine genes is 
shown in Table 5-1, where genes are presented in order of their fold-change 
induction.  
 
 
Figure 5-1 Heatmap of differentially expressed chemokines identified by microarray analysis 
Microarray analysis was performed using RNA from brains of Aldara treated and control mice. 
Following statistical analysis, differentially expressed chemokine genes were identified. A heatmap 
was generated using GeneSpring GX software to depict the 7 differentially expressed chemokines 
and 1 chemokine receptor in Aldara treated and control brains. The five treatment samples are 
shown in red and the five control samples in green. 
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Table 5-1 A list of the chemokine genes that were upregulated in the Aldara model 
Symbol Gene name Fold change p-value 
CCL5 chemokine (C-C motif) ligand 5 25.65 1.17E-09 
CXCL13 chemokine (C-X-C motif) ligand 13 21.38 1.53E-09 
CCL3 chemokine (C-C motif) ligand 3 18.67 4.10E-10 
CXCL9 chemokine (C-X-C motif) ligand 9 6.40 1.57E-06 
CXCL16 chemokine (C-X-C motif) ligand 16  5.46 1.30E-07 
CCL9 chemokine (C-C motif) ligand 9 4.52 2.91E-07 
CXCL10 chemokine (C-X-C motif) ligand 10 4.25 1.27E-04 
CCR5 chemokine (C-C motif) receptor 5  3.74 
 
4.31E-08 
 
5.2.1 QPCR verification of the chemokine signature in the brain 
and PBL in response to Aldara treatment  
To verify the expression of the 8 target chemokine genes following Aldara 
treatment, SYBR Green QPCR analysis was performed using RNA from brains and 
PBL isolated 24 hours after the final Aldara treatment. If a chemokine response 
was identified in the PBL, it may be that the expression found in the brain was 
the result of a contaminating signal from the blood. Therefore, by using the PBL 
as a comparator, this part of the study would ensure that blood contamination 
was not a factor in the brain response. Although the microarray data 
demonstrated significant induction of the gene encoding CXCL9, this appeared to 
be below the detection limit of the QPCR assay and could not be validated in the 
PBL and the brain (data not shown). It was therefore excluded from further 
analysis. Expression of each gene was normalised to that of the housekeeping 
gene, TBP, and each treatment group was compared to the corresponding 
control group, which were normalised to a fold change value of 1. The fold 
change induction of each gene in the brain and PBL is shown in Figure 5-2. 
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The results of the QPCR confirmed that the 6 chemokines and 1 chemokine 
receptor were significantly induced in the brains of Aldara treated mice when 
compared with the control brains. The fold-change induction of the genes 
ranged from around 2-fold to 200-fold. Both CCL5 and its receptor, CCR5, 
exhibited the highest inductions in the brain, upwards of 200-fold (Figure 5-2B + 
G).  
With regards to the PBL, only one of the genes, CCL9, was significantly induced 
following Aldara treatment (Figure 5-2C). In addition, one of the genes, CXCL16, 
was significantly downregulated in the PBL of the treated group when compared 
with the control group (Figure 5-2F). The expression levels of the remaining 5 
genes were consistent between the control and treated groups.  
To determine whether or not the response in the brain was significantly greater 
than the response in the PBL, data were analysed using two-way ANOVA. With 
the exception of CCL9, the induction of all of the genes was higher in the brain 
than in the PBL, with the most significant difference being seen with expression 
of CXCL10 and CXCL16.  
Together, the results of the QPCR analysis confirmed the presence of a distinct 
chemokine response in the brain following Aldara treatment when compared 
with controls. Although this treatment led to the induction of CCL9 in the 
periphery, the overall chemokine response was not mimicked in the PBL.     
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Figure 5-2 QPCR analysis of chemokines in brains and PBL following Aldara treatment 
Mice were treated with 80mg Aldara cream or control cream every 24hrs for 5 consecutive days. 
Mice were euthanised 24hrs after the final application. Cardiac puncture was performed to retrieve 
PBLs and perfused brains were extracted. RNA was isolated from both tissues. QPCR analysis of 
the target chemokine genes identified in the microarray was performed for both tissues (A-G). n= 5 
mice per group. Significance was measured within each tissue using individual students t test or 
between the tissues using two-way ANOVA with Bonferroni multiple comparison post-tests *** 
(+++) = p ≤ 0.001 **(++) = p ≤ 0.01 *(+) = p ≤ 0.05 
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5.3 QPCR analysis of the chemokine signature in the 
brain and PBL in response to TPA treatment  
Having confirmed the induction of chemokine genes in the brain following Aldara 
treatment, the same genes were assessed following TPA treatment, to again 
establish whether or not TLR ligation was a prerequisite for this response. To 
determine the expression of the 7 chemokine genes following TPA treatment, 
SYBR Green QPCR analysis was performed using RNA from brains, and PBL, 
isolated 24 hours after the fifth and final treatment. Each gene was normalised 
to the housekeeping gene, TBP, and each treatment group was compared to the 
corresponding control group, which were normalised to a fold change value of 1. 
The fold change induction of each gene in the brain and PBL is shown in Figure 
5-3. 
The results of the QPCR showed that none of the chemokine genes were 
significantly induced in the brains of TPA-treated mice when compared with 
control mice. Some of the genes showed a slight downwards trend in the treated 
brains, including CCL3, CCL5 and CXCL10, however none of these reached 
significance.  
With regards to the PBL, again none of the chemokine genes was significantly 
induced in the treated mice when compared with the control mice. The cycle 
threshold values for many of the samples were high (data not shown) which is 
perhaps why there was such a high degree of variability within the groups, 
indicated by the size of the error bars. CXCL16 expression in the PBL of both 
control and TPA treated mice was below the level of detection (Figure 5-3F).  
Two-way ANOVA was used to compare the brain and the PBL to establish 
whether the responses were significantly different. CCL9 was the only gene to 
reach significance, whereby the induction in the PBL following TPA treatment 
was significantly greater than the induction in the brain (Figure 5-3C). None of 
the other genes was significantly differentially expressed between the brain and 
the PBL. 
Together, the results of the QPCR analysis showed that topical TPA treatment 
failed to induce a similar chemokine response in the brain, or in the PBL, to that 
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seen with Aldara. These results are consistent with the ISG expression in the 
brain, reported in Chapter 4, despite TPA application inducing a similar 
inflammatory skin phenotype. These results highlight the differential response 
between mice treated with an “infective” model versus a “sterile” model and 
strengthen the hypothesis that the brain response following Aldara treatment is 
TLR driven.       
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Figure 5-3 QPCR analysis of chemokines in brains and PBL following TPA treatment 
Mice were treated with 150µl 100µM TPA, or equivalent volume of acetone, every 24hrs for 5 
consecutive days. Mice were euthanised 24hrs after the final application. Cardiac puncture was 
performed to retrieve PBLs and perfused brains were extracted. RNA was isolated from both 
tissues. QPCR analysis of the target chemokine genes identified in the microarray was performed 
for both tissues (A-G). n= 5 mice per group. Significance was measured within each tissue using 
individual students t test or between the tissues using two-way ANOVA with Bonferroni multiple 
comparison post-tests *** (+++) = p ≤ 0.001 **(++) = p ≤ 0.01 *(+) = p ≤ 0.05 
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5.4 QPCR analysis of the chemokine signature in the 
brain and PBL during the Aldara time-course  
The previous two sections confirmed the presence of a chemokine response in 
the brain following topical Aldara and established that such a response was not 
generated following TPA application. This differential pattern of expression 
between the two models mirrors the pattern of the ISG response that was 
reported in Chapter 4. It was also established that, rather than the day 5 time-
point studied initially, the peak of the ISG response in the brain appeared to be 
day 3. Therefore, to determine whether or not the expression of the 7 
chemokine genes followed the same temporal pattern as the ISGs, SYBR Green 
QPCR analysis was performed using RNA from brains and PBL isolated 24 hours 
after 1, 3 and 5 applications of Aldara. Each gene was normalised to the 
housekeeping gene, TBP, and each treatment group was compared to the 
corresponding control group, which were normalised to a fold change value of 1. 
The fold change induction of each gene in the brain and PBL is shown in Figure 
5-4. 
The results of the QPCR suggested that the chemokine response shared the same 
temporal pattern in the brain as the ISGs, as the peak of the response appeared 
to be at day 3. All 6 chemokines and 1 chemokine receptor analysed were 
significantly induced in the brains of Aldara treated mice at day 3 when 
compared with control mice. CCL3, CCL5 and CXCL10 (Figure 5-4A, B + D) 
showed striking upregulations, with around 1000-fold inductions in the brain at 
this time-point. None of the chemokine genes was significantly induced at day 1 
and by day 5, 5 out of the 7 genes remained significantly induced in the brain. 
The induction of CCL5 at day 5 was still very high, at around 800-fold, whereas 
all other genes were 100-fold or less. 
With regards to the PBL, the response at all time-points remained below a 20-
fold induction. CCL3 was the only gene to be significantly induced in the PBL at 
all three time-points, with a consistent 3-4-fold upregulation (Figure 5-4A). Both 
CXCL10 and CCR5 were significantly induced at day 1 when compared with the 
PBL from control mice. At day 3, CCL5 and CCR5 were significantly induced in 
the treated group. With the exception of CCL3, none of the chemokine genes 
were significantly induced at day 5. 
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Statistical comparisons were performed to determine whether the induction in 
the brain was significantly different to the induction in the PBL in Aldara-treated 
mice. At day 3, the induction in the brain was significantly greater than the 
induction in the PBL for all 7 chemokine genes. With the exception of CCL3 and 
CXCL10, this remained true for all genes at day 5. None of the genes was 
significantly induced in the brain at day 1 when compared with the induction in 
the PBL; however one gene, CCR5, was induced in the PBL to a significantly 
greater extent at day 1 than it was in the brain. This was the only gene to be 
more strongly induced in the PBL than the brain at any of the time-points 
analysed.  
The results suggested that, like the ISG response detailed in Chapter 4, the 
chemokine response in the brain following Aldara treatment appeared to peak at 
day 3. This response, which was particularly strong with respect to CCL3, CCL5 
and CXCL10 at day 3, persisted in the brain at day 5, in accordance with the 
results shown in Section 5.2.1. Aldara treatment did appear to induce a 
chemokine response in the PBL but, with the exception of CCR5, the chemokine 
response was significantly higher in the brain than it was in the PBL. These data 
highlighted how the response in the brain and PBL differed, both in kinetics and 
magnitude, and suggested that the brain response was independent of the PBL 
response.    
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Figure 5-4 QPCR analysis of chemokines in brains and PBL following Aldara treatment 
Mice were treated with 80mg Aldara cream or control cream every 24hrs for 1, 3 or 5 days. Mice 
were euthanised 24hrs after the final application. Cardiac puncture was performed to retrieve PBLs 
and perfused brains were extracted. RNA was isolated from both tissues. QPCR analysis of the 
target chemokine genes identified in the microarray was performed for both tissues (A-G). n= 4 
mice per group. Significance was calculated for individual tissues (control vs treated), between 
tissues (treated only, PBL vs brain) and between time-points (treated only, d1 vs d3 vs d5) using 
two-way ANOVA with Bonferroni multiple comparison post-test. *** p ≤ 0.001. ** p ≤ 0.01, * p ≤ 0.05 
 
5.5 QPCR analysis of the chemokine signature in the 
brain and PBL during the TPA time-course  
It has been demonstrated in this Chapter that peripheral Aldara treatment leads 
to a distinct transcriptional chemokine response in the brain, which peaks 
following the third application. This response does not appear to be induced 
following TPA treatment; however the earlier time-points were not investigated. 
Therefore, to determine whether or not any of the 7 chemokine genes could be 
found in the brain or PBL at an earlier time, SYBR Green QPCR analysis was 
performed using RNA from brains and PBL isolated 24 hours after 1, 3 and 5 
applications of TPA or acetone. Each gene was normalised to the housekeeping 
gene, TBP, and each treatment group was compared to the corresponding 
control group, which were normalised to a fold change value of 1. The fold 
change induction of each gene in the brain and PBL is shown in Figure 5-5. 
With regards to the brain, none of the chemokine genes was significantly 
induced in the TPA treated mice compared with the control mice at any of the 
time-points. Several of the genes showed a slight downregulation in the brain; 
however none of the reductions reached significance.  
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The same was true of the PBL analysis, where the QPCR results confirmed that 
none of the genes was significantly induced in the treated group when compared 
with the control group. Many of the apparent downwards trends in expression 
coincided with a high degree of error, suggesting that the expression levels were 
close to the minimum detection levels of the assay.  
As none of the genes was significantly differentially expressed between the 
control and treated groups of each tissue, there was no significant difference 
between the treated groups of the brain and PBL. The expression levels were 
quite consistent ‘across the board’, both control versus treated and brain versus 
PBL.  
These results confirmed that topical TPA application failed to induce a 
transcriptional chemokine response in the brain or PBL 1, 3 or 5 days following 
treatment. In addition, this experiment showed that the chemokine response 
appeared to be similar in kinetics to the ISG response identified in Chapter 4.  
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Figure 5-5 QPCR analysis of chemokines in brains and PBL following TPA treatment 
Mice were treated with 150µl 100µM TPA, or equivalent volume of acetone, every 24hrs for 1, 3 or 
5 days. Mice were euthanised 24hrs after the final application. Cardiac puncture was performed to 
retrieve PBLs and perfused brains were extracted. RNA was isolated from both tissues. QPCR 
analysis of the target chemokine genes identified in the microarray was performed for both tissues 
(A-G). n= 4 mice per group. Significance was calculated for individual tissues (control vs treated) 
and between tissues (treated only, PBL vs brain) using two-way ANOVA with Bonferroni multiple 
comparison post-test. 
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5.6 QPCR analysis of the chemokine signature in the 
brain and PBL following intraperitoneal IMQ treatment  
To determine the importance of a localised skin response in the generation of a 
transcriptional chemokine response in the brain, the 7 chemokine genes were 
evaluated following the intraperitoneal injection of IMQ. SYBR Green QPCR 
analysis was performed using RNA from brains and PBL isolated 24 hours after 
the fifth administration of I.P. IMQ or saline. Each gene was normalised to the 
housekeeping gene, TBP, and each treatment group was compared to the 
corresponding control group, which were normalised to a fold change value of 1. 
The fold change induction of each gene in the brain and PBL is shown in Figure 
5-6. 
With regards to the brain, only two of the chemokine genes, CCL5 and CCR5 
(Figure 5-6B + G, respectively), were significantly induced in the brains of IMQ-
injected mice compared with the brains of saline-injected mice. The expression 
of many of the genes in the brain, particularly CXCL10, CXCL13 and CXCL16, was 
highly variable, as shown by the large error bars, perhaps indicating that the 
expression of the genes was very low.   
Only one gene was significantly induced in the PBL of the treated group when 
compared with the control group. CCL5 was upregulated 3-fold in the PBL of the 
treated mice, an almost identical fold-induction to that of the brain (Figure 
5-6B). Again, many of the chemokine genes had a high degree of error, 
suggesting that the expression levels were close to the minimum detection levels 
of the assay.  
CCL9 was the only gene found to be significantly differentially expressed 
between the brain and the PBL (Figure 5-6C). The results suggested that the 
fold-change induction of CCL9 in the brain was greater than the induction in the 
PBL; however the induction of this gene failed to reach significance in the 
individual tissues.  
These results indicated that I.P. administered IMQ was not able to induce a 
transcriptional chemokine response in the brain or PBL similar to that seen 
following topical IMQ administration.  
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Figure 5-6 QPCR analysis of chemokines in brains and PBL following I.P IMQ injection 
Mice were treated with 100µl 1mg/ml IMQ, or equivalent volume of saline, every 24hrs for 5 
consecutive days. Mice were euthanised 24hrs after the final application. Cardiac puncture was 
performed to retrieve PBLs and perfused brains were extracted. RNA was isolated from both 
tissues. QPCR analysis of the target chemokine genes identified in the microarray was performed 
for both tissues (A-G). n= 5 mice per group. Significance was measured within each tissue using 
individual students t test or between the tissues using two-way ANOVA with Bonferroni multiple 
comparison post-tests *** (+++) = p ≤ 0.001 **(++) = p ≤ 0.01 *(+) = p ≤ 0.05 
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5.7 QPCR analysis of the chemokine signature in the 
brain and PBL following topical IMQ treatment  
Results from Chapter 4 showed that I.P administration of IMQ failed to induce an 
ISG response in the brain. In agreement, section 5.6 of this chapter showed that 
this model also failed to induce the upregulation of the target chemokine genes. 
This could be due to the lack of isostearic acid; however topically applied IMQ 
did induce an ISG response in the brain (shown in Chapter 4); indicating that the 
more likely reason for the lack of a brain response was due to the route of 
administration. To determine whether IMQ alone could induce a chemokine 
response if it was applied topically, SYBR Green QPCR was performed on RNA 
from the brain and PBL of mice treated with topical IMQ in aqueous cream.  
The results of the brain analysis showed that all seven of the chemokine genes 
were significantly induced in the brains of IMQ-treated mice compared with 
control mice. The induction of three of the genes, CCL3, CCL5 and CCR5, was 
extremely high in the brain with increases of around 10,000-fold (Figure 5-7A, B 
+ G).  
In stark contrast, none of the genes was significantly induced in the PBL of the 
IMQ-treated mice. Interestingly, four of the seven genes, CCL5, CCL9, CXCL10 
and CXCL16, were significantly downregulated in the PBL, highlighting the 
difference between the response in the brain and the response in the periphery.  
This difference was emphasised following statistical analysis of the brain 
response compared with the PBL response. Results showed that the fold-change 
induction in the brain was significantly greater than the induction in the PBL for 
all seven chemokine genes analysed. 
Together, the results showed that topically applied IMQ induced a significant 
chemokine response in the brain that was not mimicked in the PBL. Along with 
ISG data from Chapter 4, the results indicated that this model was the most 
potent at inducing a transcriptional brain response out of all the models studied 
in this thesis.   
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Figure 5-7 QPCR analysis of chemokines in brains and PBL following topical IMQ 
Mice were treated with 80mg IMQ (5%v:v), or equivalent quantity of control cream, every 24hrs for 
5 consecutive days. Mice were euthanised 24hrs after the final application. Cardiac puncture was 
performed to retrieve PBLs and perfused brains were extracted. RNA was isolated from both 
tissues. QPCR analysis of the target chemokine genes identified in the microarray was performed 
for both tissues (A-G). n= 5 mice per group. Significance was measured within each tissue using 
individual students t test or between the tissues using two-way ANOVA with Bonferroni multiple 
comparison post-tests *** (+++) = p ≤ 0.001 **(++) = p ≤ 0.01 *(+) = p ≤ 0.05 
  191 
5.8 CD3 T cell infiltration into the brain following Aldara 
treatment 
A fundamental function of chemokines is to mediate immune cell migration404. 
Chemokine expression in the brain has been shown to induce the influx of 
inflammatory cells including monocytes and T cells229, 233, 234. Following Aldara 
treatment, we have shown that several inflammatory chemokines have been 
significantly upregulated in the brain. Thus we next sought to investigate 
whether or not Aldara treatment led to immune cell infiltration into the brain. 
Several of the chemokines induced in the brain following treatment are ligands 
for chemokine receptors expressed by different subsets of CD3+ T cells, 
therefore this was the cell type thought to be most likely recruited. To 
investigate this, mice were treated with Aldara cream or control cream every 24 
hours for 1, 3 or 5 consecutive days. Perfused brains were extracted and 
formalin fixed before being sectioned and stained for CD3.  
Representative images from control and Aldara-treated mice at the different 
time-points are shown for the cerebellum (Figure 5-8A) and hippocampus (Figure 
5-8B). It was immediately clear that Aldara treatment induced the influx of CD3+ 
cells after the third and fifth treatments. The positive cells were found 
throughout the brain parenchyma and did not appear to have any localised, 
region-specific anatomical distribution. Very few CD3+ cells were seen in the 
control mice, as was expected. The number of CD3+ cells in the brain was 
quantified by performing blind cell counts of whole brain sections. Three whole 
sagittal sections from the brain were counted for each mouse (Figure 5-8C). The 
cell counts confirmed that Aldara-treatment induced a significant influx of CD3+ 
cells into the brain following the third and fifth applications, averaging around 
300 cells on day 3 and 550 cells on day 5.  
These data confirmed that topical Aldara treatment induced the influx of CD3+ T 
cells into the brain parenchyma, which was likely due to the distinct chemokine 
response identified in the brain following treatment.     
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Figure 5-8 CD3+ T cell infiltration into the brain following Aldara treatment 
Mice were treated with 80mg Aldara cream or control cream every 24hrs for 5 consecutive days. 
Perfused brains were formalin fixed and embedded in wax. Brain sections were stained for CD3 
and representative 200X magnified images from cerebellum (A) and hippocampus (B) are shown. 
Inserts on each image show respective field of view at 50X magnification. Cell counts were 
performed blind on 3 sections per brain (C). n=4 mice/group. Significance was measured using 
two-way ANOVA with Bonferroni multiple comparison post-tests *** = p ≤ 0.001 
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5.9 Assessment of burrowing behaviour with chemokine 
blockade 
The results presented in this thesis have, so far, shown that topical Aldara 
treatment induced a chemokine response in the brain, the influx of immune cells 
into the brain parenchyma and a reduction in burrowing behaviour. Next, we 
wanted to determine whether blocking inflammatory chemokine responses would 
have an effect on burrowing behaviour to see if this functional output was being 
mediated by chemokine expression. If chemokines were mediating the 
behavioural changes, perhaps burrowing activity could be restored if responses 
to these chemokines were blocked.  
Two different pharmaceutical agents were used to test this hypothesis, both of 
which have been used to investigate the role of chemokine receptors in viral 
encephalitis405. CCR5 blockade would inhibit the effects of CCL3, CCL4, CCL5 
and CCL8, whereas CXCR3 blockade would inhibit CXCL9, CXCL10 and CXCL11 
activity. Mice were treated with topical Aldara or control cream every 24 hours 
for 3 consecutive days. Aldara-treated mice were, in addition, treated with 
either CCR5 blocker, CXCR3 blocker or a CXCR3 mimic control. Burrowing 
behaviour was evaluated in each of the groups as previously described (Section 
3.6).  
The results showed that co-treatment with CCR5 blocker reduced burrowing 
behaviour in Aldara-treated mice (Figure 5-9A). By the second and third 
treatment days, mice burrowed very little. The withdrawal from burrowing 
behaviour appeared to be more rapidly induced than in Aldara-treated mice that 
did not receive the blocker, particularly at day 1; however the difference did 
not reach significance. As has been shown previously, the burrowing activity of 
control mice increased over the course of the treatment period. These data 
suggested that blocking the activity of CCR5, and its corresponding chemokine 
ligands, could not restore burrowing activity.  
The same study was performed using a CXCR3 blocker (Compound 21). The 
results showed that mice treated with Aldara along with blocker experienced 
reduced burrowing activity (Figure 5-9B). However, the blocker itself had no 
effect on this response as the suppression of burrowing activity was in line with 
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that seen in Aldara-treated mice without blocker and in mice that received the 
CXCR3 mimic. These results again suggested that the activity of CXCR3, and its 
ligands, was not directly mediating the behavioural response to Aldara 
treatment.  
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Figure 5-9 Burrowing activity of Aldara-treated mice with chemokine blockade 
WT mice were treated with ~80mg Aldara cream, control cream or Aldara cream along with CCR5 
blocker, CXCR3 blocker or mimic. Mice were assessed for burrowing activity on three consecutive 
days. Four hours following treatment application, mice were single caged with a burrowing tube 
containing 200g of food pellets for 2 hours. At the end of this time point, mice were caged again in 
groups and the remaining weight of food pellets in the tubes was recorded. The weight left in the 
tube following treatment with CCR5 blocker (A) and CXCR3 blocker (B) is shown. n=5 mice per 
group.  
  196 
5.10 Discussion 
The aim of this chapter was to investigate the chemokine response that was 
identified following microarray analysis and gene ontology clustering of brains 
from Aldara-treated mice. QPCR analysis was used to assess the chemokine 
response in the brain and PBL following Aldara treatment, TPA treatment, I.P. 
IMQ administration and topical IMQ treatment. In addition, immune cell 
infiltration into the brain parenchyma was assessed in Aldara-treated mice to 
determine whether or not peripheral cutaneous inflammation could induce the 
recruitment of cells. Finally, chemokine blockers were used in conjunction with 
the burrowing model to investigate whether inflammatory chemokines were 
driving the behavioural phenotype in response to cutaneous Aldara treatment.      
The results of the QPCR analysis confirmed the presence of a distinct chemokine 
profile in the brain in response to Aldara treatment and topical IMQ treatment, 
but not in response to TPA or I.P. administered IMQ. This was in keeping with the 
ISG data shown in Chapter 4 and it would appear that ISG induction and 
chemokine induction were two aspects of a general brain response since they 
followed the same temporal pattern. Similar patterns of chemokine upregulation 
have been described in studies using LPS-induced immune stimulation. Both 
Erikson et al and Thomson et al report a specific chemokine response in the 
brain following peripheral inflammation which is not mimicked in the PBL377, 406. 
It is therefore possible that the transcriptional response we see in the brain may 
be the result of general TLR stimulation in the periphery.    
Many of the inflammatory chemokines induced in the brain are involved in 
immune cell migration. Specifically, CCL3, CCL5 and CXCL10 are important in 
mediating CD4+ and CD8+ T cell migration, as these cells express the 
corresponding receptors, CCR5 and CXCR3. Several groups have shown that 
chemokine induction in the brain can induce immune cell infiltration, both under 
neuroinflammatory conditions234, 244, 407-409 and in response to peripheral 
inflammation230. Here, we have shown that, consistent with the literature, 
peripheral immune stimulation led to the infiltration of CD3+ T cells into the 
brain parenchyma. To our knowledge, we are the first to show this following 
cutaneous inflammation. These infiltrating T cells were found throughout the 
brain parenchyma and did not appear to be restricted to any specific anatomical 
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region, or regions, of the brain. To confirm that this influx was the direct result 
of chemokine upregulation, the experiment would have to be repeated in the 
models that did not show a chemokine response in the brain or through the use 
of chemokine blockers. However, it is plausible to hypothesise that this response 
was a direct consequence of inflammatory chemokine expression in the brain.   
We next sought to establish whether chemokine induction in the brain could be 
driving the behavioural phenotype described in Chapter 0. To investigate this, 
burrowing activity was assessed in Aldara-treated mice co-treated with 
chemokine blockers. Two different chemokine receptor antagonists were used in 
this experiment, a CCR5 blocker and a CXCR3 blocker. Neither was found to have 
an effect on the behavioural response to Aldara treatment as all groups, both 
with and without the administration of blocker, showed a similar suppression of 
burrowing activity. These blockers have been used previously to demonstrate the 
role of chemokines in viral encephalitis, with their administration leading to a 
reduction in immune cell infiltration into the brain405. It would therefore be 
useful to investigate whether the numbers of CD3+ T cells in the brain is reduced 
following co-treatment with chemokine blockers. Nonetheless, the results from 
this experiment suggest that, although inflammatory chemokines may be 
important for initiating the response to Aldara treatment, modulating their 
function does not appear to affect the consequential phenotypes.  
Although we can show that Aldara treatment caused a transcriptional chemokine 
response in the brain and T cell infiltration into the parenchyma, we have been 
unable to identify the exact mechanisms by which this response is generated. 
Further analysis would be required to try to better understand the relationship 
between the different aspects of this response.        
In summary, the results in this Chapter have identified a distinct chemokine 
profile in the brain and have linked peripheral skin inflammation with immune 
cell infiltration into the brain and impaired burrowing activity that could not be 
rescued using chemokine blockers. This study has demonstrated that peripheral, 
tissue-specific skin inflammation can induce both a transcriptional and 
functional response in the brain and highlights the importance for further 
investigation into the role of inflammatory chemokines as potential mediators of 
ensuing CNS inflammation. 
  
 
 
 
 
 
 
Chapter 6 
ACKR2 in the brain 
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6 ACKR2 in the brain 
6.1 Introduction 
Data presented in Chapter 5 have shown that treatment with topical Aldara and 
topical IMQ induced a chemokine response in the brain. Amongst the chemokine 
genes induced, CCL3 and CCL5, along with their receptor, CCR5, were the most 
highly upregulated in the brain following treatment. Both of these inflammatory 
chemokines bind to ACKR2, an atypical chemokine receptor which was described 
in detail in Chapter 1115. ACKR2 acts as a scavenger, binding to inflammatory CC 
chemokines and removing them from the microenvironment, and is therefore 
considered to have anti-inflammatory properties114.  
Interestingly, ACKR2 is expressed throughout the adult brain, as well as in 
specific structures including the dentate gyrus and the olfactory bulb (Figure 
6-1). The distinct anatomical distribution of ACKR2 in the brain could suggest 
that the scavenging receptor is there to regulate inflammatory chemokine 
function. In addition, since these regions of expression are also sites of adult 
neurogenesis, ACKR2 may have a role to play in regulating the generation and 
maintenance of new neurons. Therefore, the aim of this Chapter was to 
investigate the regulatory role of ACKR2 in the brain response to cutaneous 
inflammation using ACKR2 KO mice. We hypothesised that the inflammatory 
response would be exacerbated in the absence of ACKR2.   
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Figure 6-1 Expression of ACKR2 in the adult mouse brain 
Images showing the anatomical distribution of ACKR2 in the mouse brain (A), highlighting the 
concentrated expression in the dentate gyrus of the hippocampus (B). Images taken from the Allen 
Brain Atlas http://www.brain-map.org/  
 
6.2 Aldara model of skin inflammation in ACKR2 KO mice 
The model was first validated, whereby mouse weights, spleen weights and 
treated skin were evaluated in Aldara-treated wild-type mice and Aldara-treated 
ACKR2 KO mice (Figure 6-2). The results showed that the weight loss was similar 
between WT and ACKR2 KO mice for the first three treatment days; however 
ACKR2 KO mice started to recover some weight between day 3 and day 4, 
whereas WT mice continued to lose weight (A). ACKR2 KO mice were 
significantly heavier than WT mice at day 5, suggesting that they recovered 
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more quickly than the WT mice. There was no significant difference between the 
spleen weights of WT and KO mice, although the WT spleens were more variable 
(B), and they were visually very similar in size (C). With regards to the treated 
skin, both WT and KO skin showed signs of inflammation with marked epidermal 
hyperplasia and hyperkeratosis (D). It should be noted that many hair follicles 
were seen in the skin, indicative of hair cycle, which can alter the response to 
inflammation, however the presence of hair follicles was consistent between the 
two strains of mice. As no overt differences between WT and KO mice were 
observed, these results suggested that ACKR2 was not integral to the regulation 
of the cutaneous response to Aldara treatment.  
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Figure 6-2 Evaluation of the response to Aldara treatment in WT and ACKR2 KO mice 
WT mice and ACKR2 KO mice were treated with ~80mg Aldara cream every 24hrs for five 
consecutive days and were weighed following each application (A). In addition, spleens were 
removed and were weighed (B) and photographed (C). H&E staining was performed using 5µm 
thick sections of Aldara- or control- treated skin which were visualised at 200X magnification (D). (A 
& B) n = 10/ group from two independent experiments (C & D) n = 5/ group. Significance was 
measured using two-way ANOVA with Bonferroni multiple comparison post-tests *** = p ≤ 0.001.   
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6.2.1 QPCR analysis of the chemokine response to Aldara 
treatment in ACKR2 KO mice 
Although ACKR2 did not appear to be regulating the response in terms of the 
phenotypes examined in Section 6.2, it may be regulating other aspects of the 
response. For example, immune cell infiltration into the skin is dependent on 
chemokines, which may be under the influence of ACKR2. Indeed, it has 
previously been shown that ACKR2 KO mice have an exacerbated skin response 
following TPA treatment410, 411. A heightened local response may result in an 
increased response in the brain, thus the panel of chemokine genes examined in 
Chapters 3 and 4 were evaluated in the brain and PBL of ACKR2 KO mice 
following topical Aldara treatment (Figure 6-3). ACKR2 should not directly 
influence chemokine transcript expression as it functions at the protein level; 
therefore the absence of ACKR2 should not, in theory, affect chemokine levels in 
the brain under steady state conditions. Any differences in chemokine expression 
would likely be a secondary effect as the result of a heightened inflammatory 
response.  
The QPCR results showed that, with the exception of CXCL10, all of the 
chemokine genes were significantly induced in the brains of ACKR2 KO Aldara 
treated mice when compared with control ACKR2 KO mice. CCL5 was the most 
highly induced, with an upregulation of around 100-fold (Figure 6-3B).  
With regards to PBL, three of the genes, CCL5, CCL9 and CXCL13, were 
significantly induced in the PBL of the treated mice. Interestingly, two of the 
genes, CXCL10 and CXCL16, were significantly downregulated in the PBL of 
ACKR2 KO treated mice (Figure 6-3D + F).  
When the two tissues were compared, the fold-change induction in the brain was 
significantly greater than that of the PBL for all seven genes analysed. Although 
CXCL10 had not been significantly induced in the brain, it was significantly 
downregulated in the PBL, accounting for the differential expression between 
the two tissues.  
These results suggested that topical Aldara treatment induced a chemokine 
response in the brains of ACKR2 KO mice, similar to that seen in WT mice. 
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Despite some of the genes being significantly induced in the PBL, this was to a 
lesser extent than in the brain. Although it has been reported that ACKR2 KO 
mice are more sensitive to inflammation in a number of models, and we would 
therefore expect to see a heightened response to Aldara treatment, if we look 
back to the results in Figure 5-2, the induction of chemokines in the brain 
appears to be somewhat comparable to that of the WT mice. This would suggest 
that the response to Aldara cream is not dependent on the actions of ACKR2, 
either as a modulator or an inducer.  
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Figure 6-3 QPCR analysis of chemokines in brains and PBL of ACKR2 KO mice following 
Aldara treatment 
ACKR2 KO mice were treated with 80mg Aldara cream, or equivalent quantity of control cream, 
every 24hrs for 5 consecutive days. Mice were euthanised 24hrs after the final application. Cardiac 
puncture was performed to retrieve PBLs and perfused brains were extracted. RNA was isolated 
from both tissues. QPCR analysis of the target chemokine genes identified in the microarray was 
performed for both tissues (A-G). n= 4 mice per group. Significance was measured within each 
tissue using individual students t test or between the tissues using two-way ANOVA with Bonferroni 
multiple comparison post-tests *** (+++) = p ≤ 0.001 **(++) = p ≤ 0.01 *(+) = p ≤ 0.05 
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6.2.2 The effect of Aldara treatment on neurogenesis in WT and 
ACKR2 KO mice 
Neurogenesis continues throughout adult life at distinct anatomical locations 
within the brain, including the dentate gyrus and the olfactory bulb. It has been 
shown that this process is sensitive to inflammation, suggesting that disrupted 
neural generation and plasticity could be a mechanism by which immune 
stimulation can cause neurological phenotypes412. As shown in Figure 6-1, ACKR2 
expression in the brain is centralised to the dentate gyrus and olfactory bulb; 
however its function in the CNS has yet to be identified. Such anatomical 
specificity highlighted the possibility that ACKR2 may function as a regulator of 
neurogenesis by minimising local inflammation. Therefore the aim of this section 
was two-fold. First, to investigate whether or not topical Aldara treatment 
impaired neurogenesis and, second, to determine the importance of ACKR2 in 
maintaining adult neurogenesis. 
Doublecortin (DCX), which is expressed only by neural precursor cells, was 
assessed in the dentate gyrus of the hippocampus in WT and ACKR2 KO mice 
treated with topical Aldara or control cream. DAPI (blue) was used to stain the 
nuclei of the cells and FITC (green) was used to identify DCX-expressing cells. 
Figure 6-4A shows representative DCX staining of the dentate gyrus in WT control 
mice (I), WT Aldara-treated mice (II), ACKR2 KO control mice (III) and ACKR2 KO 
Aldara-treated mice (IV). A negative control and an isotype control were 
included to ensure the specificity of the staining and are shown in Figure 6-4B. It 
was immediately clear from the images that treated mice, both WT and ACKR2 
KO, had reduced DCX staining, however quantification was required in order to 
determine whether the differences were significant.  
  207 
 
Figure 6-4 Doublecortin staining of the dentate gyrus  
WT and ACKR2 KO mice were treated with ~80mg Aldara cream, or an equal volume of control 
cream, every 24 hours for 5 consecutive days. Perfused brains were extracted, formalin fixed and 
embedded in wax before being cut into 7µm sections. Sections were stained for DCX and were 
imaged at 400X magnification (A). Negative and isotype staining controls were included (B). n=4 
mice per group.   
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6.2.2.2 Quantification of DCX staining 
In order to quantify the DCX staining, slides were ‘blinded’ and a counting 
strategy was determined. As such, DCX+ cells were counted in three areas of the 
dentate gyrus for each section, one from the top, one from the middle and one 
from the bottom, as indicated in Figure 6-5A. A mean of these three areas was 
then calculated. A minimum of 11 sections from at least 3 mice were counted 
for each group and the results are plotted in Figure 6-5B. The results showed 
that treatment with Aldara caused a significant reduction in the number of DCX+ 
cells in both WT and ACKR2 KO mice. This indicated that peripheral immune 
stimulation with Aldara caused impaired neurogenesis in the dentate gyrus. 
However, there was no significant difference between the two mouse strains 
suggesting that ACKR2 is not a major regulator of this CNS process.  
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Figure 6-5 Counting strategy and DCX+ counts  
WT and ACKR2 KO mice were treated with ~80mg Aldara cream, or an equal volume of control 
cream, every 24 hours for 5 consecutive days. Perfused brains were extracted and were stained for 
DCX. Cell counts were performed on 3 different areas of the dentate gyrus for each section (A) and 
a minimum of 11 sections from at least 3 mice were counted (B). Significance was measured using 
unpaired two-tailed student’s t tests. ** p ≤ 0.01 *** p ≤ 0.001. n=3/4 mice per group. 
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6.2.4 Assessment of burrowing behaviour in Aldara-treated 
ACKR2 KO mice  
Having established that ACKR2 KO mice responded to topical Aldara treatment in 
a similar fashion to WT mice in terms of the chemokine response in the brain and 
in terms of neurogenesis, we next sought to establish if this treatment could also 
diminish burrowing activity. As detailed in Chapter 3, this model was used to 
assess the extent to which mice burrow during a 2 hour window following 
treatment. ACKR2 KO mice were treated at the same time each morning with 
~80mg of either Aldara cream or control cream, as described previously, and 
were then single-housed for the testing period 4 hours later.  
The results showed that, as seen previously in WT mice, ACKR2 KO mice treated 
with Aldara cream burrowed less than those treated with control cream. Figure 
6-6A shows that control mice burrowed more over time, as the weight of food 
left in the tubes declined over the three day period, whereas the burrowing 
activity of Aldara-treated mice was minimal. ACKR2 KO mice treated with Aldara 
appeared to burrow slightly more actively after the third application, a trend 
that was not seen with WT mice in Chapter 3; however this was still significantly 
less than the ACKR2 KO mice treated with control cream. The results were also 
portrayed as a percentage burrowing activity based on baseline measurements, 
which were considered 100% (B). This showed the variation in burrowing activity 
within the two groups and more clearly showed the increase in burrowing 
activity of the treated group after the third Aldara application. The results from 
the ACKR2 KO mice were compared with those from WT mice to determine if a 
lack of ACKR2 significantly affects the burrowing response to Aldara cream. 
Figure 6-6C shows a clear separation between the control mice and the treated 
mice; however there was no apparent difference between the WT mice and the 
ACKR2 KO mice. These results add to the evidence suggesting that the response 
of ACKR2 KO mice to Aldara treatment was very similar to that of WT mice. It 
would suggest that, whilst inflammatory CC chemokines may be important for 
generating the response to Aldara application, the response is not being overtly 
regulated by the scavenging receptor ACKR2.     
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Figure 6-6 Burrowing activity of ACKR2 KO Aldara-treated mice 
ACKR2 KO and WT mice were treated with ~80mg Aldara cream or control cream and were 
assessed for burrowing activity on three consecutive days. Four hours following treatment 
application, mice were single caged with a burrowing tube containing 200g of food pellets for 2 
hours. At the end of this time point, mice were caged again in groups and the remaining weight of 
food pellets in the tubes was recorded. The weight left in the tube following the 2 hour period is 
shown (A) or presented as a percentage of baseline tests, where baseline readings were 
considered 100% (B). To identify differences in burrowing activity between the two strains of mice, 
ACKR2 KO mice were compared with WT mice (C). n=4/5 per group. Significance was measured 
using two-way ANOVA with Bonferroni posttests *= p ≤ 0.05.     
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6.4 Discussion 
The results in Chapter 5 identified a distinct chemokine response in the brain 
following topical Aldara treatment. To further investigate the functional 
consequences of the response, and to determine whether inflammatory 
chemokines in the brain were regulated by scavenging receptor ACKR2, the 
Aldara model of cutaneous inflammation was repeated using ACKR2 KO mice. 
QPCR analysis was used to determine the chemokine response in the brain and 
burrowing behaviour was assessed as a functional output. In addition, due to the 
specific nature of ACKR2 expression in the brain, neurogenesis was measured in 
both WT, and ACKR2 KO, Aldara-treated mice.  
The results suggested that the phenotypic, cutaneous response to topical Aldara 
application was similar between WT and ACKR2 KO, as no overt differences in 
skin pathology were identified. Subsequently, the transcriptional chemokine 
response in the brain and PBL was assessed in the mutant mice. Although this 
gene deletion should not directly affect the transcript levels of chemokines as it 
functions at the protein level, Jamieson et al and Baldwin et al have suggested 
that cutaneous inflammation is exacerbated in ACKR2 KO mice410, 411. Thus, the 
tissue-specific, or systemic, inflammatory response to Aldara treatment may be 
heightened in these mice, which may in turn cause a greater response in the 
brain. However, the results showed that the transcriptional chemokine 
upregulation in the brains of ACKR2 KO mice followed a similar pattern when 
compared with WT mice, suggesting that ACKR2 was not an essential regulator of 
the chemokine response in the brain. 
The distinct anatomical distribution of ACKR2 in the brain, which is localised to 
the dentate gyrus and the olfactory bulb, indicated that it may be involved in 
regulating adult neurogenesis. As mentioned in Chapter 1, the process of 
neurogenesis is thought to be important for synaptic and neural plasticity and 
increased cognitive function332, 413. Therefore, using DCX staining, neurogenesis 
was assessed in Aldara-treated WT and ACKR2 KO mice. The results showed that 
neurogenesis was significantly impaired in mice treated with topical Aldara when 
compared with control mice. Although neurogenesis has been shown to be 
modulated by immune stimulation414-416, this is the first report to show that 
distal, cutaneous inflammation can have a negative effect. However, the results 
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presented in this Chapter suggested that, whilst cutaneous inflammation 
significantly impaired neurogenesis, ACKR2 did not appear to regulate this 
response as neurogenesis was reduced to a similar extent in WT and KO mice.    
In summary, the results in this Chapter suggest that ACKR2 KO mice respond in a 
similar fashion to topical Aldara-treatment as WT mice. The transcriptional 
chemokine response in the brain, the impairment of adult neurogenesis and the 
reduction in burrowing behaviour is consistent between the two different mouse 
strains. It may be that the scavenging effects of ACKR2 are subtle and the 
redundancy of the chemokine family and the magnitude of the brain response 
overwhelmed the regulatory effects of ACKR2 in this system. However, taken 
together, the results indicate that ACKR2-dependent regulation of inflammatory 
CC chemokines is not an essential mechanism in the brain response to peripheral 
inflammation.  
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7 Discussion 
Neuropsychiatric conditions are commonly associated with chronic inflammatory 
diseases that affect the periphery417, 418. However, the mechanisms underpinning 
this relationship are unclear, not least because the brain is an ‘immune-
specialised’ tissue137, 179. Studies have attempted to investigate this and, 
although our understanding of the communication between the brain and the 
periphery has increased in recent years, many unanswered questions remain. In 
addition, a large proportion of these studies have relied upon the administration 
of potent systemic inflammatory agents, inflammatory models that are unlike 
the tissue-specific conditions affecting humans. To try to further our knowledge 
with regards to the mechanisms underpinning the relationship between 
peripheral inflammation and the onset of neurological conditions, this thesis 
used a pathologically relevant mouse model of cutaneous inflammation to 
investigate the brain response to peripheral inflammation.  
The Aldara model of psoriasis-like skin inflammation is well documented363, 372, 
401, but has never before been used to investigate the central response to 
peripheral inflammation. In the studies described in Chapter 3, this model was 
used to determine the brain response to cutaneous inflammation using 
transcriptional profiling techniques. The microarray analysis identified a 
distinct, and pronounced, ISG response in the brain following Aldara treatment. 
This brain response was confirmed using QPCR and was found to correlate with a 
reduction in burrowing behaviour, indicating behavioural dysfunction in Aldara-
treated mice. In Chapter 4, the ISG response in the brain was evaluated in a 
number of different inflammatory models and was found to be induced following 
topical IMQ treatment, the TLR-specific active component of Aldara cream. The 
brain signature was not, however, identified following TPA-induced skin 
inflammation or following I.P. administration of IMQ. The temporal pattern of 
the response to Aldara application was also investigated and it was discovered 
that the brain response, which peaked following the third application, was not 
mimicked by a similar response in the PBL. In Chapter 5, the microarray dataset 
was revisited and a chemokine signature in the Aldara-treated brains was 
identified. When compared with the other models, we found that the chemokine 
response followed the same temporal expression pattern as the ISG response and 
was present in the topical IMQ model, but not in the TPA model or the I.P IMQ 
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model. In addition to the transcriptional response, topical Aldara treatment also 
induced the influx of CD3+ T cells into the brain parenchyma. We showed, 
through the use of two chemokine receptor blockers, that impaired burrowing 
behaviour did not appear to be dependent on the individual activity of 
chemokine receptors CCR5 or CXCR3. Finally, the role of ACKR2 was investigated 
through the use of ACKR2 KO mice. The data presented in Chapter 6 indicated 
that ACKR2 was not an important mediator in the response to cutaneous 
inflammation as results from the transcriptional analysis of the brain, and results 
from the two functional studies, were consistent between WT and KO strains. 
Although no strain difference was observed, analysis of emerging neurons in the 
dentate gyrus showed that cutaneous inflammation caused a reduction in adult 
neurogenesis. Whilst some debate remains as to the functional relevance of 
adult neurogenesis413, it is thought to promote learning and memory and support 
cognition419.          
It is difficult to determine the role of an ISG and chemokine response in the 
brain, and whether or not their induction would be beneficial or detrimental to 
the host. Although we have shown that Aldara treatment, and the subsequent 
transcriptional response in the brain, correlate with decreased burrowing 
activity and impaired neurogenesis, we have been unable to identify the causal 
relationship between these observations. The role of many specific ISGs remains 
unknown; however their purpose as a whole is to mediate a potent anti-viral 
response. This has been shown following the intranasal administration of viruses 
and, although the viruses only infected the olfactory bulb, the subsequent ISG 
response was found throughout the brain and in distant, uninfected sites393. It is 
therefore possible that the brain ISG response that we see following cutaneous 
TLR7 stimulation is the same classic response to virus infection that one would 
expect to see in the localised area, but is somehow projected to this distant 
tissue. More recent studies performed in our lab have investigated the 
transcriptional response to topical Aldara treatment in other tissues including 
the liver, spleen and lungs. Interestingly, the gene induction in these tissues was 
minimal, which suggests enhanced chemokine expression following cutaneous 
inflammation may be unique to the brain (Louis Nerurkar, unpublished data). It 
would be interesting to determine if an ISG response is present in other tissues, 
such as the liver and spleen following Aldara and IMQ treatment. Evidence as to 
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how ISGs in the brain might affect homeostatic functions are limited, therefore 
it is difficult to hypothesise whether or not the ISGs are the direct cause of any 
of the functional outputs we observed.  
It is likely that the induction of CCL3, CCL5, CXCL9 (identified in the microarray 
only) and CXCL10 were driving the influx of CD3+ T cells into the brain as these 
are ligands for chemokine receptors expressed by T cells. Indeed, this has been 
shown in a model of viral encephalitis234. If time had allowed, this mechanism 
could have been confirmed by performing CD3 immunohistochemistry on brains 
from Aldara-treated mice co-treated with the CXCR3 blocker and CCR5 blocker. 
It remains unclear as to whether or not chemokines in the brain could drive the 
behavioural changes and suppression of neurogenesis identified following Aldara 
treatment. Although the use of ACKR2 KO mice did not appear to alter the 
results in any way, this genetic modification would only impact on two of the 
chemokines induced in the brain, CCL3 and CCL5, as ACKR2 is a scavenging 
receptor for inflammatory CC chemokines. Chemokines are thought to be 
involved in the regulation of neurogenesis, both during development and in 
adulthood153, 414. In particular, CXCR4-directed migration of neuronal precursors 
and CX3CL1-dependent crosstalk between neurons and microglia are thought to 
be important152, 210. These data would suggest that if the levels of chemokines 
were altered in the brain, this in turn could impact the level of neurogenesis. 
However, none of the key chemokines reported to be involved in neurogenesis 
were identified as being differentially expressed in the brain following Aldara 
treatment. As mentioned in Chapter 1, it has been suggested that chemokines 
can act as neurotransmitters, supporting the communication between neurons 
and glial cells and modulating GABAergic neurotransmission211, 215, 224. However, 
there is a lot of contradictory literature regarding the role of chemokines within 
the healthy adult brain and CCL5 was the only chemokine upregulated in 
response to cutaneous Aldara treatment that has been reported to act as a 
neurotransmitter. Furthermore, despite numerous studies into the role of 
chemokines in neuropsychiatric conditions, findings are often inconsistent and 
mainly focus on two prototypical inflammatory chemokines, CXCL8 and CCL2374, 
neither of which were induced in the brain following Aldara treatment. It would 
therefore appear that the chemokines induced in the brain in response to Aldara 
treatment have the primary role of promoting an inflammatory response through 
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the recruitment of immune cells into the brain. To link chemokines to the other 
functional outputs, the reduction in neurogenesis and impaired burrowing 
activity, would require further studies.       
7.1 Hypotheses 
The mechanisms by which tissue-specific cutaneous inflammation can affect the 
brain remain to be established, therefore we can only speculate as to the 
potential mechanisms based on the evidence we have obtained. The results in 
this thesis implicate TLR ligation and ‘non-canonical’ TLR signalling as one 
potential mechanism driving the brain response. For example, although a brain 
response was detected following topical Aldara and topical IMQ application, a 
similar but non-TLR based stimulus, TPA, failed to induce an ISG or chemokine 
response in the brain. These findings are in agreement with previous studies that 
have shown an ISG and chemokine response in the brain following LPS 
administration; a response which could not be reproduced following systemic 
cytokine administration377. As mentioned in Chapter 1, TLR ligation leads to a 
downstream signalling event which results in the activation of the transcription 
factor NF-κB and the production of inflammatory cytokines33. However, certain 
TLRs can signal through alternative pathways to activate different transcription 
factors33, 387. Interestingly, in addition to the ‘classical’ TLR signalling pathway, 
TLR4 and TLR7, which bind LPS and IMQ respectively, can also signal through 
non-canonical pathways which lead to the production of Type I IFNs (Figure 
7-1)420. These ‘alternative’ signalling pathways provide us with a mechanism 
through which LPS and IMQ could mediate an ISG response in the brain following 
peripheral stimulation. We have shown that LTA, a ligand for TLR2, which can 
only signal through the ‘classical’ pathway, was unable to induce an ISG 
response in the brain, again suggesting that the ISG response is the result of the 
‘alternative’ TLR signalling pathways377.  
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Figure 7-1 TLR4 and TLR7 signalling pathways  
Diagram showing the signalling pathways following TLR4 and TLR7 ligation. Both signal through 
‘alternative’ signalling pathways that lead to Type I IFN production, in addition to the the NF-κB-
dependent ‘classical’ pathway that leads to the production of inflammatory cytokines.     
  
However, the results presented in this thesis provide a number of caveats that 
need to be considered. For example, the plasma levels of inflammatory 
cytokines following topical Aldara and topical IMQ treatment were low and 
variable and diminished over the course of the treatments. It was apparent from 
the results that the brain response did not correlate with a strong inflammatory 
cytokine profile in the periphery and, most notably, we did not find high 
expression of IFNγ, although Type I IFNs were not assessed. This was surprising 
as pro-inflammatory cytokines and Type I IFNs are classically induced following 
TLR7 stimulation. Some cytokines may be produced early in the acute response 
and it may be the case that expression levels would be higher had they been 
assessed at an earlier time point; however, if we propose that circulating 
cytokines are driving the brain response we see at day 3 and day 5, we would 
expect detectable levels in the blood plasma.  
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In addition, if the brain response was dependent on non-canonical TLR signalling, 
we would have expected to see a similar brain response following intraperitoneal 
administration of IMQ to that seen following topical IMQ. However, only a very 
mild response was detected in the brain following I.P. IMQ compared with mice 
treated with topical IMQ. This less severe response to intraperitoneal TLR7 
agonists has also been reported in the literature421 and, although it could simply 
be a consequence of the dose used in this thesis, it could imply that the brain 
response to IMQ was dependent on the localised skin response. However, we 
have also shown that topical IMQ failed to induce cutaneous inflammation as this 
aspect of the response was likely caused by the vehicle component, isostearic 
acid. Independently of overt tissue inflammation in the skin, topical IMQ 
treatment induced the most striking brain response out of all of the models 
investigated. In light of this, we propose a second hypothesis to serve as an 
alternative mechanism by which the effects of topical IMQ are being mediated; 
through the inflammatory reflex291.  
One way in which the presence of IMQ in the skin might be detected is through 
the activation of the vagus nerve. Like all tissues highly exposed to the external 
environment, the skin is innervated with sensory nerve fibres that are sensitive 
to heat, pain and touch. These sensory neurons are responsive to danger and 
inflammatory stimuli via the expression of three different types of receptor, 1) 
receptors that recognise PAMPS, including TLRs and NLRs 2) receptors that 
recognise DAMPS and 3) receptors for inflammatory cytokines422. As mentioned in 
Chapter 1, the afferent branches of the vagus nerve are also surrounded by 
macrophages and DCs that can be activated in response to inflammatory 
cytokines or PAMPs282. Through the use of vagotomy studies, it has been shown 
that, in order to sense inflammatory stimuli in the periphery, an intact vagus 
nerve is required288, 423, 424. This transmits signals directly to the brain and can 
mediate responses including cytokine-induced fever425 and sickness behaviours423 
and is therefore considered key in maintaining immunological homeostasis. In 
addition, electrical stimulation of the vagus nerve has been shown to attenuate 
inflammation through the cholinergic anti-inflammatory pathways284, 424. This 
mechanism of immune-to-brain communication might help explain our findings, 
that topically applied IMQ induced a brain response without the need for an 
overt inflammatory response in the periphery. If IMQ was directly activating the 
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peripheral nervous system, there would not be the need for high levels of 
inflammatory cytokines or for a localised inflammatory response in the skin. In 
this way, the response would still rely on the function of TLR7, but the action of 
local inflammatory mediators would be complemented by the direct 
communication with the brain.  
7.2 Conclusions  
The results in this thesis demonstrate that peripheral inflammation can induce a 
profound response in the brain. We have shown that cutaneous inflammation 
leads to the induction of an ISG and chemokine response in the brain, along with 
impaired dentate neurogenesis, a reduction in burrowing behaviour and the 
influx of inflammatory cells into the brain parenchyma. We hypothesise that 
these functional changes may be mediated through the TLR7-dependent 
activation of the afferent vagus nerve, conferring direct communicating with the 
brain. Despite being considered an ‘immune-specialised’ tissue, these findings 
highlight the sensitivity of the brain to peripheral, tissue-specific immune 
stimulus. These results could help forward our understanding as to how 
peripheral inflammatory diseases are so commonly associated with the onset of 
neuropsychiatric conditions. However, to fully understand the mechanisms that 
define this relationship, further investigations would be required.      
7.3 Future directions 
The work in this thesis has generated some interesting and novel data; however 
many of the findings are observational and would require further investigation to 
clarify the relationships and identify the underlying mechanisms. Several 
experiments could be performed to help advance our understanding.  
The results have relied upon the analysis of global gene expression in the brain, 
rather than focusing on distinct brain regions and specific neural cell types. To 
my knowledge, this was the first study to investigate the brain response to 
cutaneous Aldara treatment; therefore it made sense to begin with an unbiased, 
broad-spectrum approach. However, these results would be complemented with 
the use of fluorescent in-situ hybridisation (FISH) techniques that would allow us 
to identify the regional and cellular specificity of the gene expression, focusing 
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on our identified panel of genes of interest. This would help us to determine 
whether the transcriptional response was the result of infiltrating immune cells 
or whether it was the direct activation of glial cells. It would also be beneficial 
to look for a wider panel of infiltrating immune cells in the brains of Aldara-
treated mice. Although our focus was CD3+ T cells, the chemokines induced in 
the brain also regulate the chemotaxis of other immune cells, particularly 
neutrophils and monocytes.    
To test our hypotheses, that the brain response is mediated by non-canonical 
TLR signalling through the activation of the vagus nerve, several studies could be 
performed. To identify the involvement of the different TLR signalling pathways, 
IRF7-deficient mice or NF-κB inhibition could be used426, 427. In addition, the role 
of Type I IFNs in behaviour and neurogenesis could be assessed using IFNAR-
deficient mice428. To determine whether or not the brain response to cutaneous 
inflammation was generated via the afferent vagus nerve, vagotomy experiments 
could be performed. Alternatively, the vagus nerve could be directly, and 
specifically, stimulated using IMQ and a non-TLR stimulus in order to compare 
the responses.  
Finally, this study would benefit from more in depth behavioural analyses to 
fully profile the functional output of topical Aldara treatment. The burrowing 
behavioural test is a basic model that was selected for this thesis as it satisfied 
the constraints of our animal license. However, there are other models that 
could be used in order to identify specific impairments in memory, learning, 
cognitive function and depression-like sickness behaviours55, 429, 430. 
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Appendices 
Appendix 1 List of genes identified using microarray analysis 
Gene Symbol Gene Name Fold Change p-value  
Cd72 CD72 antigen 28.13216 2.30E-11 
Ccl5 chemokine (C-C motif) ligand 5 25.649666 1.17E-09 
Gm11428 predicted gene 11428 23.267797 1.74E-10 
Ms4a6c membrane-spanning 4-domains, subfamily A, member 6C 22.076183 1.19E-09 
Cxcl13 chemokine (C-X-C motif) ligand 13 21.38037 1.53E-09 
Ccl3 chemokine (C-C motif) ligand 3 18.673525 4.10E-10 
Ms4a7 membrane-spanning 4-domains, subfamily A, member 7 16.419401 1.11E-09 
Clec4a1 C-type lectin domain family 4, member a1 15.462207 6.18E-10 
Oasl2 2'-5' oligoadenylate synthetase-like 2 14.909811 1.68E-08 
Ifi44 interferon-induced protein 44 14.84326 8.11E-07 
Ifit1 interferon-induced protein with tetratricopeptide repeats 1 
14.149096
5 2.26E-07 
AI607873  13.953218 4.32E-09 
Ifit3 interferon-induced protein with tetratricopeptide repeats 3 13.801712 3.73E-08 
Irf7 interferon regulatory factor 7 13.696917 3.23E-08 
Cybb cytochrome b-245, beta polypeptide 13.394899 7.46E-11 
Emr1 EGF-like module containing, mucin-like, hormone receptor-like sequence 1 12.654873 6.06E-10 
Usp18 ubiquitin specific peptidase 18 12.629435 8.64E-07 
H2-K1 histocompatibility 2, K1, K region 12.393708 4.71E-11 
Cd52 CD52 antigen 12.29611 1.60E-09 
Lyz2 lysozyme 2 12.252241 4.53E-10 
0 MHC class I like protein GS10 | histocompatibility 2, Q region locus 5 11.900996 8.21E-09 
Ms4a6d membrane-spanning 4-domains, subfamily A, member 6D 11.575372 7.73E-09 
Ms4a4c membrane-spanning 4-domains, subfamily A, member 4C 11.117746 1.64E-06 
Plbd1 phospholipase B domain containing 1 10.889762 6.35E-09 
Fcgr4 Fc receptor, IgG, low affinity IV 10.599809 1.14E-08 
C3ar1 complement component 3a receptor 1 10.397596 3.88E-10 
H2-
Q6|LOC68395 
histocompatibility 2, Q region locus 6 | 
histocompatibility 2, Q region locus 6-like 10.238313 2.92E-08 
Clec12a C-type lectin domain family 12, member a 9.760899 1.91E-10 
Clec4a3 C-type lectin domain family 4, member a3 9.502658 1.55E-08 
Trim30 tripartite motif-containing 30 9.322903 7.06E-07 
Lgals3bp lectin, galactoside-binding, soluble, 3 binding protein 8.6376915 5.24E-09 
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Fcer1g Fc receptor, IgE, high affinity I, gamma polypeptide 8.5139475 8.67E-11 
Gm885 predicted gene 885 8.477824 1.39E-09 
Ptprc protein tyrosine phosphatase, receptor type, C 8.296488 3.43E-09 
Tgfbi transforming growth factor, beta induced 8.292485 4.72E-09 
Cd180 CD180 antigen 7.9570346 6.19E-10 
Sirpb1b| 
Sirpb1a| 
LOC100038947 
|LOC630976| 
LOC641195 
signal-regulatory protein beta 1B | signal-regulatory 
protein beta 1A | signal-regulatory protein beta 1-like 
| similar to SIRP beta 1 isoform 3 | similar to SIRP 
beta 1 isoform 1 
7.933538 8.64E-09 
Ifitm3 interferon induced transmembrane protein 3 7.9153414 6.25E-09 
I830012O16Rik RIKEN cDNA I830012O16 gene 7.8779535 2.29E-05 
Fyb FYN binding protein 7.656857 2.61E-10 
Pilra paired immunoglobin-like type 2 receptor alpha 7.5580826 9.62E-10 
H2-D1|H2-L histocompatibility 2, D region locus 1 7.542797 6.61E-11 
Rtp4 receptor transporter protein 4 7.315761 3.52E-07 
Pld4 phospholipase D family, member 4 7.2694716 2.81E-10 
AW112010  7.258376 2.05E-10 
Ctsc cathepsin C 7.220582 2.65E-10 
Saa3 serum amyloid A 3 7.173075 2.25E-06 
Apobec1 apolipoprotein B mRNA editing enzyme, catalytic polypeptide 1 7.168513 5.67E-10 
Acp5 acid phosphatase 5, tartrate resistant 7.1567636 4.93E-08 
C4b|C4a complement component 4B (Childo blood group) | complement component 4A (Rodgers blood group) 7.0189023 2.26E-10 
Irgm1 immunity-related GTPase family M member 1 6.9834146 4.35E-07 
Gbp3 guanylate binding protein 3 6.911741 3.71E-06 
Ms4a6b membrane-spanning 4-domains, subfamily A, member 6B 6.896093 4.91E-08 
Ifi204|Mnda interferon activated gene 204 | myeloid cell nuclear differentiation antigen 6.8321 1.04E-05 
Gbp2 guanylate binding protein 2 6.5060687 3.34E-06 
Serpina3n serine (or cysteine) peptidase inhibitor, clade A, member 3N 6.447621 1.85E-10 
Cxcl9 chemokine (C-X-C motif) ligand 9 6.4027085 1.57E-06 
Gm4951 predicted gene 4951 6.300047 2.04E-05 
  6.2691884 7.58E-06 
Igsf6 immunoglobulin superfamily, member 6 6.205959 1.68E-09 
Mpa2l|Gbp10| 
EG634650|Gbp8 
macrophage activation 2 like | guanylate-binding 
protein 10 | predicted gene, EG634650 | guanylate-
binding protein 8 
6.181138 1.17E-06 
Lilrb4 leukocyte immunoglobulin-like receptor, subfamily B, member 4 6.1702504 3.61E-07 
Mpeg1 macrophage expressed gene 1 6.138617 1.42E-11 
Oas1g|Oas1a 2'-5' oligoadenylate synthetase 1G | 2'-5' oligoadenylate synthetase 1A 5.8706975 1.18E-05 
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H2-Q7|H2-
Q6|H2-Q8 
histocompatibility 2, Q region locus 7 | 
histocompatibility 2, Q region locus 6 | 
histocompatibility 2, Q region locus 8 
5.8335204 2.45E-11 
Ifi27l2a interferon, alpha-inducible protein 27 like 2A 5.8044176 8.40E-07 
Tlr13 toll-like receptor 13 5.718304 6.51E-09 
Ddx58 DEAD (Asp-Glu-Ala-Asp) box polypeptide 58 5.7036858 3.45E-06 
Ctsh cathepsin H 5.6594315 8.12E-10 
  5.598447 1.10E-05 
Cxcl16|Zmynd15 chemokine (C-X-C motif) ligand 16 | zinc finger, MYND-type containing 15 5.4621305 1.30E-07 
Rnf213 ring finger protein 213 5.451237 5.37E-06 
  5.329549 9.26E-06 
Gpnmb glycoprotein (transmembrane) nmb 5.3048334 6.56E-07 
Cd53 CD53 antigen 5.291279 2.81E-10 
Cyp4f18 cytochrome P450, family 4, subfamily f, polypeptide 18 5.2113914 2.80E-07 
Stat1 signal transducer and activator of transcription 1 5.2003345 2.13E-06 
  5.1890216 1.68E-05 
Pik3ap1 phosphoinositide-3-kinase adaptor protein 1 5.1737046 1.50E-09 
Klra2 killer cell lectin-like receptor, subfamily A, member 2 5.165078 2.34E-08 
Ctss cathepsin S 5.161943 1.94E-10 
AI451617  5.0858283 1.23E-05 
Il2rg interleukin 2 receptor, gamma chain 5.0607347 1.28E-07 
Ms4a4a membrane-spanning 4-domains, subfamily A, member 4A 4.9973893 1.52E-08 
  4.9876914 1.59E-05 
  4.9528537 1.64E-05 
  4.9109077 3.17E-05 
Irgm2|Igtp immunity-related GTPase family M member 2 | interferon gamma induced GTPase 4.905407 1.01E-06 
Lcp1 lymphocyte cytosolic protein 1 4.82637 1.62E-08 
  4.824545 1.84E-05 
H2-T22|H2-
T9|H2-T10 
histocompatibility 2, T region locus 22 | 
histocompatibility 2, T region locus 9 | 
histocompatibility 2, T region locus 10 
4.7803392 2.80E-07 
Iigp1 interferon inducible GTPase 1 4.7393727 5.79E-05 
Oas1b 2'-5' oligoadenylate synthetase 1B 4.6943526 2.57E-05 
Sirpb1a|Sirpb1b| 
LOC100038947| 
LOC630976 
signal-regulatory protein beta 1A | signal-regulatory 
protein beta 1B | signal-regulatory protein beta 1-like 
| similar to SIRP beta 1 isoform 3 
4.6814513 1.42E-08 
Samd9l sterile alpha motif domain containing 9-like 4.6794043 2.95E-05 
Ddx60 DEAD (Asp-Glu-Ala-Asp) box polypeptide 60 4.6703634 2.19E-05 
Itgb2 integrin beta 2 4.578407 6.79E-08 
Ly86 lymphocyte antigen 86 4.5482535 1.10E-09 
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Sh2d1b1 SH2 domain protein 1B1 4.548108 1.29E-06 
  4.5266757 2.33E-05 
Ccl9 chemokine (C-C motif) ligand 9 4.517743 2.91E-07 
Aoah acyloxyacyl hydrolase 4.4741716 6.13E-09 
D14Ertd668e DNA segment, Chr 14, ERATO Doi 668, expressed 4.4590044 7.04E-04 
C3 complement component 3 4.4247837 2.86E-08 
Lcn2 lipocalin 2 4.392422 2.19E-09 
Ms4a14 membrane-spanning 4-domains, subfamily A, member 14 4.35078 2.38E-06 
Gbp4 guanylate binding protein 4 4.3316245 1.37E-06 
Hck hemopoietic cell kinase 4.327205 1.56E-07 
Eif2ak2 eukaryotic translation initiation factor 2-alpha kinase 2 4.2970195 3.46E-05 
  4.283881 7.76E-05 
Rnf213 ring finger protein 213 4.264224 1.62E-05 
Cxcl10 chemokine (C-X-C motif) ligand 10 4.246946 1.27E-04 
Sirpb1b|Sirpb1a| 
LOC100038947| 
LOC641195 
signal-regulatory protein beta 1B | signal-regulatory 
protein beta 1A | signal-regulatory protein beta 1-like 
| similar to SIRP beta 1 isoform 1 
4.2158923 1.83E-08 
Gpr65 G-protein coupled receptor 65 4.1929426 1.23E-09 
Psmb8 proteasome (prosome, macropain) subunit, beta type 8 (large multifunctional peptidase 7) 4.1857376 6.08E-06 
Vav1 vav 1 oncogene 4.172101 3.47E-08 
H2-Q8 histocompatibility 2, Q region locus 8 4.132269 6.47E-07 
Tgtp1|Tgtp2| 
Gm12185 
T-cell specific GTPase 1 | T-cell specific GTPase 2 | 
predicted gene 12185 4.123084 3.62E-05 
Ube2l6 ubiquitin-conjugating enzyme E2L 6 4.117248 4.18E-05 
Tgtp1|Tgtp2| 
Gm12185 
T-cell specific GTPase 1 | T-cell specific GTPase 2 | 
predicted gene 12185 4.114396 2.22E-05 
Ifit2 interferon-induced protein with tetratricopeptide repeats 2 4.1017013 9.34E-05 
Gbp6 guanylate binding protein 6 4.0850587 1.01E-05 
Unc93b1 unc-93 homolog B1 (C. elegans) 4.079613 5.62E-10 
Rac2 RAS-related C3 botulinum substrate 2 4.0723453 6.72E-08 
Lgals9 lectin, galactose binding, soluble 9 4.061534 3.03E-06 
H2-t9|EG547347 MHC class Ib T9 | predicted gene, EG547347 4.0322742 7.58E-09 
H2-T23| 
C920025E04Rik 
histocompatibility 2, T region locus 23 | RIKEN 
cDNA C920025E04 gene 3.994959 4.41E-07 
Naip2 NLR family, apoptosis inhibitory protein 2 3.9914474 1.63E-07 
Rsad2 radical S-adenosyl methionine domain containing 2 3.9893818 9.71E-05 
Cd48 CD48 antigen 3.9850123 7.09E-08 
Xaf1 XIAP associated factor 1 3.9349377 1.86E-05 
Arhgdib Rho, GDP dissociation inhibitor (GDI) beta 3.9166377 4.25E-08 
Bst2 bone marrow stromal cell antigen 2 3.9156516 1.18E-05 
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Casp8 caspase 8 3.900089 7.32E-09 
Ifih1 interferon induced with helicase C domain 1 3.8993988 4.05E-05 
Irf9 interferon regulatory factor 9 3.8860035 7.60E-08 
Slfn4 schlafen 4 3.8827317 5.75E-04 
Cd68 CD68 antigen 3.8816974 1.55E-09 
Itgam integrin alpha M 3.8755326 5.37E-08 
Ifi30 interferon gamma inducible protein 30 3.872788 4.07E-07 
Tyrobp TYRO protein tyrosine kinase binding protein 3.807827 3.37E-11 
Pyhin1 pyrin and HIN domain family, member 1 3.7786415 4.61E-06 
9930111J21Rik2
| 
9930111J21Rik1
| 
Gm5431 
RIKEN cDNA 9930111J21 gene 2 | RIKEN cDNA 
9930111J21 gene 1 | predicted gene 5431 3.7734895 7.22E-08 
Slc11a1 solute carrier family 11 (proton-coupled divalent metal ion transporters), member 1 3.761288 3.36E-07 
Ifi203 interferon activated gene 203 3.7605247 1.28E-05 
Gm5431 predicted gene 5431 3.750554 3.24E-06 
Ccr5|Ccr2 chemokine (C-C motif) receptor 5 | chemokine (C-C motif) receptor 2 3.7445805 4.31E-08 
Tap1 transporter 1, ATP-binding cassette, sub-family B (MDR/TAP) 3.7434745 3.13E-07 
Ccr5|Ccr2 chemokine (C-C motif) receptor 5 | chemokine (C-C motif) receptor 2 3.7419653 4.14E-08 
C1qc complement component 1, q subcomponent, C chain 3.691437 9.21E-09 
Cyba cytochrome b-245, alpha polypeptide 3.6912851 2.94E-08 
Fcrl5 Fc receptor-like 5 3.6699855 2.10E-05 
Sp100  3.6670215 4.49E-07 
Sfpi1 SFFV proviral integration 1 3.6336854 5.97E-08 
9930111J21Rik2
| 
9930111J21Rik1
| 
Gm5431 
RIKEN cDNA 9930111J21 gene 2 | RIKEN cDNA 
9930111J21 gene 1 | predicted gene 5431 3.624132 5.27E-08 
Cd84 CD84 antigen 3.619827 6.09E-08 
Parp12 poly (ADP-ribose) polymerase family, member 12 3.6093345 4.74E-06 
C1qa complement component 1, q subcomponent, alpha polypeptide 3.5933928 1.21E-09 
Lcp2 lymphocyte cytosolic protein 2 3.5550501 1.57E-08 
Dock2 dedicator of cyto-kinesis 2 3.542894 2.29E-07 
Tagap T-cell activation Rho GTPase-activating protein 3.5305424 4.78E-08 
C1qb complement component 1, q subcomponent, beta polypeptide 3.4979184 2.85E-10 
Laptm5 lysosomal-associated protein transmembrane 5 3.4805212 8.98E-10 
Itgax integrin alpha X 3.4801943 3.22E-06 
Nckap1l NCK associated protein 1 like 3.4672332 1.23E-09 
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Cd93 CD93 antigen 3.434816 5.93E-07 
Tlr1 toll-like receptor 1 3.4326348 8.31E-07 
Slamf7 SLAM family member 7 3.408035 3.06E-05 
AB124611  3.40638 1.79E-07 
Pik3cg phosphoinositide-3-kinase, catalytic, gamma polypeptide 3.3917887 1.08E-07 
Glipr1|Krr1 
GLI pathogenesis-related 1 (glioma) | KRR1, small 
subunit (SSU) processome component, homolog 
(yeast) 
3.3862197 6.39E-08 
Serping1 serine (or cysteine) peptidase inhibitor, clade G, member 1 3.3831935 2.65E-07 
  3.3748608 
0.00102
2 
Grn granulin 3.3616664 1.59E-09 
Ly6a lymphocyte antigen 6 complex, locus A 3.3566322 6.88E-09 
Slfn8 schlafen 8 3.346721 1.03E-04 
Gfap glial fibrillary acidic protein 3.312322 8.63E-11 
Arpc1b|Gm5637 actin related protein 2/3 complex, subunit 1B | predicted pseudogene 5637 3.3091986 5.15E-09 
Dtx3l|Parp9 deltex 3-like (Drosophila) | poly (ADP-ribose) polymerase family, member 9 3.2979794 2.54E-06 
Alox5ap arachidonate 5-lipoxygenase activating protein 3.2976754 5.21E-09 
Gp49a|Lilrb4 glycoprotein 49 A | leukocyte immunoglobulin-like receptor, subfamily B, member 4 3.2844298 1.17E-04 
Il10ra interleukin 10 receptor, alpha 3.2723858 1.31E-08 
Dhx58 DEXH (Asp-Glu-X-His) box polypeptide 58 3.2714343 6.17E-05 
Slamf9 SLAM family member 9 3.2574503 1.06E-06 
Tlr7 toll-like receptor 7 3.2499063 1.90E-07 
Apobec3 apolipoprotein B mRNA editing enzyme, catalytic polypeptide 3 3.2438989 7.50E-08 
  3.2321565 2.57E-05 
Neurl3 neuralized homolog 3 homolog (Drosophila) 3.2239246 5.04E-08 
Nkg7 natural killer cell group 7 sequence 3.2131076 1.10E-05 
Myo1f myosin IF 3.205457 1.74E-08 
Isg20 interferon-stimulated protein 3.1826715 4.01E-04 
Bcl2a1a| 
Bcl2a1d| 
Bcl2a1b| 
Bcl2a1c 
B-cell leukemia/lymphoma 2 related protein A1a | B-
cell leukemia/lymphoma 2 related protein A1d | B-
cell leukemia/lymphoma 2 related protein A1b | B-
cell leukemia/lymphoma 2 related protein A1c 
3.1532354 6.08E-05 
Gm11711|Clm3 predicted gene 11711 | CMRF-35-like molecule 3 3.1490738 2.86E-08 
Fcgr1 Fc receptor, IgG, high affinity I 3.1478186 8.17E-07 
Oas2 2'-5' oligoadenylate synthetase 2 3.1414037 5.05E-05 
Trim12| 
LOC100048060 
tripartite motif-containing 12 | similar to tripartite 
motif protein TRIM12 3.1135898 5.97E-05 
Aif1 allograft inflammatory factor 1 3.112917 2.21E-06 
BC013712  3.102906 7.42E-08 
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F11r F11 receptor 3.092533 5.43E-10 
Herc5 hect domain and RLD 5 3.0876677 4.30E-05 
Lyn Yamaguchi sarcoma viral (v-yes-1) oncogene homolog 3.0821068 6.15E-09 
Top2a topoisomerase (DNA) II alpha 3.0800803 4.27E-07 
Ly9 lymphocyte antigen 9 3.0745974 8.18E-09 
Arpc1b actin related protein 2/3 complex, subunit 1B 3.0633452 3.34E-09 
Tlr8 toll-like receptor 8 3.0540376 4.50E-07 
Mki67 antigen identified by monoclonal antibody Ki 67 3.0507367 7.68E-08 
Gm11711|Clm3 predicted gene 11711 | CMRF-35-like molecule 3 3.0498946 4.06E-08 
Fcgr2b Fc receptor, IgG, low affinity IIb 3.0432014 9.66E-08 
Msn moesin 3.0280933 2.14E-09 
Parp9|Dtx3l poly (ADP-ribose) polymerase family, member 9 | deltex 3-like (Drosophila) 3.0247502 1.85E-05 
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